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ABSTRACT 
 
Human cytochrome P450 (CYP) 2A6 is highly expressed in the liver and the encoding gene 
is regulated by various stress activated transcription factors, such as the nuclear factor 
(erythroid-derived 2)-like 2 (Nrf-2). Unlike the other xenobiotic metabolising CYP enzymes 
(XMEs), CYP2A6 only plays a minor role in xenobiotic metabolism. The CYP2A6 is highly 
induced by multiple forms of cellular stress conditions, where XMEs expression is normally 
inhibited. Recent findings suggest that the CYP2A6 plays an important role in regulating BR 
homeostasis.  
A computer based sequence analysis on the 3 kb proximate CYP2A6 promoter revealed 
several putative binding sites for p53, a protein that mediates regulation of antioxidant and 
apoptosis pathways. In this study, the role of p53 in CYP2A6 gene regulation is demonstrated. 
The site closest to transcription start site (TSS) is highly homologous with the p53 consensus 
sequence. The p53 responsiveness of this site was confirmed by transfections with various 
stepwise deleted of CYP2A6-5’-Luc constructs containing the putative p53RE. Deletion of the 
putative p53RE resulted in a total abolishment of p53 responsiveness of CYP2A6 promoter. 
Specific binding of p53 to the putative p53RE was detected by electrophoresis mobility shift 
assay. A point mutation at the binding site abolished both the binding and responsiveness of 
the recombinant gene to p53. Benzo[α]pyrene treatments of MCF-7 cells upregulated 
endogenous p53, which enhanced the expression of p53 responsive positive control and the 
CYP2A6-5’-Luc construct containing the intact p53 binding site but not the mutated CYP2A6-
5’-Luc construct. Endogenous CYP2A6 expression in C3A cells was induced by 
benzo[α]pyrene in a dose dependent pattern at the mRNA and protein levels along with 
elevated p53 levels in nucleus.  
It has been shown that the p53- mediated gene expression often involves interaction with 
other factors. The identified functional p53RE is only five base pairs upstream of the REs that 
govern the constitutive CYP2A6 gene expression. “Stress cluster” on the proximal CYP2A6 
promoter is described in which the stress activated transcription factors: CAR, C/EBPα-Oct-
1, and the p53, together with HNF-4α, regulate the encoding CYP2A6 gene. Overexpression 
of these transcription factors individually in the C3A cells upregulated (with the exception of 
CAR) a recombinant gene consisting of proximal CYP2A6 promoter containing all the REs of 
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the regulatory proteins. Specific binding of these transcription factors to their REs on the 
CYP2A6 promoter was demonstrated by using an EMSA analysis. A series of site mutations 
of the REs on the proximal CYP2A6 promoter region followed by transfection of these REs 
mutated CYP2A6 promoters into the C3A cells demonstrated that the CAR and C/EBP/Oct-1 
could support the promoter activity partially independently, while for the p53 and the HNF-
4α mediated CYP2A6 transactivation, interaction with the other factors is required. Co-
transfection of the p53 together with the REs mutated CYP2A6 promoters respectively into 
the C3A cells further demonstrated that the p53- mediated CYP2A6 transactivation involved 
interaction with CAR and C/EBP/Oct-1, and its full activity was complemented by HNF-4α. 
Replacing the p53RE on the proximal CYP2A6 promoter with a consensus p53RE resulted in 
an extremely high expression of the recombinant gene regardless of p53 overexpression. 
While unexpected, this result agrees with the rest of the evidence and supports a model where 
the stress activated proteins form a compact cluster, assisted by the liver specific HNF-4a for 
full activity.      
It has been shown that p53 interacts with Nrf-2 exerting a role in regulating several stress 
activated genes. Co-transfection of Nrf-2 and p53 together with CYP2A6 promoter in C3A 
cells demonstrated that the Nrf-2 restrained the p53- mediated CYP2A6 transactivation 
probably through the “stress cluster” present on the promoter region. Stepwise truncations of 
the distal CYP2A6 promoter followed by transfection of these promoters into the C3A cells 
also suggested that the potential suppressor(s) may exist on the “-2253 to -1700bp” and “-688 
to-250bp” regions of the promoter.  
Collectively, the results provide a mechanistic explanation for previous observations that the 
CYP2A6 is induced by various structurally unrelated toxic insults.  
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1. INTRODUCTION 
 
          The metabolism of drugs and other xenobiotics by the cytochrome P450 (CYP) system 
is not always a benign process. Often, reactive electrophilic metabolites are formed which 
can strongly bind to cellular macromolecules such as proteins, lipids and DNA leading to 
toxic effects. Electrophilic molecules may be detoxified by nucleophilic glutathione through 
scavenging. However, if glutathione is depleted, or if critical targets associated with 
maintenance of redox status are affected, oxidative stress will ensue. If redox balance is not 
restored, the cell will eventually undergo necrotic cell death.   
The response to oxidative stress is therefore critical in ensuring recovery of the cell. 
When confronted with oxidative stress, the cell invokes specific redox-sensitive signalling 
pathways to activate the expression of genes that influence the cell to survive or die. For 
example, the transcription factor erythroid-derived 2-like 2 (Nrf2) regulates the coordinated 
activation of antioxidant genes that encode haem oxygenase 1 (HMOX1)  and phase II 
(conjugative) drug-metabolising enzymes to ensure cell survival (Alam et al., 1999; Baird 
and Dinkova-Kostova, 2011). Another important transcription factor that activates major 
signalling pathways in response to oxidative stress is the p53, a protein that has both pro- and 
anti-oxidant functions. Depending on the degree of cellular stress, p53 regulates genes that 
are important in regulation of normal cell growth, cell death, or tumorigenesis (Bensaad and 
Vousden, 2005).  
 Most CYP forms are down-regulated in response to oxidative stress. The exceptions 
appear to be some CYP2A forms: CYP2A6 in humans and CYP2A5 in mice (Fernandez-
Salguero and Gonzalez, 1995; Ling et al., 2004).  Importantly, the Nrf2 has been shown to 
regulate the expression of CYP2A6 gene (Yokota et al., 2011).  
 Transcription factor binding site search on the CYP2A6 promoter conducted in the 
beginning of this investigation revealed several putative binding sites for p53. This attracted 
our attention and raised the question of whether the identified putative p53REs are functional 
and what their roles may be in CYP2A6 gene expression.  
 The constitutive expression of CYP2A6 is regulated by a battery of transcription 
factors that activate the CYP2A6 promoter, including CAR, C/EBPα, C/EBPβ, Oct-1 and 
HNF-4α (Pitarque et al., 2005). Intriguingly, the CAR, C/EBPβ and Oct-1 have been found 
to be activated by different forms of stress, which include serum starvation stress, 
endoplasmic reticulum stress, oxidative stress, radiation and DNA damage (Zhao et al., 2000; 
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Jin et al., 2001; Osabe et al., 2009; Meir et al., 2010). Since the CYP2A6 is known to be 
induced by a variety harmful, structurally unrelated chemicals and pathophysiological 
conditions (Kirby et al., 1994; Donato et al., 2000; Niemela et al., 2000; De-Oliveira et al., 
2006; Kirby et al., 2011; Abu-Bakar et al., 2013), and is highly expressed in the liver 
(Nakajima et al., 2006), lung, oesophagus, intestinal, oral and bronchial epithelium (Su et al., 
1996; Koskela et al., 1999; Janmohamed et al., 2001; Oyama et al., 2006), where the cells 
typically suffer from high oxygen and chemical exposures, it is possible that the enzyme has 
a protective function in cells. This assumption is supported by the recent finding that 
CYP2A6 oxidises bilirubin ─ a potent antioxidant at low intracellular concentration but toxic 
at high concentration ─ to biliverdin which can be reduced back to bilirubin by biliverdin 
reductase when there is a depletion of intracellular bilirubin (Abu-Bakar et al., 2012). The 
purpose of this investigation was to find out whether or not the p53 is a regulator of the 
CYP2A6 gene and its possible interaction with other stress activated TFs in the CYP2A6 
regulation.  
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2. LITERATURE REVIEW 
 
2.1 Cytochrome P450 gene family and enzyme regulation  
 
2.1.1 Cytochrome P450 
 
    The cytochrome P450 (CYP) is a superfamily of haem-containing mono-oxygenase 
enzymes that catalyse the oxidation of endobiotics and xenobiotics to produce both 
biologically inactive and, in some cases, reactive metabolites. They most commonly catalyse 
the monooxygenation of carbon and heteroatom centres on lipophilic chemicals using 
molecular oxygen and NADPH as a reducing cofactor, and release water as a by-product 
(Meunier et al., 2004). The CYP genes exist in virtually all species and to date there are 
18,687 named protein-coding CYP genes with putative functions: 5442 in animals; more than 
6800 in plants; more than 4800 in fungi; 247 in Protozoa; more than 1200 in Eubacteria; 48 
in Archaebacteria; and two in viruses (http://drnelson.uthsc.edu/cytochromeP450.html). The 
enzymes are arranged into families and subfamilies based on percent amino acid sequence 
identity (Nebert et al., 1987; Nelson et al., 1996). The membrane-bound CYPs are localised 
mainly in endoplasmic reticulum (ER) and predominantly found in the liver of higher 
organisms. This enzyme system is also found in the lungs, kidney, brain, lymphocytes, 
vascular smooth muscle, intestinal epithelium, olfactory and nasal mucosa (Lohr et al., 1998; 
Su et al., 1998; Bhagwat et al., 1999). 
 The human genome contains 18 CYP families, divided into 41 protein-coding 
subfamilies encoding 57 genes (Nebert et al., 2013). Families 4 and above are considered 
most important in metabolism of endobiotic compounds, such as steroids, fatty acids, and 
prostaglandins, and mainly to be found in the mitochondria (Nebert et al., 2013). Families 1-3 
are generally regarded as xenobiotic-metabolising enzymes (XMEs) responsible for the 
oxidative clearance of drugs and environmental chemicals. These XMEs form part of a 
coordinated system for xenobiotic clearance, which also includes other enzymes such as 
glucuronosyl transferases and a series of nuclear receptors and transcription factors that 
regulate the response to chemical challenge (Nebert et al., 1984; Nebert and Dalton, 2006). 
Members of these families are typically promiscuous in their substrate specificities, 
metabolising wide and overlapping ranges of chemicals as befits a system for chemical 
defense. 
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2.1.2 Regulation of CYP enzymes  
 
             Generally, the expression of xenobiotic-metabolising enzymes (XMEs) is governed 
by a group of transcription factors and cofactors. These transcription factors may be divided 
into factors that mediate their constitutive and inducible expression, respectively. 
Transcription factors, such as the hepatocyte nuclear factor (HNF)-1, HNF-4, HNF-6, 
Forkhead box A (FoxA), CAAT/enhancer-binding proteins (C/EBP) and D-site binding 
protein (DBP) are essential in maintaining the constitutive CYP enzyme expressions (Schrem 
et al., 2002).  
            Inductions of CYPs by xenobiotics are often mediated by ligand-binding nuclear 
receptors, such as the aryl hydrocarbon receptor (AhR), constitutive androstane receptor 
(CAR) and pregnane X receptor (PXR) (Fujii-Kuriyama and Mimura, 2005; Timsit and 
Negishi, 2007). Prior to activating a gene, AhR binds to a complex of Hsp90, XAP2 and p23 
within the cytoplasm. Exposure to specific ligands would release AhR from the AhR-hsp90 
complex to be translocated to the nucleus. In the nucleus, AhR forms a heterodimeric 
complex with the aryl hydrocarbon nuclear translocator (ARNT). The complex then binds to 
xenobiotic response elements (XREs) on the promoter regions of target genes (Fujii-
Kuriyama and Mimura, 2005). Similarly, CAR and PXR are also activated by their ligands. 
Ligand binding disassociates CAR and PXR from their co-chaperone partners: cytoplasmic 
CAR retention protein (CCRP) and Hsp90. This results in translocation of CAR and PXR. 
The activated CAR and PXR dimerise with the retinoids X receptor (RXR), and bind to the 
phenobarbital-responsive enhancer module (PBREM) and the xenobiotic responsive enhancer 
module (XREM) respectively, triggering gene activation (Timsit and Negishi, 2007).  
           Besides the ligand activated transcription factors, the oxidative stress responsive 
transcription factor ─ nuclear factors (erythroid-derived 2)-like 2 (Nrf-2) and the p53 ─ are 
also involved in CYP regulation (Abu-Bakar et al., 2007; Yokota et al., 2011; Goldstein et 
al., 2013). In addition to the DNA binding of transcription factors, some corepressors and 
coactivators such as proliferator activated receptor-γ coactivator-1α (PGC-1α), govern 
transcriptional events through protein-protein binding (Ding et al., 2006).  
           The crosstalk among transcription factors is quite common, regulating each other’s 
expression by competing with the co-repressor or co-activator and interfering with each 
other’s regulatory pathways, such as the crosstalk between Nrf-2 and p53 (Faraonio et al., 
2006; You et al., 2011). It should also be noted that some other nuclear receptors, such as 
peroxisome proliferator activated receptors (PPARs), vitamin D receptor, farnesoid receptor, 
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glucocorticoid receptor, and liver X receptor are involved in the regulation of CYP enzymes 
(Ioannides, 2008).  
            Besides transcriptional regulation, CYP enzyme expression can be regulated at the 
post-transcriptional and post-translational levels through the interactions with 3’-UTR of their 
mRNAs by proteins such as the hnRNPA1 and micro RNA complexes (Glisovic et al., 2003; 
Christian et al., 2004; Tsuchiya et al., 2006), and by protein stabilisation (Abu-Bakar et al., 
2012).   
             Most drug metabolising CYPs are designed to accept several substrates. 
Disadvantage of this is that they often tend to be poorly coupled, with a large proportion of 
the reducing equivalents from the cofactor NADPH released as reactive oxygen species 
(ROS) through futile cycling (Zangar, 2004). This is particularly pronounced when the 
substrate is a poor fit to the CYP active site. However, reduction of the CYP and consequent 
uncoupling also occurs in the absence of substrate for some forms (Zangar, 2004). The ROS 
generated could contribute to oxidative stress in the cells. 
             One of cellular responses to oxidative stress is to limit CYP-generated ROS by 
downregulating CYP isoforms that are prone to uncoupling, such as CYP families 1-3 
(Zangar, 2004). For instance, ROS inactivation of nuclear factor (NF-1) blocks the NF-1 
activation of CYP1A1 transcription thereby leading to down regulation of CYP1A1. The 
cysteine residue 427 in the NF-1 transactivation domain appears to have an essential role in 
the mediation of the CYP1A1 down-regulation as the ROS oxidises the residue inactivating 
the NF-1 transcription. However, the same amount of ROS did not block the transactivation 
and DNA binding domains of another transcription factor CP1, suggesting that NF-1 is 
particularly responsive redox sensor (Morel et al., 2000). In addition to the inactivation of 
transcription factors by ROS, oxidative stress may regulate the expression of cytokines, 
which may have a downregulating effect on CYPs expression. For example, the cytokine 
tumour necrosis factorα (TNFα) has been found to repress CYP1A1 expression in HepG2 
cells through the NF-1 pathway (Morel and Barouki, 1998). Besides downregulation of the 
CYPs expression at the transcriptional level, the cytokines: TNFα, interleukin-1β (IL-1β) and 
interferon-γ (IFNγ) have been shown to stimulate intracellular nitric oxide (NO) synthesis, 
which blocks the CYP2B6 expression at the post-transcriptional level (Aitken et al., 2008).  
              Although exposures to agents or pathophysiological conditions that exert oxidative 
stress have always been associated with diminished total CYP content (Morgan, 1997), one 
particular CYP, the murine CYP2A5 and its human orthologue CYP2A6, have been shown to 
constantly be induced in response to oxidative stress (reviewed in Abu-Bakar et al., 2013). 
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The CYP2A6 has also has been found to be induced in fatty, inflamed or cirrhotic livers 
associated with microorganism infections and harmful alcohol consumption (Kirby et al., 
1996; Satarug et al., 1996; Raunio et al., 1998; Niemela et al., 2000; Fisher et al., 2009). The 
way in which the murine CYP2A5 is regulated during oxidative stress has been described 
extensively (Raffalli-Mathieu et al., 2002; Glisovic et al., 2003; Abu-Bakar et al., 2004; Abu-
Bakar et al., 2005; Abu-Bakar et al., 2007; Abu-Bakar et al., 2011; Kirby et al., 2011; Lamsa 
et al., 2012), but little is known about the mechanism(s) by which the human CYP2A6 is 
regulated under these conditions.  
 
2.2 Structure and function of CYP2A6 
 
2.2.1  Cytochrome P450 subfamily 2A (CYP2A) 
 
           Today, more than 20 CYP2A genes have been identified in different mammalian 
species (Raunio et al., 2008). The human CYP2 gene cluster is localised on human 
chromosome 19, which is made up of six different subfamilies (CYP2A, CYP2B, CYP2F, 
CYP2G, CYP2S and CYP2T). The human CYP2A subfamily contains three functional genes: 
the CYP2A6, CYP2A7 and CYP2A13. However, its mouse orthologue has four functional 
genes, namely Cyp2a4, Cyp2a5, Cyp2a12 and Cyp2a22 (Hoffman et al., 2001).  
          Human CYP2A genes contain 9 exons, which are distinguished by the consensus 
sequence GT and AG on the boundaries between the introns and exons (Hoffman et al., 
2001). The gene sequence similarity is quite high among the transcribed human CYP2A 
subfamily members: the CYP2A6, CYP2A7 and CYP2A13 share more than 85% sequence 
identity in their exonic sequences (Hoffman et al., 2001).  
          Among the CYP2A family members the mouse CYP2A5 and human CYP2A6 have 
attracted most research attention for several reasons. Firstly, a number of drugs and toxins, 
such as halothane and aflatoxin B1 (AFB1) have been found to be metabolised by the 
CYP2A5 and CYP2A6, which suggests a role in pharmaco- and toxico-kinetics (Kirby et al., 
1993; Pelkonen et al., 1994; Pelkonen et al., 1997; Abu-Bakar et al., 2013). Secondly, 
diverse groups of structurally unrelated toxicants, such as metals and pesticides are known to 
induce CYP2A5 and CYP2A6 expression (Lamsa et al., 2010; Abass et al., 2012). This 
indicates a common event, perhaps a secondary response to the inducers, regulating the 
expression instead of the inducers per se. Thirdly, recent findings that the CYP2A5 and 
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CYP2A6 catalyse the oxidation of bilirubin — the breakdown product of haem — to 
biliverdin (BV), indicate a significant role in the cellular haem homeostasis and in the 
regulation of cellular redox balance (Abu-Bakar et al., 2011; Abu-Bakar et al., 2012; Abu-
Bakar et al., 2013). In accordance with this, the mouse CYP2A5 has been shown to be 
recruited into mitochondria during oxidative stress induced cellular damage, potentially 
conferring membrane protection (Muhsain et al., 2015). Together, these findings indicate that 
CYP2A5 and CYP2A6 may play an essential role in defense against toxic insults. Due to 
their response to diverse toxic insults, they may also be used as excellent markers for liver 
toxicity (Abu-Bakar et al., 2013).  
 
2.2.2 CYP2A6 enzyme structure  
 
           The CYP proteins contain about 500 amino acid residues, divided into α- and β-
domains. The α-domain contains 13 α-helices (A-L and B’), which form the haem binding 
pocket. The β-domain has 5-β-sheets (β1 – β5), which include the N-terminus (Otyepka et al., 
2007). The CYP2A6 crystal structure depicts a typical mammalian CYP protein fold with two 
short helices (F’ and G’) in the F-L loop region and a compact hydrophobic active site 
(Figure2.1). A channel near F’ helix is formed from the surface of the protein to the active 
site by the F, G and B’ helices, which facilitates the substrate binding of the enzyme (Yano et 
al., 2006). The CYP2A6 amino acid residues in the I, F and B’ helices are crucial to its 
catalytic activity and substrate specificity. The Asn 297 which is located in the hydrophobic 
cavity of the protein active site, forms a hydrogen bond with substrates, such as coumarin, 
methoxsalen and amine derivatives. The upper surface of the active site cavity is surrounded 
by the phenylalanine residues: Phe107, Phe111, Phe118, Phe209 and Phe480, which stabilise 
the compact structure of the enzyme and reduce the volume of the active site. These aromatic 
residues also promote the protein binding to aromatic ligands through π-π stacking and edge 
to face interaction (Yano et al., 2005; Yano et al., 2006).  
           The hydrophobic amino acids at the CYP2A6 active site dictate its catalytic activity as 
demonstrated in mutagenesis studies. For instance, coumarin 7-hydroxylation activity is 
significantly reduced after mutation of Val117 to Ala (He et al., 2004). Additionally, 
mutation of residue Asn297 changed the Km and Ks value of many substrates, such as 
coumarin or 7-methoxycoumarin (Kim et al., 2005). These observations suggest that 
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alteration of the residue size and polarity in the active site modified the interaction between 
protein and substrate, which in turn affect substrate binding and orientation. 
                           
Figure 2.1: Tertiary structure of CYP2A6 protein. α-helices and β-sheets are shown in red 
and light blue respectively. Coumarin (dark blue) is above of haem (dark grey) at active site 
(centre of the protein). Image is adapted from (Abu-Bakar et al., 2013).  
 
2.2.3 Tissue specific expression and CYP2A6 polymorphism  
 
            CYP2A6 is predominantly expressed in the liver and commonly found in sex steroid-
responsive tissues such as breast, ovary, uterus, testis, and adrenal gland (Nakajima et al., 
2006), lung, nasal mucosa, oesophagus, trachea and skin (Su et al., 1996; Koskela et al., 
1999; Janmohamed et al., 2001). The gene is highly polymorphic with over 37 allelic variants 
identified (see http://www.cypalleles.ki.se/cyp2a6.htm for a regularly updated list). The 
genetic variations are known to alter the expression, stability, and function of the CYP2A6 
enzyme with regard to the metabolism of a number of its substrates, such as coumarin, 
nicotine, and tegafur, (reviewed in Di et al., 2009). For example, CYP2A6*1 has been 
identified as an extensive phenotype to catalyse coumarin and nicotine (Peamkrasatam et al., 
2006). Asians have a lower frequency of CYP2A6*1 expression (50%-60%) than Caucasians 
(88.8%-97.1%) or black Africans (92.4%) (Gyamfi et al., 2005; Peamkrasatam et al., 2006), 
indicating that Asians on average may have a lower CYP2A6 enzyme activity compared to 
Caucasians and black Africans. Some CYP2A6 gene variants have shown decreased 
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enzymatic activities. For example, CYP2A6*4A and CYP2A6*2A have a complete loss of 
function or maintain an enzymatic activity less than 50%. CYP2A6*9A and CYP2A6 *12A 
have shown an averaged enzymatic activity around 75% compared with wildtype 
CYP2A6*1A (Akrodou, 2015).  
 
2.2.4 CYP2A6 in drug metabolism  
 
            Although CYP2A6 participates in the metabolism of several therapeutics drugs and 
toxic chemicals, it catalyses a minor metabolic pathway for the majority of these compounds 
(Raunio et al., 2008), often with a high Km and a low Vmax. This indicates that CYP2A6 
plays a minor role in terms of the overall metabolism of the particular drugs at relevant in 
vivo concentrations. 
             A series of substrates, such as coumarin, nicotine, AFB1, methoxyflurane, and 
halothane that are metabolised by CYP2A6 have been reviewed by Abu-Bakar et al (2013). 
Most of the substrates are detoxified but some of them are activated by the enzyme. For 
example, the tobacco-specific nitrosamine, 4-(methy1nitrosamio)-1-(3-pyridyl)-1-butanone 
(NNK) and AFB1 can be activated by CYP2A6 to genotoxic intermediates known to form 
DNA-adducts associated with cancer (Miyazaki et al., 2005). The most selective substrates 
for CYP2A6 are coumarin and nicotine. Coumarin is a natural plant component present in a 
number of herbal medicinal products used for various disorders in some European countries. 
The CYP2A6 enzyme specifically metabolise coumarin to 7-hydroxycoumarin. Thus, 
coumarin is used as a diagnostic substrate for phenotyping CYP2A6 activity both in vivo and 
in vitro (Pelkonen et al., 2000). With regard to nicotine, CYP2A6 accounts for 70% to 80% 
nicotine metabolism to cotinine, which is further metabolised to trans-3-hydroxycotinine 
(Hukkanen et al., 2005; Raunio et al., 2008). 
             The endogenous substrate for CYP2A6 has only recently been identified (Abu-Bakar 
et al., 2012). In a study with recombinant CYP2A6, bilirubin (BR) — a breakdown product 
of pro-oxidant haem — was oxidised to biliverdin (BV). The affinity of BR to CYP2A6 is in 
the same range as the diagnostic substrate, coumarin (Km = 1 - 2 µM) (Abu-Bakar et al., 
2012). Molecular docking analyses with the crystal structure of CYP2A6 demonstrated that 
BR interacts with the key amino acid residues of the CYP2A6's active site (Figure 2.2). The 
interaction promotes stabilisation of bilirubin into a conformation that favours BV formation 
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(Abu-Bakar et al., 2012). This study shows that BR is a high affinity endogenous substrate 
for the CYP2A6. 
 
Figure 2.2: Simulation of bilirubin docking on the CYP2A6 active site. Bilirubin (BR) 
interacts with amino acid residues Phe107, Phe111, Val117, Phe118, Asn297, Ile300, 
Thr305, Leu370, Ala371, and Phe480. The propionic acid groups of BR form hydrogen 
bonds with Asn297 and Thr305. The central methylene bridge of BR coordinated towards 
haem iron (Black Square on the right side). Molecules in red represent BR. Adapted from 
(Abu-Bakar et al., 2013). 
             Importantly, BR a potent antioxidant at physiological concentrations (< 10µM) and a 
cyto-toxin at concentrations above 10 µM, is a regulator of the CYP2A6 (Abu-Bakar et al., 
2012). It was demonstrated that treatment of HepG2 cells with 5 µM BR increased the 
CYP2A6 protein and activity levels up to 12 h, with no effect on the corresponding mRNA. 
Co-treatment with cycloheximide (CHX), a protein synthesis inhibitor, resulted in increased 
half-life of the CYP2A6 compared to cells treated only with CHX (Abu-Bakar et al., 2012). 
These observations indicate that the induction of CYP2A6 by BR is via protein stabilisation.  
 
2.2.5 Cyp2a5 deficient mouse model 
 
            The in vivo role of CYP2A5/CYP2A6 in drug metabolism, pharmacokinetics, as well 
as subsequent effect on drug efficacy and toxicity is well elucidated by using Cyp2a5 
deficient mouse model. It has been shown that the Cyp2a5 null mice have a lower metabolic 
rate of many CYP2A5 substrates such as the carcinogen NNK (Zhou et al., 2012), antithyroid 
drug methimazole (MMZ) (Xie et al., 2011), environmental pollutant naphthalene (NA) (Hu 
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et al., 2014), nicotine and cotinine (Zhou et al., 2010), indicating an essential role of 
CYP2A5 in metabolism of these chemicals. The loss of this gene in mouse has also led to a 
significant decrease of testosterone hydroxylation in various tissues such as olfactory mucosa, 
lung, liver and brain (Wei et al., 2013). Notably, the role of CYP2A5 in cellular defense 
against toxic chemical exposures has been addressed by the recent studies. Acetaminophen 
(APAP), a model compound to study the mechanisms of chemical toxicity has been found to 
be metabolised to a toxic intermediate, N-acetyl-p-benzoquinoneimine, which can be 
detoxified via conjugation with cellular antioxidant glutathione (GSH) (Hinson et al., 2004). 
The Cyp2a5 null mice have shown a reduced level of APAP-GSH conjugation in lateral nasal 
gland, suggesting a role of CYP2A5 in maintaining GSH mediated APAP detoxification 
(Zhou et al., 2011). It has been reported that thioacetamide (TAA) induced a more severe 
liver injury in Cyp2a5 null mice than that observed in wildtype mice. This suggests that 
CYP2A5 may protect against TAA induced liver injury (Hong et al., 2016). In addition, 
ethanol has been found to induce CYP2A5 expression in wildtype mice but not in Cyp2a5 
null mice, and that ethanol induced oxidative stress was significantly higher in the knockout 
mice than the wildtypes (Hong et al., 2015). Collectively, these studies seem to imply a 
substantial role of CYP2A5 in cellular defense against toxic chemical exposures. However, 
the underlying mechanisms by which the enzyme is regulated in cells still remain largely 
unanswered. 
 
2.3 Current knowledge of the CYP2A6 gene regulatory pathways  
 
           The expression of CYP2A6 can be regulated by both transcription and post-
transcription pathways. The transcription factors Oct-1, C/EBP and HNF-4α have been found 
to govern CYP2A6 basal expression through the mediation by the related response elements 
present on the proximal CYP2A6 promoter region (Pitarque et al., 2005). Xenobiotic 
induction of CYP2A6 has been identified to be regulated at transcriptional level. For 
instance, the induction of CYP2A6 by phenobarbital and rifampicin was found to be 
mediated through the PXR and CAR pathways (Itoh et al., 2006), and via estrogen receptor 
by estrogen (Higashi et al., 2007).  
             The induced CYP enzyme has a significant role in the metabolism and clearance of 
the substrate/inducer itself and some other co-administered drugs. However, sometimes more 
toxic metabolites can be produced during the metabolic oxidation, which may alter the 
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cellular redox balance and enhance oxidative stress. A variety of chemicals of unrelated 
structures, as well as some heavy metals were found to induce CYP2A6 expression (reviewed 
in Abu-Bakar et al., 2013). It seems that the induction of CYP2A6 in these cases may be 
activated through the mediation of “stress responding” element(s) present in the promoter 
region of the CYP2A6. More specifically, the oxidative stress activated transcription factor 
Nrf-2 has been found to participate in the regulation of CYP2A6 gene expression by binding 
of Nrf-2 to the ARE on the CYP2A6 promoter region (Yokota et al., 2011).  
             Additionally, CYP2A6 mRNA was found to be stabilised by the heterogeneous 
nuclear ribonucleoprotein A1 (hnRNPA1) binding to the 3’-UTR of CYP2A6 mRNA thus 
upregulating the gene (Christian et al., 2004). Interestingly, hnRNPA1 a multifunctional 
stress activated gene regulator seems to contribute to strong and fast upregulation of the 
CYP2A5 during cellular stress (Glisovic et al., 2003). A recent study has also shown that the 
microRNA-126 binds to the 3’-UTR of CYP2A6 mRNA leading the translational repression 
of CYP2A6 expression (Nakano et al., 2015). Overall, regulation of the CYP2A6 by 
transcriptional and post-transcriptional mechanisms serves as a common cellular defense 
mechanism partly by detoxifying toxicants and more importantly, by alleviating oxidative 
stress by maintaining BR homeostasis (as discussed in section 2.2.4). A schematic depiction 
of the CYP2A6 gene regulation in response to different stresses and xenobiotic substances is 
illustrated in Figure 2.3.    
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Figure 2.3: A schematic depiction of current knowledge on xenobiotic and stress 
activated CYP2A6 gene regulatory pathways. CYP2A6 is transcriptionally regulated by the 
liver enriched transcription factors C/EBPs and HNF-4α, ubiquitously expressed factor Oct-1, 
stress activated Nrf-2 and xenobiotic activated PXR CAR and ER. HnRNPA1 post-
transcriptionally regulates CYP2A6 gene expression by stabilising CYP2A6 mRNA. Micro 
RNA-126 binds to the 3’-UTR of CYP2A6 mRNA blocking CYP2A6 translation. The 
abbreviations used in the diagram include: PXR (Pregnane X receptor); RXR (Retinoid X 
receptor); hsp90 (heat shock protein 90); CAR (Constitutive androstane receptor); CCRP 
(Cytoplasmic CAR Retention Protein); PP2A (protein phosphatase 2A); PGC1(Peroxisome 
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proliferator-activated receptor-gamma coactivator-1); E2 (Estradiol); ERα (Estrogen 
Receptor α); Nrf-2 (Nuclear factor (erythroid-derived 2)-like 2); Keap-1 (Kelch-like ECH-
associated protein 1); Maf (Muscle aponeurosis fibromatosis); p53 (transcription factor p53); 
Hdm-2 (Human double minute-2); C/EBP (CCAAT/enhancer binding protein); Oct-1 
(Octamer-1); HNF-4α (Hepatocyte nuclear factor 4α); HnRNPA1 (Heterogeneous nuclear 
ribonucleoprotein A1); miRNA (microRNA), DR-4RE (Direct repeat-4 response element); 
ERE (Estrogen response element); ARE (Antioxidant response element); C/EBPRE (C/EBP 
response element); Oct-1RE (Oct-1 response element); HNF-4αRE (HNF-4α response 
element);TSS (Transcription start site); S (protein stabiliser).  
 
2.3.1 Transcriptional regulation of CYP2A6 by CAR, Oct-1, C/EBPs, HNF-4α 
 
            The proximal promoter region of the CYP2A6 gene has been found to be essential in 
mediating the constitutive CYP2A6 gene expression. The region spanning -122 to -60 bp 
contains overlapping response elements for CAR, C/EBPα, C/EBPβ, Oct-1, and HNF-4α. 
The liver enriched transcription factors HNF-4α, C/EBPα, and the ubiquitously expressed 
factor Oct-1 have been found to cooperatively mediate CYP2A6 transactivation. However, the 
C/EBPβ has been shown to inhibit CYP2A6 promoter activity (Pitarque et al., 2005). A DR-4 
like element was identified at the proximal region, where it locates at the position -112 of the 
CYP2A6 gene, showing a weak binding of the transcription factor CAR (Pitarque et al., 
2005). These response elements on the proximal CYP2A6 promoter region seem to play an 
essential role in constitutive CYP2A6 transactivation.  
            Despite their roles in maintaining the constitutive expression of the CYP2A6, it has 
been shown that transcription factors CAR, C/EBPβ and Oct-1 can be activated by different 
forms of stress. Under serum starvation, the CAR has been found to be induced in HepG2 and 
SW480 cells via the stress-activated protein kinase (SAPK) signalling pathway (Osabe et al., 
2009). The endoplasmic reticulum (ER) stress has been found to induce C/EBPβ expression 
in both mouse and human cell models (Li et al., 2008; Meir et al., 2010). The C/EBPβ 
mRNA can be translated into two forms of full length transcriptional activators (LAP) and a 
truncated variant of transcriptional repressor (LIP). During the early phase of ER stress, LAP 
is highly expressed to attenuate ER stress triggered cell death. However, when the ER stress 
is strengthened, LIP is dominantly expressed to augment ER stress triggered cell death (Li et 
al., 2008). Notably, it has been shown that increased production of ROS and activation of 
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Nrf-2 induces the C/EBPβ (both LAP and LIP) expression in mouse 3T3-L1 cells (Hou et al., 
2012). The induction of Oct-1 by several DNA damaging agents has been found to activate 
GADD45 gene expression, involved in the control of cell cycle check point, apoptosis and 
DNA repair (Jin et al., 2001). It is still unclear whether these factors regulating constitutive 
expression of the CYP2A6 gene also contribute to its upregulation during cellular stress.  
 
2.3.2 Transcriptional regulation of CYP2A6 by PXR/CAR, ER 
 
             Even though CYP2A6 is not a major enzyme involved in the metabolism and 
detoxification of xenobiotics, several of them may serve as its substrates, reviewed in (Abu-
Bakar et al., 2013).  
            CAR and PXR are major transcription factors regulating xenobiotic metabolism. They 
can be activated by numerous ligands including drugs and other xenobiotics such as 
rifampicin, phenobarbital and 6-(4-chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde 
O-(3,4-dichlorobenzyl)oxime. Ligand binding causes their translocation to nucleus and 
dimerization with retinoid X receptor (RXR)-α. The heterodimer of CAR/RXRα or 
PXR/RXRα binds to the enhancing region of the target genes, which triggers recruitment of 
nuclear receptor coactivators such as peroxisome proliferator-activated receptor-gamma 
coactivator-1 (PGC-1) or glucocorticoid receptor-interaction protein-1(GRIP-1). The formed 
multi-protein complex then drives the initiation of gene transcription (Kliewer et al., 1998; 
Lehmann et al., 1998; Itoh et al., 2006). CYP2A6 was shown to be induced via PXR and 
PGC-1α through the DR4-like elements at the distal response region. These elements are 
located at the positions -6698, -5476 and -4618 of the CYP2A6 promoter. Although both 
CAR and PXR dimerize with the retinoid X receptor and bind to these elements, only 
PXR/RXR dimer complex together with PGC-1α was found to trigger CYP2A6 gene 
transcription (Itoh et al., 2006).    
            In addition, CYP2A6 expression was found to be induced by the estradiol. An 
estrogen response element (ERE) was identified at the position -2436 on the CYP2A6 
promoter region (Higashi et al., 2007). 
            It should be noted that the pesticide isoproturon, chlorfluzuron and hexaflunuron 
induce CYP2A6 expression but do not activate either CAR or PXR (Abass et al., 2012), and 
that some other structurally unrelated compounds such as heavy metals, carbon tetrachloride, 
chloroform, cocaine, ethanol, and pyrazole up-regulate the CYP2A6 expression as well (Abu-
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Bakar et al., 2013). This indicates that mechanisms independent of CAR and PXR may 
contribute to the induction.   
 
2.3.3 Post-transcriptional regulation of CYP2A6 by hnRNPA1 
 
            In addition to regulation at the transcriptional level, regulation at the post-
transcriptional level by heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) has been 
observed. HnRNPA1 is a multifunctional protein, with a substantial role in various stages of 
mRNA metabolism (Krecic and Swanson, 1999; Lau et al., 2000). The hnRNPA1 is located 
in both cytosol and nucleus. However, certain form of stress such as transcription inhibition, 
inflammation or UV irritation, may cause its subcellular relocalisation (van der Houven van 
Oordt et al., 2000; Glisovic et al., 2003). The hnRNPA1 has been shown to bind to AG-rich 
motifs of the 3’UTR of HIV1, TAT and H-ras pre-mRNAs, exerting an essential role in the 
stabilisation of the RNAs (Damgaard et al., 2002; Guil et al., 2003). The sequence 
alignments between the 3’UTRs of CYP2A5 and CYP2A6 mRNAs have shown two highly 
conserved 12- to 14-nt long AG-rich motifs that can be targeted by the hnRNPA1 (Christian 
et al., 2004). Similarly to its mouse ortholog CYP2A5, the human hnRNPA1 regulated 
CYP2A6 expression was found to be mediated through a post-transcriptional pathway. The 
interaction of hnRNPA1 with the 3’UTR of the CYP2A6 mRNA stabilises the transcript 
when transcription is impaired (Christian et al., 2004). This mechanism enables the CYP2A6 
mRNA translation during transcriptional arrest, and helps to maintain cellular CYP2A6 
expression levels. The elevated CYP2A6 has an important role in the maintenance of cellular 
redox homeostasis as a response to oxidative stress.  
 
2.3.4 Post-transcriptional regulation of CYP2A6 by micro-RNA 126 
 
            Since the discovery of miRNA, its role in regulating gene expression has been 
extensively studied (Ambros, 2004). The miRNAs are 20- to 22- nucleotide duplex bearing 
two nucleotide single-stranded 3’ extensions, which regulate the expression of a gene by 
binding to the 3’-UTR of mRNA as a miRNA/RISC complex (RNA Induced Silencing 
Complex). Eventually, the binding blocks translation and leads to mRNA degradation (Bartel, 
2004; Molnar et al., 2008). miRNA/RISC complexes have been found to repress many 
cytochrome P450 proteins through directly binding to the 3’-UTR of CYP mRNAs or 
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indirectly through binding to the MRE (miRNA response element) sequences of xenosensor 
mRNA. For instance, miRNA-27b has been found to regulate the translation of CYP3A4 and 
CYP1B1 proteins by directly binding to the 3’UTR of their mRNAs (Tsuchiya et al., 2006; 
Pan et al., 2009). miRNA-378 has also been found to repress CYP2E1 translation (Mohri et 
al., 2010). As the expression of several CYPs is regulated by xenosensors such as VDR, RXR 
and PXR, some miRNAs such as the miRNA-27b and miRNA-148a block translation of 
those xenosensors by binding to MREs of related mRNAs, resulting in indirect repressive 
effect on CYPs proteins (Takagi et al., 2008; Pan et al., 2009). Recent findings have 
demonstrated that CYP2A6 is a direct target of miRNA-126, where it binds to 3’-UTR of 
CYP2A6 mRNA and inhibits CYP2A6 translation (Nakano et al., 2015). Whether or not 
miRNA regulates the CYP2A6 in response to oxidative stress is not known.  
 
2.3.5 Transcriptional regulation of CYP2A6 by Nrf-2  
 
            Recent studies have demonstrated that the CYP2A6 gene, like the mouse Cyp2a5, is 
regulated by the Nrf2 pathway (Yokota et al., 2011; Jin et al., 2012). The Nrf2 is a member 
of the Cap 'n' collar/basic leucine zipper (CNC/bZIP) family. It is ubiquitously expressed in a 
wide range of tissues and cell types (Moi et al., 1994; McMahon et al., 2001). Nrf2 is a 68 
kDa protein (Moi et al., 1994), but the cellular and in vitro translated Nrf2 have been shown 
to run at 100 kDa in SDS-PAGE (Moi et al., 1994). Nrf2 is activated by changes in cellular 
redox state, and the activity is controlled by Kelch-like ECH associated protein 1 (Keap1): a 
sensor of oxidative stress (Kansanen et al., 2013). Under balanced redox condition, Keap1 
forms a complex with Nrf2, which is targeted for ubiquitination, and recognised by the cullin 
3-Rbx 1 (Ring box protein 1) E3 ubiquitin ligase complex for proteosomal degradation. 
Degradation of Nrf2 is dependent on several reactive cysteine residues at the Keap1 protein 
(Kansanen et al., 2013). 
            Under oxidative stress, the reactive cysteine residues of Keap1 are modified, 
decreasing the rate of ubiquitination and degradation of Nrf2. The active Nrf2 then 
translocates to the nucleus (Kansanen et al., 2013) where it forms heterodimers with small 
Maf (muscle aponeurosis fibromatosis) proteins. The heterodimers bind to the AREs of target 
genes and activate transcription (Hayes et al., 2010).  
            Interestingly, a putative Antioxidant Response Element (ARE) — the Nrf2 binding 
site — was identified in the CYP2A6 promoter region at position -1212 to -1193 (Yokota et 
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al., 2011). In exploring the functionality of this site, Nrf2 expression plasmid was co-
transfected with the CYP2A6 promoter spanning the Nrf2 binding site in HepG2 cells. The 
co-transfection did not activate transcription of the promoter. By contrast, in vivo transfection 
experiment in the mouse liver demonstrated that CYP2A6 promoter activation is mediated by 
the Nrf2 pathway (Yokota et al., 2011). Together these observations indicate that: (a) Nrf2 
potentially binds to the ARE of the CYP2A6 promoter to mediate the expression of CYP2A6; 
(b) the CYP2A6 promoter may contain response elements for negative regulatory factors in 
response to Nrf2; and (c) HepG2 cells may lack some critical transcription factors for the 
activation of CYP2A6 transcription.  
   The Nrf2-mediated induction of CYP2A6 was also demonstrated in the U937 
monocytic cell line (Jin et al., 2012). Ethanol significantly increased ROS formation, induced 
nucleotranslocation of Nrf2, and induced CYP2A6 mRNA and protein in U937 cells. 
Induction of CYP2A6 and ROS formation were completely blocked by the treatment with 
vitamin C (an antioxidant). Additionally, butylated hydroxyanisole, a stabiliser of nuclear 
Nrf2, increased CYP2A6 levels by 200% (Jin et al., 2012). These observations confirmed the 
earlier findings of Yokota et al (2011) that the CYP2A6 expression is regulated by the Nrf2 
pathway. Importantly, the study indicates that ethanol-induction of CYP2A6 is a secondary 
response to increased ROS formation by ethanol. It is important to note that regulation of 
CYP2A6 by the Nrf2 pathway is not confined to the hepatocytes only, emphasising 
importance of CYP2A6s’ response to oxidative stress.    
 
2.4 The role of CYP2A6 against oxidative stress 
 
           As discussed in the section 2.3, the CYP2A6 enzyme is induced by multiple forms of 
stress and pathophysiological conditions such as microorganism infections, inflamed and 
cirrhotic livers, harmful alcohol consumption, and many structurally unrelated toxic 
chemicals (Kirby et al., 1996; Satarug et al., 1996; Raunio et al., 1998; Niemela et al., 2000; 
Fisher et al., 2009). The enzyme is highly expressed in the liver (Nakajima et al., 2006), and 
parts of lung, nasal mucosa, oesophagus, trachea and skin (Su et al., 1996; Koskela et al., 
1999; Janmohamed et al., 2001): sites typically exposed to high levels of oxygen and 
chemicals. Importantly, several studies have demonstrated that the CYP2A6 is regulated by a 
group of stress activated transcription factors (Christian et al., 2004; Pitarque et al., 2005; 
Yokota et al., 2011). This together with a recent finding that CYP2A6 regulates intracellular 
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BR levels (Abu-Bakar et al., 2012) suggest that the CYP2A6 may play a significant role in 
the cellular defense against oxidative stress.   
 
2.4.1 Oxidative stress 
 
            Cellular oxidative stress occurs when ROS levels overwhelm endogenous antioxidant 
defense systems, which leads to direct or indirect ROS-mediated damage of nucleic acids, 
proteins and lipids (Ray et al., 2012). ROS generation in mammalian cells is often mediated 
by their response to toxicants. During continuous metabolism of xenobiotics, the uncoupling 
process between substrates and CYP enzymes will emerge, leading to significant ROS 
generation in cells. The catalytic cycle of cytochrome P450s is illustrated in Figure 2.4. 
Binding of the substrate (SH) to a resting state of the low-spin ferric (Fe3+) enzyme (A) 
changes the spin state to a high-spin substrate bound complex (B). The Fe3+SH is reduced to 
a ferrous (Fe2+) state (C) by accepting the first electron from NADPH cytochrome P450 
reductase (CPR). An oxy-P450 complex (D) is formed after oxygen binding to the ferrous 
state, which is the last relatively stable intermediate in this cycle. A peroxo-ferric 
intermediate (E) is formed after the reduction of the oxy-P450 by receiving a second electron 
from CPR. This introduction of protons in the peroxo-ferric intermediate (E) splits the O-O 
bond and forms “oxenoid” compound (F) and water. The oxygenated substrate SOH is 
formed by insertion of the heam bound activated oxygen atom from the “oxenoid” compound 
(F) into the substrate, returning the enzyme to its initial state. In addition to the main reaction 
cycle, there are at least three side reactions occurring under physiological conditions. Firstly, 
the autoxidation of the oxy-ferrous enzyme (D) turns it back to its resting state and produces 
superoxide anion. Secondly, the coordinated peroxide or hydrogen-peroxide anion is 
dissociated from the iron to form hydrogen peroxide and thereby completing the 
unproductive (in relation to substrate turnover) two-electron reduction of oxygen. Thirdly, 
instead of oxygenation of the substrate, the ferryl-oxo intermediate (F) is oxidised to its ferric 
state through an oxidase uncoupling process (Denisov et al., 2005). A large amount of ROS is 
formed during this process.  
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Figure 2.4: Catalytic cycle of cytochrome P450 (CYP). Fe represents the iron atom of the 
prosthetic group of CYP; Substrate and its oxygenated product are shown as SH and SOH, 
respectively; ROS production in the cycle is indicated by red arrows (Adapted from Denisov 
et al., 2005).  
 
             In addition to xenobiotic metabolism, ROS can be produced through some other 
mechanisms depending on the tissue and cell types. It has been well demonstrated that the 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (containing 7 distinct 
isoforms) catalyse the transfer of electrons from NADPH to molecular oxygen across the 
plasma membrane thereby generating superoxide and other downstream ROS (Bedard and 
Krause, 2007). Some other oxidoreductases have also been found to contribute ROS 
generation in mammalian cells, which include (i) nicotinamide adenine dinucleotide 
(NADH): ubiquinone oxidoreductase, an enzyme involved in mitochondrial electron transport 
chain (ETC) (Lambert and Brand, 2004); (ii) nitric-oxide synthase, the catalyst for 
intracellular nitric oxide production (Förstermann and Sessa, 2012); and (iii) cyclooxygenase, 
an enzyme involved in biosynthesis of prostaglandins (Ricciotti and FitzGerald, 2011). 
Moreover, clearance of superoxide also produces ROS in cells. Superoxide has been found to 
be converted into hydrogen peroxide by superoxide dismutase (SOD) first, and is further 
metabolised by catalase and glutathione peroxidase (GPX) to water (Culotta, 2001). The 
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formed hydrogen peroxide and superoxide can generate a highly reactive hydroxyl radical 
through the Haber-Weiss reaction, which is another source of cellular oxidative stress 
(Kehrer, 2000).  
 
2.4.2 Bilirubin oxidase as part of an anti-oxidant complex against intracellular 
oxidative stress 
 
           The recent discovery of BR acting as a high affinity endogenous substrate for the 
CYP2A6 together with its regulation by several stress ─ activated signalling pathways has 
led to the hypothesis that CYP2A6 is a player in cellular defense against oxidative stress 
(Abu-Bakar et al., 2012). It has been well demonstrated that BR production is enhanced in 
response to oxidative stress. Haem oxygenase 1 (HMOX1), the enzyme that catalyses the first 
step in BR production from haem, is highly induced by a variety of physiological and non-
physiological stimuli that generate oxidative stress (Maines, 2005). These stimuli include 
inflammatory cytokines, bacterial endotoxin, ultraviolet-A radiation, sodium arsenite, 
ethanol, and cadmium  (Alam et al., 1989; Keyse and Tyrrell, 1989; Cantoni et al., 1991; 
Rizzardini et al., 1994; Gomes et al., 2010; Yeligar et al., 2010). Given that some of these 
agents are also known to induce CYP2A6 (Abu-Bakar et al., 2013) and that BR is an inducer 
and a substrate of CYP2A6 with a Km approximately one tenth of the cytotoxic concentration 
(Abu-Bakar et al., 2012), it is plausible that induction of CYP2A6 in response to oxidative 
stress is to mitigate oxidative damage by maintaining BR homeostasis. 
           This hypothesis has been well supported by studies on Cyp2a5 (mouse orthologue of 
human CYP2A6) gene regulation. The expression of CYP2A5 is regulated through both 
transcriptional and post-transcriptional mechanisms. Three oxidative stress related 
transcription factors ─ the AhR, Nrf-2 and hnRNPA1 ─ have been found to regulate the 
transcription of Cyp2a5 gene under oxidative stress conditions (Glisovic et al., 2003; Abu-
Bakar et al., 2007; Arpiainen et al., 2007). Alterations in cellular redox state by chemicals 
activate these factors, leading in their translocation and accumulation in nucleus, where they 
bind to their respective response elements and drive the transcription of the Cyp2a5 gene.  
          Additionally, the Cyp2a5 gene can be regulated at post-transcriptional level. The 
CYP2A5 mRNA can be stabilised by hnRNPA1 interacting with the 71 nucleotide long 
putative hairpin loop at the 3’-UTR of CYP2A5 transcript (Glisovic et al., 2003). The 
transcriptional and post-transcriptional mechanisms seem to be coordinated to induce 
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CYP2A5 in response to oxidative stress. Evidence suggest that the induced CYP2A5 is 
essential in the maintenance of cellular BR homeostasis and regulation of cellular redox 
balance. The “stress responding” cluster on the Cyp2a5 promoter region (Figure 2.5) plays a 
key role in the regulation of CYP2A5 expression (reviewed in Abu-Bakar et al., 2013).  
 
Figure 2.5: “Stress responding” cluster present on Cyp2a5 promoter region. The Cyp2a5 
gene expression is regulated by three stress activated transcription factors binding to its 
promoter region, including AhR, Nrf-2 and hnRNPA1. The abbreviations used in the diagram 
include: AhR (Aryl hydrocarbon receptor); Arnt (Aryl hydrocarbon receptor nuclear 
translocator); USF (Upstream stimulatory factor); Nrf-2 (Nuclear factor (erythroid-derived 
2)-like 2); PGC1 (Peroxisome proliferator-activated receptor-gamma coactivator-1); HNF-4α 
(Hepatocyte nuclear factor 4α); hnRNPA1 (Heterogeneous nuclear ribonucleoprotein A1); 
XRE (Xenobiotic responsive element); E-box (Enhancer box); ARE (Antioxidant response 
element); HNF-4αRE (HNF-4α response element); HnRNPA1RE (Heterogeneous nuclear 
ribonucleoprotein A1response element); TSS (Transcription start site).  
 
2.5 The p53 protein  
 
  Another important transcription factor that activates major signalling pathways in 
response to oxidative stress is the p53, a protein that has both pro- and anti-oxidant functions. 
Depending on the degree of cellular stress, p53 regulates genes that are important in the 
regulation of redox homeostasis, normal cell growth, cell death, and tumorigenesis (reviewed 
in Bensaad and Vousden, 2007). As the CYP2A6 has been suggested to play a role in cellular 
defense by contributing to bilirubin homeostasis (as discussed in section 2.2.4), and because 
its expression in response to oxidative stress is regulated by the Nrf2 and other stress 
activated TFs, it is plausible that p53 may be involved in the regulation of the CYP2A6 gene 
as well. This thesis will investigate the role of p53 in the regulation of CYP2A6 gene 
expression. 
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2.5.1 Structure and regulation of p53 protein  
 
           The tumour suppressor protein, p53, consists of 393 amino acid residues, and is 
encoded by the TP53 gene that resides on chromosome 17 p13.1 in humans. It is the most 
frequent target for mutation in human cancers (Olivier et al., 2010). The basic unit of p53 is a 
monomer, which contains an intrinsically disordered N-terminal transactivation domain 
(Met1-Asp42), a proline rich domain with multiple copies of PXXP sequence (Asp61-ser94), 
a central DNA binding core domain (Thr102-Lys292) and a C terminal domain (Pro301-
Asp393) including a tetramerization domain. The functional state of p53 is homo-tetramer 
(Saha et al., 2015).     
           The functional p53 tetramer has been shown to bind its target duplex DNA in a 
sequence-specific manner (Weinberg et al., 2004). The consensus p53 binding sequence is 
RRRCWWGYYY (R=A, G; W=A, T; Y=C, T), which can form a decameric motif (half-
site). Two decameric motifs separated by a spacer containing 0-13 base pairs are shown to act 
as a functional p53 binding element (el-Deiry et al., 1992). More recently, a genome-wide 
mapping of p53 binding sites found that most p53 response elements have consecutive half 
sites (Wei et al., 2006). It has been shown that an increase in spacer length between the 
decamer half sites correlates with a decline in p53 affinity and transactivation, as also shown 
for the TIGAR, Noxa and p21-5’ response elements (Jordan et al., 2008). The distance 
between a p53RE and the transcription start site (TSS) also has a significant impact on the 
p53- mediated gene transactivation. For example, inserting an additional 200 base pair 
segment between a p53RE and the TATA box significantly reduced the p53- mediated 
induction (Cook et al., 1995). The presence of cofactor sites and the p53RE occlusion by 
other proteins seem to have an essential role in regulating p53- mediated gene expression as 
well. It has been reported that p53 ─ dependent activation of human pro-apoptotic bcl-2 
associated X (BAX) and p53-up-regulated mediator of apoptosis (PUMA) genes require 
adjacent cofactor REs, Sp (specificity protein) families of transcription factors on their 
promoter regions. Mutations of the Sp response elements on their promoter regions totally 
wipe out the p53 ─ mediated gene transactivation but did not affect p53/DNA binding 
affinity (Thornborrow and Manfredi, 2001; Koutsodontis et al., 2005). This suggests that 
binding of p53 to DNA alone is not sufficient for p53 to activate a gene. 
            The intracellular expression of p53 is tightly regulated by posttranscriptional 
mechanisms (Xu, 2003). When cells are in a balanced stress condition, p53 is unstable and 
inactivated through its interaction with the p53 suppressor Mdm-2. Mdm-2 functions as an E3 
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ligase that ubiquitinates p53 for proteasome degradation (Haupt et al., 1997). However, when 
cells are in an unbalanced stress condition, p53 is modified post-translationally through 
methylation, acetylation, phosphorylation and sumoylation, which disrupts its binding to 
Mdm-2, and results in its activation and accumulation (Lu and Levine, 1995; Scolnick et al., 
1997; Neilsen et al., 2008).  
 
2.5.2 P53 activated signalling pathways  
 
  P53 has been found to regulate a host of processes within the cell. It can interact 
directly with pro-apoptotic factors to induce mitochondrial-dependent apoptosis or function 
as a transcription factor to regulate various genes on cellular processes (reviewed in 
Wakabayashi et al., 2010). Differential activation of p53 target genes is dependent on the 
different stages of oxidative stress (Liu and Chen, 2006). Generally speaking, p53 activates 
two broad categories of responses: anti-oxidant and pro-oxidant depending on the state of 
cells (Bensaad and Vousden, 2005).                                                                                                              
  During low levels of oxidative stress, p53 exerts primarily anti-oxidant role, in order 
to re-establish cellular homeostasis. Some of the p53 target genes, such as sestrin, aldehyde 
dehydrogenase (ALDH) and glutathione peroxidise (GPX) are induced under low oxidative 
stress to eliminate cellular ROS level. For instance, p53-regulated sestrins can generate 
peroxiredoxins, which protect cells from hydrogen peroxide induced damage (Budanov et al., 
2004). A p53 binding sequence has been identified on ALDH4 gene. GPX acts as a primary 
antioxidant enzyme, which scavenges organic hydroperoxides and hydrogen peroxide (Tan et 
al., 1999). Additionally, p53 was found to reduce intracellular ROS generation through the 
regulation of cellular metabolism. The expression of TP53-induced glycolysis and apoptosis 
regulator (TIGAR) is induced via p53, which directs glycolysis to an alternative pathway, the 
pentose phosphate pathway (PPP). PPP is a major source of NAPDH, which is needed for the 
formation of antioxidant glutathione (GSH) thereby reducing ROS levels (Tian et al., 1999). 
The expression of PGM (phosphoglyceratemutase), an antioxidant gene can be suppressed by 
p53, that enhances the glycolysis and decreases the requirement for mitochondrial respiration, 
resulting in less ROS production (Bensaad and Vousden, 2007). 
                When cells suffer from severe oxidative stress, p53 activates the expression of 
several genes that increase intracellular ROS levels (Polyak et al., 1997), thereby acting as 
pro-oxidant inducer. These genes include proline oxidase and p53 inducible gene-3 (PIG3) 
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(Polyak et al., 1997; Rivera and Maxwell, 2005). Overexpression of these proteins results in 
high levels of oxidative stress in cells. Moreover, BAX and PUMA are induced by the 
mediation of p53. This leads in the release of cytochrome C from mitochondrial which then 
triggers apoptosis (Macip et al., 2003; Liu et al., 2005). P53 is also known to inhibit the 
expression of several antioxidant genes, which leads to increased intracellular ROS and 
triggers apoptosis. Accordingly, p53 has been found to suppress the expression of SOD-2 and 
Nrf-2, triggering apoptotic process (Drane et al., 2001; Faraonio et al., 2006). 
 
2.6 Potential interplay among transcription factors in mediating CYP2A6 
gene expression  
 
          As discussed in section 2.3, the CYP2A6 transactivation is governed by a group of 
transcription factors binding to the promoter region. Many of them are stress activated. It is 
well known that transcriptional regulation of a gene often involves a complex interaction 
between the TFs and other factors such as cofactors or coactivators. Such interaction is 
essential for cells to maintain their optimal protein expressions. A crosstalk has been shown 
between the stress activated transcription factors Nrf-2 and p53 in their regulation of some 
stress responsive genes such as the X-CT, NQO-1 and GST1α1 (Faraonio et al., 2006). 
Similar interactions have been observed in the regulation of other genes. Therefore, it is 
plausible that an interplay among transcription factors may have a role in regulating the 
CYP2A6 as well, possibly to maintain its optimal expression when cells response to different 
degrees of stress.  
      
2.6.1 Nrf-2 and p53 cross talk in regulating stress responsive genes  
 
 Given the dual role of p53 in cellular response to oxidative stress and the fact that the 
Nrf2 primarily regulates antioxidant pathways, these transcription factors may interact in 
regulating cellular protection against oxidative damage.  
  For example, in response to mild oxidative stress, p53 enhanced the transcription of 
three Nrf2 target genes (X-CT, NQO-1 and GST1α1) through stabilisation of Nrf-2 binding to 
their AREs (Faraonio et al., 2006). These genes exert their anti-oxidative properties through 
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neutralising ROS. It has been hypothesised that in these conditions, a p53 target gene, p21 is 
activated and stabilises the Nrf2 by binding to Keap1 (Chen et al., 2009), which interferes 
with Keap1 ability to promote Nrf2 ubiquitylation and proteasomal degradation (Chen et al., 
2009). The disruption of Nrf2 turnover allows its nuclear translocation and subsequent 
transcription of ARE-driven genes, which then leads to a general cyto-protective response 
(Figure 2.6).  
 This hypothesis is supported by in vivo observations that: (i) the presence of p21 within 
cells is associated with prolonged Nrf-2 half-life (Chen et al., 2009); (ii) both the basal and 
induced Nrf2 expression levels are higher in the wild-type mice than in the p21-null mice 
(Chen et al., 2009); and (iii) the expressions of Nrf2 target genes, such as Nqo1 and Hmox1 
are higher in the wild-type mice than in the p21-null mice (Chen et al., 2009). By contrast, 
Nrf2 was shown to reduce p53 by regulating the basal expression of the murine double 
minute 2 (Mdm2), a protein that promotes proteasomal degradation of p53 (You et al., 2011). 
Collectively, these observations imply that the net result of the crosstalk between Nrf2 and 
p53 in response to mild oxidative stress is to promote transactivation of antioxidant genes and 
to maintain p53 at basal level in order to re-establish redox homeostasis and dampen 
apoptosis.  
 
Figure 2.6: Network of p53 and Nrf-2 in response to cellular stress. Exposure of cells to a 
low level of stress, p53 triggers cytoprotective mechanisms, which activate antioxidant gene 
expressions thereby removing intracellular ROS. Exposure of cells to a severe stress, leads 
p53 to act in a proapoptotic fashion, which inhibits the expression of antioxidant genes such 
as Nrf-2 and promotes pro-apoptotic gene expressions. This then leads ROS accumulation 
and apoptosis.  
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  On the other hand, in response to severe oxidative stress, cells invoke the strongest 
possible cell death signal by enhancing the expression of p53 and intracellular ROS 
generation (Figure 2.6). As suggested mechanism p53 directly interacts with ARE, the 
promoter element activated by Nrf2, displacing Nrf2 thus repressing Nrf2 target genes, such 
as Mdm2, NQO-1 and GST1α1 (Faraonio et al., 2006; You et al., 2011; Wang et al., 2012). 
Suppression of Mdm2 basal expression inhibits p53 proteasomal degradation, which leads to 
p53 accumulation (You et al., 2011). This, in turn results in the upregulation of proapoptotic 
genes, which enhance the intracellular ROS generation thereby inducing cell apoptosis 
(Pandhare et al., 2006). The excess ROS generated is not neutralised by Nrf2 target genes, 
NQO-1 and GST1a1 because of transcriptional interference by p53 (Faraonio et al., 2006).  
    
2.6.2 Interplay among transcription factors in mediating gene expression  
 
            Even though the stress related transcription factors Nrf-2 and p53 have been well 
demonstrated to interact in mediating some stress activated gene expressions, the potential 
mechanism(s) of crosstalk in mediating CYP2A6 gene expression is not clear. The 
interactions of other transcription factors that mediate CYP2A6 transactivation cannot be 
ignored. It has been shown that the constitutive CYP2A6 gene expression is governed by a 
group of transcription factors binding to the proximal CYP2A6 promoter region, including 
CAR, C/EBPα, C/EBPβ, Oct-1 and HNF-4α (Pitarque et al., 2005). Indeed, the CAR, 
C/EBPα and Oct-1 can be activated by different forms of stresses, as discussed in section 
2.3.1. It is likely that the stress activated p53 may also interact with these transcription factors 
in mediating the CYP2A6 gene expression.  
            Recent evidence have also shown that oxidative stress activated Nrf-2 overexpression 
in 3T3-L1 mouse pre-adipocytes has led to immediate induction of C/EBP-α and C/EBP-β 
proteins during the early events of adipogenesis (Hou et al., 2012). Human CYP2B6 
expression in HepG2 cells has been demonstrated to be regulated by the transcription factors 
C/EBP-α, HNF-4α and CAR in a synergistic regulatory pattern (Benet et al., 2010). 
Expression of CAR inhibits HNF-4α transactivation of CYP7A1 by competing with HNF-4α 
for binding to the DR-1 motif and to the common coactivator PGC-1α and GRIP-1 (Miao et 
al., 2006). Furthermore, ectopic expression of p53 in HepG2 cells has been found to repress 
HNF-4α expression through the binding of p53 to the HNF-4α P1 promoter, as well as by 
preventing HNF-6α (HNF-4α activator) binding to the HNF-4α P1 promoter (Maeda et al., 
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2006). Therefore, it is plausible that such interplay among transcription factors mediates 
CYP2A6 transactivation. The interplay of transcription factors that drive the proximal 
CYP2A6 gene expression will be addressed in this thesis. 
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3. RESEARCH PROBLEMS 
 
           As illustrated in the previous sections, CYP2A6 enzyme has been found to play a role 
not only in xenobiotic metabolism but also in cellular defense against various cellular 
stresses. This is supported by the following observations: (i) CYP2A6 expression is highly 
induced by a large number of structurally unrelated toxic insults or pathophysiological 
conditions (reviewed in Abu-Bakar et al., 2013); (ii) a group of stress activated transcription 
factors including Nrf-2, CAR, C/EBPβ and Oct-1 has been found to regulate CYP2A6 gene 
expression (Pitarque et al., 2005; Yokota et al., 2011); (iii) BR, a potent antioxidant, is 
enzymatically metabolised by CYP2A6 to biliverdin (BV), and back to bilirubin by biliverdin 
reductase (BVR) when needed (Abu-Bakar et al., 2012); (iv) CYP2A6 has been found to be 
highly expressed in the liver (Nakajima et al., 2006), bronchial epithelium, lung, nasal 
mucosa, oesophagus, trachea and skin (Su et al., 1996; Koskela et al., 1999; Janmohamed et 
al., 2001; Oyama et al., 2006), where these organs often suffer a high level of oxygen and 
chemical exposures. Why CYP2A6 is highly expressed in these organs? Could it be that the 
purpose is to maintain BR homeostasis and thereby a balanced cellular redox state? In other 
words, could the high expression of the enzyme in these organs plays a role in maintaining a 
suitable intracellular redox level?  
           Importantly, the stress activated transcription factor, p53 has also been found to 
regulate some hepatic CYP genes involved in various metabolic pathways (Goldstein et al., 
2013; Wohak et al., 2014). Eleven members from five different CYP subfamilies were 
induced by p53 (Goldstein et al., 2013). These include CYP4Fs and CYP19A1, enzymes that 
metabolise lipids and sex steroids, respectively (Goldstein et al., 2013); and CYP21A2, a 
catalyst of glucocorticoid synthesis (Goldstein et al., 2013). These findings align with recent 
advancement in p53 research that acknowledges a critical role for p53 in regulating 
metabolism and maintaining cellular homeostasis (Meek, 2015). P53 role in regulating drug 
metabolism was acknowledged in a recent work demonstrating direct p53 interaction on the 
p53REs of the CYP3A4 promoter, leading to transactivation of the gene (Goldstein et al., 
2013). The p53-dependent activation of CYP3A4, the main enzyme responsible for clearing 
chemotherapeutics, was heightened following a chemotherapeutic stimulus (Goldstein et al., 
2013). This observation indicates a systemic role for p53 in response to chemotherapy. 
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            Intriguingly, the sequence analysis of CYP2A6 promoter region has revealed several 
putative p53 response elements, which suggest a potential role for p53 in regulating CYP2A6 
(Figure 3.1). As CYP2A6 is not a major drug metabolising enzyme, what is the physiological 
significance of the possible p53-mediated transactivation of CYP2A6? Could the elevated 
p53 levels by chemical exposures under stresses form a part of cyto-protective machinery to 
induce the CYP2A6 expression in order to maintain BR homeostasis?  
    
Figure 3.1: Putative p53REs and the functional ARE present on the CYP2A6 promoter 
regions from -2901 to +9. 
 
3.1 Research questions  
 
           Preliminary sequence analysis of the CYP2A6 promoter revealed several putative p53 
binding sites for p53. Five of them were identified on the distal CYP2A6 promoter region 
spaning from -2901 to -437bp. One putative p53RE with the highest sequence similarity 
compared to the consensus p53RE was detected at the proximal CYP2A6 promoter region at -
122 bp (Figure 3.1). However, it is unclear whether these putative p53REs are functional or 
not. As discussed in section 2.3, a group of stress activated transcription factors has been 
found to regulate the CYP2A6 gene expression, and its basal expression is governed by the 
interplay between HNF-4α, C/EBPα, C/EBPβ and Oct-1 binding to the proximal CYP2A6 
promoter (Pitarque et al., 2005; Yokota et al., 2011). Interestingly, the putative p53RE at the 
proximal promoter is only five base pair upstream of the TFs that govern the constitutive 
CYP2A6 gene expression. It is plausible that these TFs may interact in mediating CYP2A6 
transactivation.  
           Yokota et al., (2011) demonstrated that Nrf-2 has a role in mediating CYP2A6 gene 
expression when cells suffer from unbalanced oxidative stress. They found that the basal 
expression of the distal CYP2A6 promoter was significantly weaker than that of proximal 
CYP2A6 promoter (Yokota et al., 2011), which is in accordance with previous findings on 
potential suppressor region(s) upstream the CYP2A6 promoter (Pitarque et al., 2005; Itoh et 
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al., 2006; Higashi et al., 2007).  However, the potential suppressor(s) region in blocking 
CYP2A6 transactivation and the significance of the suppressive effect in response to cellular 
stresses are currently unknown. A cross-talk between Nrf-2 and p53 in regulating stress 
responsive genes when cells deal with the different levels of oxidative stresses has been 
elucidated (as discussed in section 2.6.1). Notably, the functional ARE (Nrf-2 binding site) 
on the CYP2A6 promoter is in close proximity to one of the putative p53RE (Figure 3.1), 
suggesting a potential interaction between p53 and Nrf-2 in regulation of CYP2A6 gene 
expression. To investigate the underlying mechanisms of the CYP2A6 gene regulation, 
especially at stress conditions, some specific questions have been raised, including:  
(1) If the p53 is also involved in the regulation of CYP2A6 gene expression, in what 
conditions is the p53 activated?  
(2) How does the p53 drive the CYP2A6 gene expression?  
(3) Are other (co-)factors required for p53- mediated CYP2A6 transactivation?  
(4) Are there any interactions between these transcription factors in mediating CYP2A6 
gene expression?  
(5) What is the significance of the p53- mediated CYP2A6 gene expression?  
(6) What types of suppressor factors may be present on CYP2A6 promoter to mediate the 
CYP2A6 downregulation?  
(7) What is the significance of the CYP2A6 downregulation in term of cellular defense 
against cellular stresses?  
(8) Could there be interaction between Nrf-2 and p53, which may mediate the observed 
downregulation of CYP2A6 gene expression?  
 
3.2 Working hypotheses  
 
          Owing to the current advancement on the CYP2A6 gene regulatory mechanisms and the 
recent finding of BR as a high affinity endogenous substrate of CYP2A6, the enzyme now is 
recognised as a stress responsive gene, which may exert a role in regulating cellular stress 
through the regulation of BR-BV pathway. Importantly, several putative binding sites 
responsive to the stress activated p53 have been identified on the CYP2A6 promoter region. 
However, it is not well understood how the enzyme is regulated by these sites during cellular 
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perturbations. To have an insight into the stress activated transcription factor mediated 
CYP2A6 transactivation, several hypotheses have been established, including:  
 
(1) Bilirubin oxidase CYP2A6 is an immediate target gene of the stress activated 
transcription factor p53;   
(2) Chemically induced  p53 expression activates CYP2A6 gene expression; 
(3) CYP2A6 gene transactivation is achieved through an interplay between transcription 
factors binding to the promoter region;  
(4) Stress activated transcription factors - Nrf-2 and p53 interact in regulating CYP2A6 
gene expression.  
(5) Presence of suppressive element(s) on the distal CYP2A6 promoter region block(s) 
CYP2A6 gene transactivation; 
 
           Addressing these hypotheses will help to better understand the mechanism behind 
previous observations where the CYP2A6 is induced by a multitude of seemingly 
unrelated external insults.  
           Finally, it has been shown that elevated serum bilirubin levels negatively associate 
with the incidence of many chronic diseases including diabetes, aging, neurodegenerative 
disorder, cardiovascular disease, ischemic heart disease and cancer (Vitek et al., 2002; 
Rao et al., 2006; Kim and Park, 2012; Boland et al., 2014; Jorgensen et al., 2014; Jung et 
al., 2014). Given that the CYP2A6 plays an essential role in maintaining intracellular BR 
homeostasis, understating the mechanisms of CYP2A6 induction may possibly open new 
strategies for intervention.  
          In addition, as the CYP2A6 can be induced by a large number of toxic insults, 
understanding the underlying mechanisms may offer a possibility for applying the 
CYP2A6 promoter as an intracellular stress sensor to assess the biological response of 
toxic chemicals, and to develop in vitro bioassays for monitoring of toxic side effects of 
drugs under development.  
 
3.3 Research strategies  
 
In order to address the hypotheses, the following research strategies have been adapted:  
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A)  Study on the role of p53 in mediating CYP2A6 gene expression  
 
Aim  
i) Identification of region(s) on the CYP2A6 promoter mediating p53 
transactivation; 
ii) Establishment of cell models; 
iii) Verification of the functionality of the putative p53REs on the CYP2A6 promoter 
region.  
 
Experimental procedures:  
Two cell models were established: the human hepatoma derived cell line (C3A) and 
human breast adenocarcinoma cell line (MCF-7). A series of 5’-truncated CYP2A6 
promoter constructs were amplified through PCR technique and were inserted into a 
vector plasmid pGL3-Basic respectively. The generated pGL3-CYP2A6-Luc promoter 
constructs together with pcDNA3-hp53/pcDNA3 and pMAX-GFP were co-
transfected into C3A cells respectively to detect the possible p53 responsive region on 
the CYP2A6 promoter. The detected p53RE on the CYP2A6 promoter region was 
mutated by a site directed mutagenesis method. The p53RE mutated CYP2A6-Luc 
constructs were co-transfected with pcDNA3-hp53/pcDNA3 and pMAX-GFP into 
C3A cells to confirm the functionality of the putative p53RE. Luciferase activities of 
these CYP2A6-Luc constructs were normalised by internal control GFP activities. The 
p53 expression levels in both the pcDNA3-hp53 transfected cells and the empty 
vector (pcDNA3) transfected cells were detected by Western Immunoblotting. 
Detailed procedures are discussed in Chapter 4.  
 
B)  Study on binding of p53 to its response element on CYP2A6 promoter region 
 
Aim 
i) To harvest the recombinant p53 from the nuclear fraction of pcDNA3-hp53 
transfected C3A cells for EMSA analysis; 
ii) To synthesise probes containing the putative p53RE for EMSA analysis; 
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iii) To verify whether the p53 induced CYP2A6 transactivation is through direct 
binding of p53 to p53RE on CYP2A6 promoter region.  
 
 Experimental procedures:  
A recombinant p53 protein was produced by transfecting pcDNA3-hp53 into the C3A 
cells, which was then extracted from the nuclei of the transfected cells by using a pre-
established method. The harvested recombinant p53 was subjected for EMSA study. 
A series of CYP2A6 probes containing the putative p53RE were synthesised by PCR 
technique. EMSA analysis by incubations of the CYP2A6 probes with the 
recombinant p53 was used to detect the direct binding of p53 to p53RE on CYP2A6 
promoter region. The specificity of the binding was demonstrated by using a 
monoclonal p53 antibody that specifically recognises the formed DNA-protein 
complex. Excess unlabelled CYP2A6 probe and unlabelled consensus p53 
oligonucleotides were used in competition assays to compete out the formed DNA-
protein complex (outlined in Chapter 4).  
 
C) Study on BaP induced p53 in activation of CYP2A6 and HMOX1 gene 
expressions in MCF-7 and C3A cells  
 
Aim 
i) To detect whether the BaP treatment can induce the endogenous p53 expression 
in MCF-7 cells;  
ii) To detect whether the endogenous p53 induced by BaP has a regulatory role in 
activation of the proximal CYP2A6 promoter in MCF-7 cells; 
iii) To evaluate potential effects of BaP on hepatic expression of p53, HMOX1 and 
CYP2A6 mRNA and protein. 
 
            Experimental procedures:  
MCF-7 and C3A cells were treated by using various concentrations of BaP 
respectively. Cytosolic and nuclear fractions were extracted from treated and non-
treated cells by using a pre-established method. Total RNA was extracted from treated 
and non-treated C3A cells. Specific proteins and mRNA contents were detected by 
Western Immunoblotting and qRT-PCR techniques respectively. P53RE positive 
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control construct, intact CYP2A6-Luc construct and putative p53RE mutated CYP2A6-
Luc constructs were transfected into MCF-7 cells respectively followed by BaP 
treatments. Luciferase activities driven by the p53RE positive control, intact CYP2A6 
promoter and p53RE mutated CYP2A6 promoter were measured after normalisation 
with internal control GFP activities. Detailed procedures are described in Chapter 4.  
 
D)  Study on transcription factor interactions in mediating CYP2A6 transactivation  
 
Aim 
i) To verify direct binding of transcription factors p53, CAR, C/EBPα, Oct-1 and 
HNF-4α to the proximal CYP2A6 promoter region;  
ii) To determine the role of transcription factors p53, CAR, C/EBPα, Oct-1 and 
HNF-4α in regulating the proximal CYP2A6 gene transactivation; 
iii) To evaluate the role of each RE on the proximal CYP2A6 promoter in mediating 
the CYP2A6 gene transactivation;  
iv) To investigate whether the p53 ─ mediated CYP2A6 transactivation involves 
interactions with the other factors;   
v) To explore the potential crosstalk between p53 and Nrf-2 in regulating CYP2A6 
gene expression.  
 
            Experimental procedures:  
Binding of transcription factors p53, CAR, C/EBPα, Oct-1 and HNF-4α to the 
proximal CYP2A6 promoter was confirmed by EMSA analysis. CYP2A6-160/+9-Luc 
construct was co-transfected with p53, C/EBPα, Oct-1 and HNF-4α expression 
plasmids respectively into C3A cells to validate their roles in regulation of CYP2A6 
transactivation. The expression of these TFs in transfected cells was detected by 
Western Immunoblotting. The REs on proximal CYP2A6 promoter were mutated 
individually and in combination followed by transfection of the RE mutated 
constructs into C3A cells to detect the role of each RE in mediating CYP2A6 
transactivation. The involvement of other factors in p53- mediated CYP2A6 
transactivation and the potential crosstalk between p53 and Nrf-2 in regulating 
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CYP2A6 gene expression was demonstrated by a series of co-transfection 
experiments, which are described in Chapter 4.  
 
E) Exploring the potential suppressor region(s) on distal CYP2A6 promoter 
 
Aim 
To explore potential suppressor region(s) on the CYP2A6 promoter. 
 
            Experimental procedures:  
A series of 5’-truncated CYP2A6-Luc constructs with 200-300bp intervals were 
generated by using PCR technique and inserted into pGL3-Basic plasmid 
respectively. The basal expression profile of each CYP2A6-Luc construct was 
assessed by co-transfection of each CYP2A6-Luc construct together with pMAX-GFP 
plasmid (transfection control) into C3A cells. Detailed procedures are shown in 
Chapter 4.  
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4. MATERIALS AND METHODS  
 
4.1 List of materials and instruments  
 
          A list of materials and instruments is in Appendix A 
 
4.2 Cell culture and maintenance  
 
           Human hepatocellular carcinoma cells (C3A and HepG2) and human breast 
adenocarcinoma cells (MCF-7) were selected for gene regulation studies. The cells were 
propagated in T75 flasks in William’s Medium E containing 10% FBS, 1% Glutamax and 1% 
Penicillin-Streptomycin. The MCF-7 cells were grown in Dulbecco's Modified Eagle 
Medium supplemented with 10% FBS, 1% Glutamax and 1% Penicillin-Streptomycin. The 
cells were maintained in a humidifier incubator at 37°C in 5% CO2 and were sub-cultured at 
least two times per week. Cells with passage number between 5 and 15 were used in all 
studies. 
 
4.3 Molecular biological techniques  
 
4.3.1 Computer based promoter analysis  
 
           A computer based software “MatInspector” (http://www.genomatix.de/) was used to 
predict the putative TF binding sites on the CYP2A6 promoter region. Several regions of the 
CYP2A6 promoter containing high sequence similarity with the 10 bp consensus p53RE [5’-
RRRC(A/T)(T/A)GYYY-3’] were found, where “R” represents purine and “Y” represents 
pyrimidine (el-Deiry et al., 1992). Five putative distal sites were identified at positions -2582, 
-2461, -2208, -1617, -1056, and one putative proximal site at position -122 (Figure 3.1). 
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4.3.2 5’-truncated CYP2A6 promoter constructions 
 
          The CYP2A6 5’-flanking region -2901/+9 was amplified from a human DNA sample 
using high-fidelity PCR polymerase and cloned in front of the luciferase cDNA in pGL3-
Basic vector (Promega, Madison, WI). A series of 5’-truncated fragments of the CYP2A6 
promoter was produced by PCR amplification using the cloned longer construct as template 
and were cloned in front of the luciferase cDNA in pGL3-Basic vector (Appendix E). The 
primers used for amplification are listed in Appendix H. The generated 5’-truncated CYP2A6 
promoter constructs were transformed into XL-1 blue competent cell (Agilent technologies 
Inc., CA, USA). Detailed procedures can be found in Appendix B. The propagated plasmids 
were purified by using QIAGEN Plasmid Midi Kit according to manufacturer’s instructions 
(QIAGEN, Hilden, Germany) and were dissolved in UltraPure RNAse and DNAse free water 
(Thermo Fisher Scientific, Australia). DNA sequences of all constructed plasmids were 
verified by using gene sequencing facility at Australian Genome Research Facility (AGRF, 
Brisbane, Australia) (Appendix C). Plasmid concentrations were measured by NanoDrop 
1000 Spectrophotometer (Thermo Fisher Scientific, Australia) according to manufacturer’s 
instructions. 
 
4.3.3 Site directed Mutagenesis 
 
           In paper I, the putative p53 site on the proximal CYP2A6 promoter was analysed by 
site-directed mutagenesis. The core sequence of the site 5’-
ATTCATGGTGGGGCATGTAG-3’ (core sequences, bold) was mutated to 5’-
ATTACCAGTGGGGATCCTAG-3’ (mutated sequences, underlined) by the two steps PCR. 
The CYP2A6 constructs from -2901 or -250 to the p53RE mutated sites were amplified from 
the template plasmid CYP2A6 5’ -2901/+9 and CYP2A6 5’ -437/+9 by priming with the 
forward primers CYP2A6 5’-2901 FW or CYP2A6 5’-250 FW and reverse primer CYP2A6-
p53mut RV (Appendix H). The CYP2A6 construct from p53RE mutated site to +9 was 
amplified from the template plasmid CYP2A6 5’ -437/+9 by priming with the forward primer 
CYP2A6-p53mut FW and the reverse primer CYP2A6 5’+9 NheI RV (Appendix H). Equal 
amount of PCR products from the two reactions were mixed together to be used as a template 
to amplify the mutated p53RE. The CYP2A6-160/+9 construct containing the mutated p53RE 
was generated by priming with forward CYP2A6 5’ -160 KpnI FW and reverse primer 
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CYP2A6 5’+9 NheI RV (Appendix H). The CYP2A6-2901/+9 construct containing the 
mutated p53RE was generated by priming with forward CYP2A6 5’ -2901 KpnI FW and 
reverse primer CYP2A6 5’+9 NheI RV (Appendix H). The CYP2A6 constructs containing the 
mutated p53RE were ligated to the pGL3-Basic plasmid, respectively (Appendix E).  
           In paper II, the same method was applied to generate DR-4RE, C/EBP-Oct-1RE and 
HNF-4αRE mutated proximal CYP2A6 promoter constructs (Appendix E), where the DR-
4RE (5’-AGGTGAAATGAGGTAA-3’) was mutated to 5’-CCCCGAAATGAGGTAA-3’, 
the C/EBP-Oct-1RE (5’-GTAATTATGTAAT-3’) to 5’-GTAACACGAATTC-3’ and the 
HNF-4αRE (5’-CAGCCAAAGTCCA-3’) to 5’-CAGCCAACGTCTC-3’(mutated bases 
underlined, Appendix D). Additionally, the putative p53RE (5’-
ATTCATGGTGGGGCATGTAG-3’) was mutated to a consensus p53RE (5’-
AGACATGCCTAGACATGCCT-3’) on the proximal CYP2A6 promoter (mutated based 
underlined, Appendix D). The validity of these mutated REs on the CYP2A6 5’- promoter 
constructs was confirmed by gene sequencing (Appendix C). The primers used for site 
directed mutagenesis of these CYP2A6 promoters were obtained from Sigma-Genosys 
(Sydney, Australia), and are shown in Appendix H.  
 
4.3.4 Transient transfection assays 
 
           In paper I, the generated CYP2A6-5’-Luc and p53RE mutated CYP2A6-5’-Luc 
constructs were transiently transfected into C3A cells, either alone or co-transfected with the 
human p53 expression plasmid (pcDNA3-hp53) (Christian et al., 2008) or the empty 
expression plasmid pcDNA3.  
           In paper II, the expression plasmids including p53, CAR, C/EBPα, Oct-1 and HNF-4α 
were co-transfected with CYP2A6 -160/+9-Luc construct respectively into C3A cells.  A 
series of RE mutated CYP2A6 -160/+9-Luc constructs were transiently transfected into C3A 
cells. They were also co-transfected with either the pcDNA3-hp53 or pcDNA3 into C3A 
cells. The pGL3-Basic containing a SV-40 promoter was used as a control for transfection. 
The pGL4.38 [luc2P/p53 RE/Hygro] vector containing consensus p53RE (Promega, 
Madison, WI) was used as a positive control to indicate the ectopically expressed p53 in C3A 
cells (Paper I & II).    
           Polyethylenimine (PEI) (Polysciences Inc., PA, USA) was used to transiently transfect 
cultured cells with the various promoter constructs. PEI stock solution (1 μg/μl) was prepared 
39 
 
by dissolving 100 mg of PEI in 100 ml of sterilised water at 50°C and pH adjusted to 7 with 
HCl. The solution was passed through a 0.22 μm filter (Millipore, USA) and stored at -80°C. 
The PEI solution was warmed up to room temperature before being added to DNA plasmid 
solution at DNA:PEI ratios of 1:2 for C3A cells. The DNA-PEI mixture was then incubated 
at room temperature for 15 min before being added to each well of the 24-well plates. 
          Cells were seeded in 24-well plates (1.2 × 105 cells/well) for 24 h. Thereafter, the cells 
were washed once in 500 µl PBS, followed by addition of 500 µl of fresh FBS-free medium 
to each well. 0.3 µg of CYP2A6-5’-Luc constructs and 0.1 µg of pMAX-GFP (transfection 
control) were co-transfected into C3A cells (Paper II). The cells were also co-transfected with 
0.1 µg of pMAX-GFP, 0.1 µg of pcDNA3 or transcription factor expression plasmids, and 
0.3 µg of CYP2A6-5’-Luc constructs (Paper I & II). The transfected cells were incubated for 
24h in a humidifier incubator at 37°C in 5% CO2. Thereafter, the luciferase activity was 
measured (BriteliteTMplus Reporter Gene Assay System, PerkinElmer, USA). Transfection 
under each condition was performed in quadruplets. The fluorescence and luminescence 
signals were captured on a FLUOstar Omega multimode microplate reader with automatic 
gain settings.  
 
4.3.5 Synthesis of digoxigenin labelled probes  
 
           In paper I, double-stranded DNA corresponding to the region between -149 and -55 bp 
of the 5’-flanking CYP2A6 promoter was generated by PCR technique. The probe was 
amplified by the primer 1 and primer 2 (Appendix H). The primers, double-stranded 
oligonucleotides of putative and consensus p53RE and of the -127 to -98 bp region of the 5’-
flanking CYP2A6 promoter (Probe 2) were obtained from Sigma-Genosys (Sydney, 
Australia). CYP2A6 promoter probes used in paper I are illustrated in Figure 4.2 and listed in 
Appendix H. 
            In paper II, a series of probes corresponding to the response elements that govern the 
proximal CYP2A6 gene expression were obtained from Sigma-Genosys (Sydney, Australia). 
Those include CYP2A6-5’-127/-98, CYP2A6-5’-103/-80, CYP2A6-5’-92/-65 and CYP2A6-5’-
77/-53 (Appendix H). The probes used both in paper I and paper II were labelled with 
digoxigenin on the 3’ end of the oligonucleotide by using DIG gel shift kit (Roche, 
Germany).   
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Figure 4.1: Schematic representation of synthesised CYP2A6 promoter probes used in 
EMSA (Paper I). Solid arrows indicate the synthesised probe1 and probe 2. Open box 
represents putative p53RE on CYP2A6 promoter region.  
 
4.3.6 Electrophoretic mobility shift assay 
 
           In paper I and paper II, 32 fmol/µl of digoxigenin-labelled probe was incubated with 
16 µl of binding buffer (20 mM Hepes pH 7.6, 1 mM EDTA, 10 mM (NH4)2SO4, 1 mM 
DTT, 0.2% Tween 20, 30 mM KCl) and 4 µg of nuclear protein for 15 min at room 
temperature. The nuclear proteins were extracted from C3A cells transfected with p53, CAR, 
C/EBPα, Oct-1 and HNF-4α expression plasmids, respectively. In antibody shift assay, 1 µl 
of anti-p53, CAR, C/EBPα, Oct-1, HNF-4α or Nrf2 antibody was added to their respective 
reaction mixtures and was incubated for 15 min. The samples were loaded to a pre-
electrophoresed, non-denaturing 4-15% polyacrylamide gel in 0.5 × TBE buffer (44 mM 
Tris-HCl, pH 8, 44 mM boric acid, 1 mM EDTA). Samples were separated 
electrophoretically at 80V for 1 h and transferred onto a positive-charged nylon membrane 
Hybond-N (Amersham Biosciences, UK, Ltd) by an electro-blotting device (Bio-Rad 
Laboratories, USA) set at 1 h at 30V, 300 mA. Thereafter, the membrane was baked at 140oC 
for 15 min and crosslinked in a UV StratalinkerTM 1800 (Integrated Sciences, Australia) at 
120 mJ. The membrane was briefly rinsed for 3 min in washing buffer (0.1 M Maleic acid, 
0.15 NaCl, pH 7.5, 0.3% Tween 20) and was blocked in blocking solution for 30 min before 
immunological detection. The digoxigenin-labelled probes on the membrane were detected 
by incubating the membrane with an anti-digoxigenin-AP antibody (1:10,000). The 
chemiluminescence signals of the labelled probes were captured by ChemiDoc™ MP 
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imaging system after applying the alkaline phosphatase substrate CSPD on the membrane. In 
paper I, competition binding assay was performed to validate the specificity of protein–DNA 
interactions. 125-fold molar excess of unlabelled CYP2A6 probe I and increasing 
concentrations of unlabelled consensus p53 oligonucleotides were added to their respective 
incubation mixtures. The double-stranded consensus p53 oligonucleotide 
5’AGACATGCCTAGACATGCCT 3’ (core sequences underlined) was used as positive 
control for p53 specific binding.  
 
4.4 Biochemical procedures  
 
4.4.1 BaP treatment of the transfected MCF-7 cells 
 
         In paper I, the MCF-7 cells were seeded in 24-well plates at 1.2 × 105 cells/well and 
100 mm culture dish (Corning, USA) at 3 × 106 cells/well for 24 h. Cells in the 24-well plates 
were co-transfected with pMAX-GFP and pGL4.38 [luc2P/p53 RE/Hygro] or CYP2A6-5’-
Luc constructs at a fixed DNA:PEI ratio of 1:8. Each plasmid used was at 100 ng per well or 
2.5 µg per dish. The cells were transfected for 4 h before being treated with various 
concentrations of BaP dissolved in DMEM containing 10% charcoal stripped FBS, 1% 
Glutamax, 1% Penicillin-Streptomycin, and 0.1% DMSO. Twenty four hours after treatment 
luciferase activity was measured and nuclear proteins extracted. 
 
4.4.2 Protein analysis 
 
          In paper I and paper II, endogenous expression of p53 and HNF-4α in MCF-7 cells, 
endogenous expression of p53, CYP2A6 and HMOX1 in C3A cells, and over-expression of 
p53, CAR, C/EBPα, Oct-1 and HNF-4α in C3A cells was assessed by Western blotting. 
Nuclear and cytoplasmic extracts from cultured cells were prepared as described previously 
(Abu-Bakar et al., 2007). Cultured cells were harvested in ice cold PBS. Cell fractions were 
isolated by using cell separation buffers and centrifugation techniques, and were stored at -
80oC (Appendix F). Protein concentrations of the subcellular fractions were measured by 
using the DC protein assay kit (Bio-Rad Laboratories, USA); A 30 µg protein sample was 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The 
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proteins were electrophoretically transferred onto a Hybond ECL nitrocellulose membrane. 
The proteins were immunoblotted by specific antibodies, including mouse monoclonal anti-
p53, anti-HMOX1, anti-CYP2A6, anti-C/EBPα, anti-Oct-1 antibodies, and rabbit polyclonal 
anti-HNF-4α and anti-CAR antibodies. The formed protein-antibody complexes were 
visualised by a chemiluminescent substrate (Appendix G).   
 
4.4.3 RNA extraction and mRNA analysis 
 
            In paper I, total cellular RNA was extracted from C3A cells with TRIzol reagent 
(Gibco, Australia) in accordance with the manufacturer’s protocol. RNA was resuspended in 
20 µl DEPC-treated water, and its concentration was determined by NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Australia) at wavelength 260 and 280 nm. 
Total RNA was treated with RNA-free DNase prior to mRNA measurement by quantitative 
real time RT-PCR. One microgram of total RNA from the control and treated C3A cells was 
used to synthesise first-strand cDNA with the Invitrogen SuperScript®III First-Strand 
Synthesis kit (Life Technologies, Vic, Australia). Two microliters of the cDNA solution was 
used as template in 20 µl PCR mixture containing 10 µl of the 2 X iQ SYBR Green Supermix 
(Bio-Rad Laboratories, USA) and 2 µl of each reverse and forward primers (0.2 µM final 
concentration) (Appendix H). The PCR mixtures were incubated at 95oC for 3 min, followed 
by 40 cycles of 95oC for 20s and 63.2oC (for CYP2A6 primers), 65.7oC (for HMOX1 
primers),  or 60.4oC (for GAPDH primers) for 1 min in Corbett RotorGene 3000 (QIAGEN, 
Germany). The specificity of the PCR products was confirmed by melt curve analysis and 
amplicon size (2.5% agarose gel electrophoresis). 
 
4.5 Statistical analysis  
 
             Densitometric analysis of protein expression levels was conducted by using the 
software NIH imageJ 1.49. Two group comparisons were conducted by Student’s t test. 
Multiple group comparisons were done with one-way analysis of variance (ANOVA) 
followed by the least significant difference post hoc test. Differences were considered 
significant when p < 0.05. 
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5. RESULTS AND DISCUSSION 
 
5.1 Cell models for gene regulatory study (Paper I & Paper II) 
 
            The use of immortalised cell lines as in vitro models has been invaluable in studying 
gene regulation mechanisms because cell lines have unlimited life span, are always available 
and have a more stable phenotype than primary culture cells. Despite the obvious advantages, 
perturbations in gene expression pattern as compared to primary cells cannot be ignored. For 
instance, the expression pattern of CYP enzymes in hepatoma cells is significantly altered 
compared to that of primary hepatocytes. The alterations in the expression of key 
transcription factors dramatically reduced the expression of some CYP enzymes in hepatoma 
cell lines (Rodriguez-Antona et al., 2002). Therefore, selecting suitable cell lines for gene 
regulation studies should be carefully considered depending on the research purposes. 
CYP2A6 enzyme has been found to be highly expressed in liver and sex steroid-responsive 
tissues such as breast, ovary, uterus, testis, and adrenal gland (Nakajima et al., 2006). It is 
reasonably expressed in human hepatocarcinoma cell lines HepG2 and C3A and in human 
breast adenocarcinoma cell line MCF-7 (Higashi et al., 2007).  Therefore, these cell lines 
were selected for the studies.   
          The p53 responsiveness of the CYP2A6 promoter was assessed by co-transfection of 
pcDNA3-hp53 together with CYP2A6-Luc constructs in the three cell lines. The positive p53 
responsiveness of the CYP2A6 promoter was clearly observed in all three (Figure 5.1), 
suggesting that the p53 has a role in regulating CYP2A6 transactivation, and that the p53- 
mediated CYP2A6 transactivation is not cell specific. The C3A cells were chosen for further 
regulatory studies because p53 overexpression was the strongest in them, and because it was 
challenging to achieve consistent induction of the CYP2A6-Luc constructs in HepG2 cells.  
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Figure 5.1 Effect of p53 co-transfection on CYP2A6 distal and proximal promoter 
driven luciferase activities in MCF-7, C3A and HepG2 cells. Both the distal and the 
proximal CYP2A6 promoters were co-transfected with either pcDNA3-hp53 or pcDNA3 
empty vector, and pMAX-GFP into the three human cell lines. pGL4.38-p53RE containing 
consensus p53RE served as positive control to indicate p53 overexpression in these cell lines. 
Promoter less pGL3-Basic plasmid was used as negative control for the cell transfection. The 
firefly luciferase activities were measured 24 h after transfection. The measured activites 
were normalised against pMAX-GFP activity (transfection control plasmid) = RLA. The 
values (n = 4) represent means ± S.D. Fold induction of RLA = RLA of p53 co-transfected 
cells/ RLA of transfected cells. 
 
5.2 Bilirubin oxidase CYP2A6 is regulated by the stress activated 
transcription factor p53 (Paper I) 
 
5.2.1 CYP2A6 putative p53REs are responsive to p53  
 
Sequence analysis of the CYP2A6 promoter to detect putative p53RE 
 
           Sequence analysis of the CYP2A6 promoter region by a computer based program 
MatInspector (https://www.genomatix.de) revealed several putative p53REs (Figure 5.2A). 
These sites appear to be similar to the 10 bp consensus p53RE [5’-RRRC(A/T)(A/T)GYYY-
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3’], where “R” represents purine and “Y” represents pyrimidine. A functional p53RE in the 
genomes of many organisms is composed by two copies of half site 5’-
RRRC(A/T)(A/T)GYYY-3’, separated by a 0-21 base pairs spacer (el-Deiry et al., 1992). It 
has also been shown that a repeated 5’-RRRCATGYYY-3’ motif is favourable for p53 
binding (Osada et al., 2005). X-ray crystallography studies of the p53/p53RE DNA 
interaction indicated that the central core sequences “C(A/T)(A/T)G” are important for 
interactions with p53 (Cho et al., 1994). Five distal putative p53REs containing single 
“C(A/T)(A/T)G” sequences were identified at positions -2582, -2461, -2208, -1617 and -1056 
of the CYP2A6 promoter (Figure 5.2B). In addition, one proximal putative p53RE with the 
highest sequence similarity compared to the consensus p53RE was identified at position -122 
(Figure 5.2B). This site is adjacent to the REs that govern the constitutive CYP2A6 gene 
expression (Figure 5.2A). Therefore, in this thesis, the role of p53 in regulating CYP2A6 gene 
expression via the proximal site and its interactions with the other transcription factors was 
investigated in detail.  
A) 
 
B) 
    
Figure 5.2: Schematic representation of putative p53 REs on CYP2A6 promoter region. 
(A) Schematic diagram of the 2.9 kb CYP2A6 promoter indicating the putative p53RE sites. 
The region spanning from -122 to -60 bp contains overlapping response elements for CAR, 
C/EBPα, C/EBPβ, Oct-1 and HNF-4α (Pitarque et al., 2005). (B) The six putative p53 
binding sites identified by MatInspector (https://www.genomatix.de) and the p53 consensus 
sequence. Putative p53RE core sequences are shown in bold. R = Purine; Y = pyrimidine.  
 
Activation of CYP2A6 promoter byp53  
 
           P53 responsiveness of the CYP2A6 promoter was illustrated by co-transfection of 
pcDNA3-hp53, pGL3-CYP2A6-Luc and pMAX-GFP plasmids into C3A cells. The p53 
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protein expression levels in cells co-transfected with the pcDNA3-hp53 plasmid were 
substantially higher than in the cells co-transfected with the empty vector expression plasmid 
(pcDNA3) (Figure 5.3A), suggesting that the p53 protein was highly expressed in the C3A 
cells transfected with pcDNA3-hp53 expression plasmid.  
          The p53 co-transfection induced the distal CYP2A6-5’-2901/+9-Luc construct by ~4-
fold relative to the control, which is similar to the fold induction observed in the positive 
control cells (transfection with consensus p53RE-Luc construct) (Figure 5.3B). The induction 
was weaker with the proximal CYP2A6-5’-437/+9-Luc construct: by about 2.4-fold relative to 
the control (due partly to the elevated control levels) (Figure 5.3B). No significant luciferase 
activity was observed in cells transfected with the pGL3-Basic plasmid (negative control) 
(Figure 5.3B). These observations suggest that both the proximal and distal regions of the 
CYP2A6 promoter are responsive to p53. 
Notably, in normal cells—where p53 was not overexpressed (opened bar)—the 
luciferase activity driven by the distal promoter was significantly weaker than that driven by 
the proximal promoter (Figure 5.3B). For this reason and the fact that the luciferase activity 
of the proximal promoter was almost equal to that of the positive control in p53 
overexpressed cells, the functionality of this proximal p53RE site and its significance in the 
regulation of the CYP2A6 gene was investigated in detail.  
It is also noted that the activity of the distal promoter (CYP2A6-2901-Luc construct) is 
substantially lower than the vector control (p53RE-Luc) and the proximal promoter in both 
normal and p53-overexpressed cells (Figure 5.3B). This suggests the presence of suppressor 
region(s) upstream the CYP2A6 promoter, which is in agreement with previous studies 
suggesting such potential regions from -1013 to -185bp of the promoter (Pitarque et al., 2005; 
Itoh et al., 2006; Higashi et al., 2007). 
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A) 
 
B) 
 
 
Figure 5.3: Effect of p53 co-transfection on CYP2A6-5’-Luc construct activities in C3A 
cells.  (A) Western blotting and densitometry of p53 and β-actin (loading control) in C3A 
cells transfected with p53 expression plasmid (pcDNA-hp53) and empty expression plasmid 
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(pcDNA3). Each transfection was done in triplicate. Positive controls (+) = A-431 whole cell 
lysate for p53 and β-actin peptide. Relative p53 expression (bar graph) = the intensity of p53 
band relative to the intensity of β-actin band. (B) Effect of p53 co-transfection (pcDNA-hp53) 
on CYP2A6 distal and proximal driven luciferase activities. The firefly luciferase activities 
were measured 24 h after transfection. The measured activites were normalised against 
pMAX-GFP activity (transfection control plasmid). The values (n = 3) represent means ± 
S.D. p53 response of each reporter construct is indicated by -fold of activity to control co-
transfection with pcDNA3. Mean difference is significant from control group at ***, p < 
0.0005; **, p < 0.005; *, p < 0.05 (Student’s t test). 
 
           What repressor mechanisms may be present in the upstream region of the CYP2A6 
promoter? A conclusive explanation cannot be discerned from the present findings. However, 
previous studies together with the present findings suggest that an interaction between p53 
and Nrf-2 may be responsible for the observed suppressive effect. For example, a functional 
Nrf-2 binding site identified on the distal CYP2A6 promoter region (Yokota et al., 2011), is in 
close proximity to one of the distal putative p53REs discovered in this work (Figure 3.1). 
Importantly, direct interaction of p53 with Nrf-2 response elements have been shown to 
suppress the expression of stress responding genes including the Phase II metabolising gene, 
NQO-1 and GST-1 (Faraonio et al., 2006; Wakabayashi et al., 2010). It is thus plausible that 
interplay between p53 and Nrf-2 at the distal promoter mediates the suppression of CYP2A6 
gene expression.  
            On the other hand, the observed suppressive effect of the distal CYP2A6 promoter 
may not be via direct interaction between Nrf-2 and p53. Instead, it has been reported that 
distal p53RE may attract p53 proteins away from the p53RE near the TSS thereby leading to 
repression of gene expression (Burns et al., 2003). This possibility is supported by an 
observation that the distal p53RE of Polo-like kinase-2 (PLK-2) acts as suppressor, whereas 
the proximal p53REs are activators (Burns et al., 2003). Further work is warranted to 
determine how these distal p53REs regulate CYP2A6 gene expression, especially in the 
context of cellular perturbations.  
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5.2.2 P53- mediated CYP2A6 transactivation is through the proximal p53RE  
 
Functional validation of the proximal p53RE on CYP2A6 promoter  
 
In order to illuminate the role of the proximal p53RE in mediating CYP2A6 
transactivation, a series of 5’-truncated proximal CYP2A6 promoter-luciferase reporter 
plasmids were constructed and transfected into the C3A cells. The cells were then co-
transfected with p53 expression plasmid (pcDNA-hp53) or empty control plasmid (pcDNA3). 
P53 co-transfection up-regulated the CYP2A6-5’-437/+9-Luc construct 2.5-fold relative to 
control (Figure 5.4A). A similar response was detected with the series of constructs equal to 
or longer than -160 bp but not with the shorter construct (-74 bp) (Figure 5.4A). This suggests 
that the p53RE is located in the region from -160 to -74, which is in agreement with the 
MatInspector TF binding site search that revealed one putative p53RE at position -122 
(Figure 5.2A). This putative p53RE contains the two copies of p53 binding core sequence of 
the consensus p53RE, “CATG” (Figure 5.4B, bold letters), however, the satellite sequence of 
the putative p53RE is different from that of the consensus p53RE (Fiigure. 5.4B) 
A) 
 
B) 
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Figure 5.4 Functionality test of the p53RE site on the proximal CYP2A6 promoter. (A) 
C3A cells were co-transfeceted with a series of 5’-truncated proximal CYP2A6 promoter-
luciferase reporter plasmids and p53 expression plasmid (pcDNA3-hp53) or empty 
expression plasmid (pcDNA3). (B) The difference between putative and the consensus 
p53RE sequence. The boxed region contains the p53 binding core sequence. 
 
Functional significance of the proximal p53RE on the CYP2A6 promoter  
 
          To investigate the functional significance of the putative binding site, the core 
sequence, CATG, critical for p53 binding was mutated at the -122 site of the CYP2A6-5’-
160/+9-Luc and CYP2A6-5’-2901/+9-Luc constructs to ACCA. The mutant constructs were 
then co-transfected with the p53 expression plasmid into the C3A cells. As expected, p53 co-
transfection induced luciferase expression driven by the two constructs by about 2.6- to 3.9-
fold relative to control (Figure 5.5). Point mutation at the core binding sequence dramatically 
reduced the p53 response of both the proximal and distal promoter activity (Figure 5.5), 
which suggests that the core binding sequence within the putative p53RE element at the -122 
bp site is crucial in mediating the response. 
 
 
Figure 5.5 Effect of p53 co-transfection on the mutated and wildtype CYP2A6 proximal 
and distal promoters activities. The potential proximal p53 binding sites were mutated as 
described: TTCATG → TTACCA and GGCATG → GGATCC in CYP2A6-5’-160/p53mut-
Luc, with the mutated bases in bold and the underlined bases representing the core sequence. 
The mutated and wildtype CYP2A6-5’-Luc constructs were transfected to C3A cells and 
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luciferase activities were measured 24 h after transfection.  The measured luciferase activities 
were normalised against co-transfected pMAX-GFP control plasmid activities. The values (n 
= 4) represent the means ± S.D. p53 response of each reporter construct is indicated by -fold 
of activity to control co-transfection with pcDNA3. Mean difference is significant from 
control group at ****, p < 0.0001; **, p < 0.005 (Student’s t test). 
 
Binding of p53 to the proximal p53RE on the CYP2A6 promoter  
 
 To confirm that the observed response was due to direct interaction of p53 with the 
putative site, EMSA was performed with nuclei fractions from C3A cells transfected with 
p53 expression plasmid using three oligonucleotide probes. Probe 1 is a longer 
oligonucleotide containing the putative binding site from -149 to -55 bp (Figure 5.6A). Probe 
2 is a shorter oligonucleotide spanning the putative site from -127 to -98 bp. The third probe 
(Probe1Mut) is the longer oligonucleotide with the core sequence, CATG, critical for p53 
binding, mutated to ACCA. 
           As shown in Figure 5.6B, the transfection produced a substantial amount of p53 in the 
nucleus. Two distinct DNA-protein complexes were formed when Probe 1 was incubated 
with the C3A nuclear extract (Figure 5.6C, lane 2). The lower complex (closed arrow) was 
super-shifted with an anti-p53 antibody (Figure 5.6C, lane 3), indicating that the DNA-
protein complex contains p53. In competitive assays, both complexes were competed out by a 
125-fold excess of the unlabelled Probe 1 (S) (Figure 5.6C, lane 4, closed and open arrows). 
However, only the lower complex was competed out by increasing concentrations of the 
unlabelled consensus p53RE oligonucleotide (C) (Figure 5.6C, lanes 5-7, closed arrow). The 
results suggest presence of p53 in the lower complex and indicate that a protein other than 
p53 is forming the higher complex (open arrow) with Probe 1.   
 Indeed, detailed analysis of the probe sequence revealed a putative binding site for 
hepatocyte nuclear factor 4α (HNF-4α) (Figure 5.6A, open box). Incubation with anti-HNF-
4α antibody shifted the migration of the higher complex (open arrow) (Figure 5.6C, lane 8), 
confirming the presence of HNF-4α.  
Two additional controls were included in the analysis to confirm specific binding of 
p53 and HNF-4α. Migration of the two complexes was not shifted by an anti-Nrf2 antibody 
(Figure 5.6C, lane 9, closed and open arrows) and the smaller complex was not formed with 
the mutated Probe 1 (Figure 5.6C, lane 10). To further confirm p53 specific binding, nuclei 
proteins were incubated with the shorter Probe 2, which contains only the putative p53 
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binding site. As expected, only one DNA-protein complex was formed with Probe 2 (closed 
arrow) (Figure 5.6C, lane 12), which (closed arrow) was shifted by anti-p53 antibody but not 
with anti-HNF-4α antibody (Figure 5.6C, lanes 13 & 14). These observations strongly 
suggest specific interaction of p53 with the putative site at the proximal CYP2A6 promoter. 
Collectively, the EMSA analysis and the luciferase reporter gene assays demonstrate that the 
proximal CYP2A6 gene promoter contains a functional p53RE that potentially mediates 
transcriptional regulation of the gene. The functional p53RE appears to reside adjacent to the 
response elements that govern the constitutive CYP2A6 gene expression (Pitarque et al., 
2005). 
 
A) 
 
B) 
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Figure 5.6 EMSA analysis of p53 protein/CYP2A6 promoter interactions. (A) A 
schematic representation of the -160 to +1 region in the proximal CYP2A6 promoter. The 
closed arrows indicate orientation of the EMSA probe. The closed box highlights sequence of 
the potential p53RE that was revealed by the MatInspector transcription factor binding site 
search (http://www.genomatix.de/). The open box highlights sequence of the HNF-4α 
response element. (B) Western blot of p53 in the nuclei fractions of C3A cells transfected 
with p53 expression plasmid (pcDNA3-hp53).  Positive control (+) = A-431 whole cell 
lysate. (C) EMSA blot. Nuclei proteins extracted from C3A cells transfected with pcDNA3-
hp53 expression plasmid were incubated with digoxigenin-labelled probe, the orientation of 
which was shown in (A). Probe 1 = 94 bp oligonucleotide containing the putative binding site 
from -149 to -55 bp. Probe 2 = 29 bp oligonucleotide spanning the putative binding site from 
-127 to -98 bp. Probe1Mut = Probe 1 with the core sequence, CATG, critical for p53 
binding, mutated to ACCA. Lanes 1 & 11 represent incubation without nuclei proteins. Lanes 
3 & 13 represent incubation with nuclei proteins and anti-p53 antibody. Lane 9 represents 
incubation with nuclei proteins and anti-Nrf2 antibody. Lanes 8 & 14 represent incubation 
with nuclei proteins and anti- HNF-4α antibody The complexes with nuclear extracts were 
competed with 125-fold excess of unlabelled probe (S) (lane 4) and descending 
concentrations of unlabelled consensus p53RE oligonucleotides (C) (lanes 5-7). Lane 10 
represents incubation with nuclei proteins digoxigenin-labelled mutated probe. The closed 
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arrow indicates smaller DNA-protein complex, and the opened arrow indicates bigger 
complex. The experiment was repeated three times, and similar results were obtained.  
 
5.2.3 Endogenous p53 activates CYP2A6 gene expression  
 
BaP induced p53 in activation of the CYP2A6-5’-160/+9-Luc promoter in MCF-7 cells  
 
           To demonstrate that endogenous p53 can mediate the expression of the CYP2A6-5’-
160/+9-Luc construct, and the native CYP2A6 gene, the transfected MCF-7 and C3A cells 
were treated with different concentrations of BaP, a known inducer of p53 (Biswal et al., 
2003) for 24 h. BaP increased p53 protein levels in the nucleus of MCF-7 by 4-fold relative 
to control (Figure 5.7A and B). BaP also increased luciferase activity dose-dependently in 
cells transfected with either CYP2A6-5’-160/+9-Luc construct or reporter construct 
containing the consensus p53RE (pGL4.38-p53RE) (Figure 5.7C). However, the response 
was totally abolished when the two copies of the CYP2A6 p53RE core sequence were 
mutated (CYP2A6-5’-160/+9_p53mut-Luc) (Figure 5.7C). These observations align with the 
results shown in Figure 5.5 and Figure 5.6, and indicate that the proximal CYP2A6 p53RE is 
responsive to induced endogenous p53.  
  It is unlikely that the induced luciferase activity was mediated by HNF-4α as its level 
remained constant after BaP treatment (Figure 5.7A and B). This is in agreement with 
previous observation that HNF-4α regulates basal expression of CYP2A6 (Pitarque et al., 
2005), and corresponds with the observation of constant luciferase activity in cells transfected 
with CYP2A6-5’-160/+9_p53mut-Luc (Figure 5.7C, closed triangle), where the HNF-4α 
binding site is intact. As BaP also activates AhR leading its nuclear translocation from 
cytoplasm (Tsuji et al., 2011), the activated AhR could contribute to the transactivation of the 
recombinant CYP2A6 promoter. However, this possibility has been excluded as the detailed 
analysis of the proximal CYP2A6 promoter did not show any putative XRE (AhR binding 
site).   
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A) 
 
 
B) 
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Figure 5.7 Effect of BaP treatment on activation of CYP2A6-5’-160/+9-Luc promoter 
activity in MCF-7 cells. The cells were transfected with pGL4.38-p53-Luc, CYP2A6-5’-
160/+9-Luc, or CYP2A6-5’-160/p53mut-Luc for 4 h before being treated with various 
concentrations of BaP. Twenty-four hours after treatment nuclei proteins were extracted and 
luciferase activities were measured. (A) Western blot of p53, HNF-4α and β-actin (loading 
control) in MCF-7 cells treated with various concentrations of BaP. Positive controls (+) = A-
431 whole cell lysate for p53, HepG2 whole cell lysate for HNF-4α and β-actin peptide. Each 
blot represents one of three blots (each blot showed the same pattern of induction). (B) 
Densitometry analysis of the Western blots. Fold induction = Relative p53 or HNF-4α 
expression of treated samples / Relative p53 or HNF-4α expression of control (0 µM BaP). 
Relative p53 or HNF-4α  expression = the intensity of p53 or HNF-4α  band relative to the 
intensity of β-actin band. The values (n = 3) represent the means ± S.D. *Mean difference is 
significant from control group at p < 0.05 (Student’s t test). (C) Effect of BaP treatment on 
the luciferase activities of the putative CYP2A6 p53RE constructs. The firefly luciferase 
activities were measured 24 h after BaP treatment. The measured activites were normalised 
against pMAX-GFP activity (transfection control plasmid). The values (n = 4) represent 
means ± S.D. *Mean difference is significant from control group at p < 0.05 (Student’s t test). 
 
BaP induced endogenous p53, CYP2A6 and HMOX1expressions in C3A cells  
 
           Furthermore, BaP induced p53 dose-dependently in the nucleus of hepatocellular 
carcinoma cells (C3A) by 4-fold relative to control (Figure 5.8A and C). This confirmed 
previous observations of BaP-dependent induction of p53 at mRNA and protein levels in 
human lung adenocarcinoma (A549), mouse hepatoma (Hepa-1c1c7) and fibroblast 
(NIG3T3) cell lines, as well as in mouse skin (Pei et al., 1999; Serpi and Vähäkangas, 2003; 
Huang et al., 2012). Importantly, a recent investigation reported that BaP-induced CYP1A1 
expression was regulated through p53 binding to a p53 response element in the CYP1A1 
promoter region (Wohak et al., 2014). 
           It is noted that p53 induction by BaP aligned with dose-dependent increases of the 
CYP2A6 mRNA and apoprotein ranging from 2 to 4-fold relative to control (Figure 5.8). 
Similar pattern of HMOX1 induction at mRNA and protein levels (another p53 target gene) 
was also observed (Figure 5.8). This confirmed previous observations of BaP-dependent 
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induction of HMOX1 expression in various human cell lines (Spink et al., 2002; Lee et al., 
2009). 
 
A) 
 
B)  
 
C)  
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Figure 5.8 Effect of BaP treatment on endogenous p53, CYP2A6, and HMOX1 
expressions in C3A cells. The cells were treated with various concentrations of BaP for 24 h. 
Thereafter total RNA, nuclei and cytosolic proteins were extracted. Quantitative real time 
RT-PCR was used to detect CYP2A6 and HMOX1 mRNA expression. (A) Western blot and 
densitometry of nuclei p53 and cytosolic CYP2A6 and HMOX1. β-actin was used as  loading 
control. Each blot represents one of three blots (each blot showed the same pattern of 
induction). Positive controls (+) = A-431 whole cell lysate for p53; peptides for β-actin and 
HMOX1; and recombinant CYP2A6 yeast microsomes. Fold induction = Relative protein 
expression of treated samples / Relative protein expression of control (0 µM BaP). Relative 
protein expression = the intensity of protein band relative to the intensity of β-actin band. (B) 
Migration of RT-PCR products in 2.5% agarose gel. Lane 1 = 50 bp DNA ladder. Lanes 2, 5 
and 8 are products from control cells; lanes 3, 6 and 9 are products from treated cells; and 
lanes 4, 7 and 10 are non-template control (NTC). GAPDH = housekeeping gene. The sizes 
of the PCR products align with the amplified regions by the primers. (C) Fold induction of 
p53 proteins, CYP2A6 and HMOX1 mRNA and protein in control and treated cells. 
 
           BaP has been found to act as a AhR agonist triggering the expression of CYP1 
enzymes and initiating its own bio-activation (Baird et al., 2005). The formed metabolites 
such as BaP-quinones have a substantial role in promoting oxidative stress in cells and 
causing mitochondrial dysfunction (Zhu et al., 1995; Bolton et al., 2000). Formation of 1,6-
BPQ, 3,6-BPQ, and 6,12-BPQ (Shimada and Guengerich, 2006) leads to ROS formation, 
more specifically, superoxide anion, e.g., in human breast epithelial cells (Burdick et al., 
2003). A series of cytoprotective mechanisms are triggered as a result to minimise the ROS 
related cellular damages. For example, stress related transcription factors Nrf2 and p53 are 
induced by BaP treatment, and may exert a role in activating some antioxidant genes (Pei et 
al., 1999; Nguyen et al., 2010). In the case of human breast epithelial cells, the stress related 
transcription factors activated by BaP and its metabolites have been found to induce the 
expression of redox-homeostasis protective genes such as HMOX1 and some phase II enzyme 
genes such as NQO1, NQO2, ALDH3A1 (Burchiel et al., 2007), possibly to overwhelm the 
cellular damages caused by the unbalanced cellular redox.  
  Previous studies have demonstrated that CYP2A6 efficiently metabolises bilirubin 
(BR), and is a part of a machinery that regulates cellular BR homeostasis (Abu-Bakar et al., 
2012). The p53- mediated CYP2A6 transactivation may therefore act as a component of this 
machinery to protect cells against external stress. 
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  The present observation that BaP — a carcinogen and transactivator of p53 (Pei et al., 
1999)—concurrently induced CYP2A6 and HMOX1 expression (Figure 5.8) further suggests 
a potential role for CYP2A6 in cellular stress management. HMOX1 catalyses haem 
breakdown to biliverdin (BV), which is reduced to BR by biliverdin reductase. Bilirubin is an 
efficient scavenger of reactive oxygen and nitrogen species (Liu et al., 2003; Jansen et al., 
2010), but apoptotic at highly elevated concentrations (Rodrigues et al., 2002). Hence, 
activation of HMOX1 by p53 may lead to drastic elevation of BR concentrations, which in 
turn, may overwhelm BR oxidant scavenging activity. Consequently, there is a need for a 
protective mechanism where BR is enzymatically oxidised to BV to curb its cytotoxicity 
(which can be reduced back to BR by biliverdin reductase when needed). It appears that 
CYP2A6 may fit well this protective role as its Km for BR is within the subtoxic range (̴ 
0.5µM) (Abu-Bakar et al., 2012).  
  Importantly, the proposed role for CYP2A6 in the regulation of BR homeostasis 
during chemical onslaught is supported by a recent finding that BR elimination through 
conjugation was not elevated during the initial stage of oxidative stress, where its production 
was strongly increased (Muhsain et al., 2015), thus suggesting the existence of another 
pathway for BR elimination.  
 
5.3 Transcriptional control of CYP2A6 by p53 involves complex 
interaction with CAR, Oct-1/C/EBP and HNF-4α (Paper II) 
 
5.3.1 Role of p53, CAR, C/EBPα, Oct-1 and HNF-4α in the regulation of the CYP2A6 
gene expression 
 
Role of p53, CAR, C/EBPα, Oct-1and HNF-4α in CYP2A6 transactivation  
 
            The first part of this thesis has demonstrated the role of p53 in the regulation of 
CYP2A6 transactivation. The CYP2A6 was found to be activated by both the overexpressed 
p53 and the endogenous p53 (Hu et al., 2015). In addition, transcription factors CAR, 
C/EBPα, Oct-1 and HNF-4α have been found to interact with the proximal CYP2A6 promoter 
and may play a role in its regulation (Pitarque et al., 2005). The functional p53RE is only five 
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base pairs upstream of the REs that govern the constitutive CYP2A6 gene expression (Figure 
5.2A and 5.10).  
           As previous studies have shown that the p53- mediated gene expression often involves 
interaction with other factors (discussed in section 2.5.1), and that, like p53 the CAR and 
C/EBP/Oct-1 are also part of the cellular stress ─ responding machinery (discussed in section 
2.3.1), a series of experiments were designed to investigate possible interaction between these 
proteins in mediating the CYP2A6 transactivation. 
           To this end, the proximal CYP2A6-5’-160/+9 Luc promoter construct was co-
transfected with the transcription factor expression plasmids: p53, CAR, C/EBPα, Oct-1 and 
HNF-4α respectively into the C3A cells. The p53, HNF-4α and Oct-1 co-transfections 
increased the CYP2A6-5’-160/+9 Luc promoter activities by about 3.2-, 2.6-, and 1.3- fold 
compared with the empty vector (Figure 5.9A). By comparison, the overexpression of 
C/EBPα in C3A cells induced the CYP2A6-5’-160/+9 Luc promoter for about 22 fold (Figure 
5.9A). Interestingly, co-transfection of CAR in C3A cells had a week inhibitory effect on 
CYP2A6 gene transactivation (Figure 5.9A). These results indicate that all five transcription 
factors play a role in the regulation of the CYP2A6 gene but that the roles may differ. Levels 
of the respective transcription factors in the C3A cells, transfected with expression plasmids 
or the empty vector were confirmed by Western blotting and by subsequent semi quantitative 
scanning of the band showing that all five transcription factors were highly expressed in cells 
transfected with their expression plasmids (Figure 5.9B and C). It is worth noticing that the 
level of C/EBPα appears to be extremely low in control cells, suggesting a low endogenous 
C/EBPα expression in C3A cells (Figure 5.9B).  
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(A) 
 
(B) 
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(C) 
 
Figure 5.9: Effect of transcription factors p53, CAR, C/EBPα, Oct-1 and HNF-4α on 
CYP2A6-5’-160/+9 Luc construct activity in C3A cells. (A) Effect of p53, CAR, C/EBPα, 
Oct-1 and HNF-4α co-transfections on CYP2A6 promoter driven luciferase activities. C3A 
cells were co-transfected with either CYP2A6-5’-160/+9 Luc plasmid or pGL3-Basic plasmid 
together with p53, CAR, C/EBPα, Oct-1 or HNF-4α expression plasmids, or empty cloning 
vector (pcDNA3) respectively, and pMAX-GFP (transfection control plasmid). The firefly 
luciferase activities were measured 24 h after transfection. The measured activities were 
normalised against pMAX-GFP activity, and the expression vector/empty vector ratios were 
calculated and normalised with regard to the related pGL3-Basic activities. The CYP2A6-5’-
160/+9 Luc construct activity driven by each overexpressed transcription factor is indicated 
by -fold induction of the Relative Luciferase Activity (RLA) to control co-transfection with 
pcDNA3. The values (n = 4) represent means ± S.D. Mean difference is significant from 
control group at ****, p < 0.0001; **, p < 0.005; (Student’s t test). (B) Western blotting and 
(C) densitometry of p53, CAR, C/EBPα, Oct-1 and HNF-4α expressions in C3A cells 
transfected with p53, CAR, C/EBPα, Oct-1 and HNF-4α expression plasmids. Each 
transfection was done in triplicate. Positive controls (+), A-431 whole cell lysate was used to 
indicate p53, C/EBPα transfected C3A nuclear extract was used to indicate C/EBPα and 
HepG2 whole cell lysate was used to indicate CAR, Oct-1 and HNF-4α. Protein expression 
(bar graph) = the intensity of overexpressed bands relative to the intensity of β-actin bands. 
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The values (n = 3) represent means ± S.D. Mean difference is significant from control group 
at ****, p < 0.0001; **, p < 0.005; *, p < 0.05 (Student’s t test) 
 
Direct interaction of p53, CAR, C/EBPα, Oct-1and HNF-4α with the proximal CYP2A6 
promoter 
 
            Direct binding of the transcription factors to the proximal CYP2A6 promoter was 
demonstrated by a series of EMSA analysis. Sequences covering the respective REs and 
binding sites of the proteins at the CYP2A6 proximal promoter (Figure 5.10) were used as 
labelled probes. These probes were incubated with related nuclear proteins that were 
extracted from the transcription factor expression plasmid transfected C3A cells. The 
protein/DNA complexes can be recognised by the specific antibodies. Anti Nrf2 antibody 
was used as control for unspecific binding: (a protein present in the nuclear extract but with 
no binding site at the promoter). 
            As can be seen from figure 5.11A, B and C, a protein/DNA complex was formed 
when each probe was incubated with the nuclear proteins (lane2). The formed protein/DNA 
complexes were recognised and super-shifted by their specific antibodies, including p53, 
CAR, RXR (heterodimer of CAR upon binding to the DNA) and Oct-1, which are indicated 
by arrows. No super-shifted complexes were observed when Nrf-2 antibody was added to the 
protein/DNA mixtures. This suggests specific binding of transcription factors p53, CAR and 
Oct-1 to their respective REs. Intriguingly, only a weak and diffuse shift was observed in 
Figure 5.11D with anti C/EBPα antibody; a pattern nonetheless distinctly different from that 
obtained with anti Nrf2 antibody (Figure 5.11D, lane 4), where no trace of shift was 
observed. This could indicate a weak binding of the anti C/EBPα antibody to the protein, 
possibly due to some interference by the Oct-1 (See figure 5.16). Two complexes were 
observed when the probe specific to the HNF-4α was incubated with the protein extract 
(Figure 5.11E, lane 2). A distinct super-shifted band was observed with simultaneous 
disappearance of the upper band upon addition of the HNF-4α antibody, indicating binding of 
HNF-4α to the complex (Figure 5.11E, lane 3). Although composition of the lower complex 
is not obvious, the Nrf2 antibody did not shift the upper band or the lower band suggesting 
specific binding of HNF-4α to the RE. In conclusion, p53, CAR, C/EBPα, Oct-1 and HNF-4α 
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binding to the proximal CYP2A6 promoter have a significant role in its transactivation, which 
is in agreement with this study and previous studies (Pitarque et al., 2005; Hu et al., 2015). It 
is to be noted that the current observations demonstrate a remarkably high C/EBPα mediated 
CYP2A6 transactivation yet a relatively low binding affinity of C/EBPα to the promoter in 
comparison with the findings demonstrated by Pitarque et al., 2005. This may be due to cell 
specific effect on activation of the promoter. A recombinant C/EBPα extracted from 
transfected C3A cells was used in the study instead of using HepG2 cells and rat liver extract 
by Pitarque et al., 2005. However, whether these transcription factors interact with each other 
in regulating the CYP2A6 gene expression is still obscure and will be elucidated in the next 
section.  
 
Figure 5.10: Schematic representation of the response elements on the CYP2A6-5’-
160/+9 Luc construct. Four REs including p53RE, DR-4RE for CAR binding, C/EBP-Oct-
1RE and HNF-4αRE are underlined. 
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 Figure 5.11: EMSA analysis of the transcription factors p53, CAR, C/EBPα, Oct-1 and 
HNF-4α binding to the proximal CYP2A6 promoter. EMSA procedures are shown under 
Materials and Method. The DNA probes covering the respective REs on the proximal 
CYP2A6 promoter region and the antibodies used in the assay are shown above the EMSA 
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blot. The nuclei protein fractions were extracted from the transcription factor expression 
plasmids transfected C3A cells. The Nrf-2 antibody was used as control for unspecific 
binding (a protein present in the nuclear extract but with no binding sites at the promoter). 
(A) The probe CYP2A6-5’-127/-98 corresponding to the p53RE was incubated with p53 
overexpressed nuclear extract (lane 2). The formed DNA/protein complex was super-shifted 
by p53 antibody (lane 3) but not with the Nrf-2 antibody (lane 4). (B) The probe CYP2A6-5’-
103/-80 corresponding to the DR-4RE was incubated with CAR overexpressed nuclear 
extract (lane 2). The formed DNA/protein complex was recognised by CAR and RXR 
(heterodimer of CAR) antibodies (lane 3 & lane 4), but not with the Nrf-2 antibody (lane 5).  
(C) and (D) The probe CYP2A6-5’-92/-65 corresponding to the C/EBPα-Oct-1RE was 
incubated with Oct-1 or C/EBPα overexpressed nuclear extracts (C and D, lane 2). The 
formed DNA/protein complex was shifted by Oct-1 antibody (C, lane 3), but only weakly and 
diffusely shifted by C/EBPα antibody (D, lane 3). No super-shifted complex was observed 
when the mixtures were incubated with Nrf-2 antibody (C and D, lane 4). (E) The probe 
CYP2A6-5’-77/-53 corresponding to the HNF-4αRE was incubated with HNF-4α 
overexpressed nuclear extract, forming two DNA/protein complexes (lane 2). Only the upper 
complex was totally pulled up by HNF-4α antibody (lane 3). No super-shifted complex was 
observed with the Nrf-2 antibody (lane 4). Lane 1 in all EMSA blots represents probe 
incubations without nuclei proteins. The super-shifted DNA-protein complexes are indicated 
by arrows. The experiment was repeated 3 times with similar results.  
 
5.3.2 Contribution by p53, CAR, C/EBP/Oct-1 and HNF-4α REs to CYP2A6 
transactivation  
 
            To investigate the contribution of the REs on proximal CYP2A6 promoter region to 
CYP2A6 gene transactivation, a series of the RE mutated CYP2A6-5’-160/+9 Luc promoters 
were generated, followed by transfections of these mutated promoter constructs together with 
pMAX-GFP into the C3A cells. Figure 5.12 shows the locations of the respective binding 
sites at the CYP2A6 promoter region. These sites were mutated individually and in 
combination.   
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Figure 5.12: Site direct mutagenesis of the response elements on proximal CYP2A6 
promoter region. Schematic representation of the mutated REs on the CYP2A6-5’-160/+9 
Luc construct. The REs were mutated individually and in combination (mutated bases in 
bold).  
           Figure 5.13A shows that mutating each of these REs on the CYP2A6-5’-160/+9 Luc 
promoter significantly reduced the promoter activity by about 40% – 55% compared to the 
wildtype. The SV-40 promoter driven luc - activity, used as a control, was expressed at about 
50% of the activity of the wild type CYP2A6 (Figure 5.13D). As expected, no significant 
activity was observed in the cells transfected with pGL3-Basic plasmid (negative control). 
The results demonstrate that each of the four response elements, present on the proximal 
CYP2A6 promoter, has a role in mediating CYP2A6 gene transactivation essentially 
confirming results summarised in Figure 5.9 and 5.11. In the case of CAR, apparently 
opposite effects were found with its overexpression respectively mutation of the RE (Figure 
5.9 and 5.13A). 
           It has been shown that p53- mediated gene transactivation often involves complex 
machinery including recruitment of other cofactors, as discussed in section 2.5.1. Thus, the 
interplay between p53 and the other four proteins in mediating the CYP2A6 transactivation 
was investigated. To demonstrate the possible interaction among the transcription factors, a 
series of multiple RE mutations were introduced, as shown in Figure 5.13B, C and D. The 
mutated promoters were transfected into the C3A cells respectively. A total abolishment of 
the activity was observed, when all 4 REs were mutated on the promoter, as could be 
expected (Figure 5.13D). Intriguingly, when the promoter was triple mutated with the p53RE 
or HNF-4αRE intact, almost a total abolishment of the promoter activity was observed. 
However, when either CAR or C/EBP/Oct-1 RE was kept intact, a significant expression at 
about 40% to 60% from the wild type could be observed (Figure 5.13B). These results 
suggest that while all the REs on the CYP2A6 promoter are necessary for optimal activity, 
their respective roles in assembling the transcription complex seem different. The activation 
of CYP2A6 by p53 and HNF-4α requires the other factors, while CAR and particularly 
C/EBP/Oct-1 seem to be able to function partially independently although not in their full 
capacity. 
          When a series of double mutations was introduced an even more complex picture 
emerged (Figure 5.12C).  A zero level activity was observed when only the p53 and HNF-4α 
REs were intact supporting the observation above that these TFs need the other two proteins 
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to function. In addition, this result seems to suggest that p53 and HNF-4α do not interact 
directly with each other to support transcription. On the other hand, when p53RE was kept 
intact together with either CAR or C/EBP/Oct-1 RE, the expression could partially be 
restored suggesting an interaction between these proteins and the p53. 
           In conclusion, the results suggest a complex interaction between the five proteins 
where all of them are needed for optimal transcriptional activity, and where the p53 cannot 
act alone but needs interaction with the other proteins in regulating the expression of the 
CYP2A6 gene. The results also suggest a tight interaction between the stress activated p53, 
CAR, C/EBPα and Oct-1, complemented by the HNF-4α for full activity. 
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 Figure 5.13:  Mutational analysis of the CYP2A6-5’-160/+9 Luc construct in C3A cells.  
(A) Effect of single RE mutations on the proximal CYP2A6 promoter activities in C3A cells. 
(B) Effect of triple RE mutations on the proximal CYP2A6 promoter activities in C3A cells. 
(C) Effect of double RE mutations on the proximal CYP2A6 promoter activities in C3A cells. 
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(D) Effect of all sites mutations on the proximal CYP2A6 promoter activities in C3A cells. 
The REs on the CYP2A6-5’-160/+9 Luc construct were mutated individually and in 
combination (Figure 5.12), followed by co-transfection of the mutated promoters and pMAX-
GFP into the C3A cells. The negative and positive controls for transfection were indicated by 
transfections of pGL3-Basic and pGL3 containing SV-40 promoter into the C3A cells 
respectively. A schematic representation of the mutated CYP2A6-5’-160/+9 Luc construct is 
shown on the left, where the mutated REs for transcription factors are shown with a cross. 
The promoter activity of each mutated construct was compared against the pGL3-Basic 
activity and wildtype proximal CYP2A6 promoter activity, indicated by “*” and “#” 
respectively. The firefly luciferase activities were measured 24 h after transfection. The 
measured activities of each mutated construct were normalised against pMAX-GFP activity 
(transfection control plasmid), and were expressed as arbitrary units relative to the wildtype 
proximal CYP2A6 promoter activity. The values (n = 4) represent means ± S.D. Mean 
difference is significant at ****, p < 0.0001; ***; p < 0.0005; ####, p < 0.0001 (one-way 
analysis of variance (ANOVA) followed by the least significant difference post hoc test). 
 
5.3.3 Over-expression of p53 emphasises its interaction with CAR and C/EBP/Oct-1 in 
the regulation of CYP2A6    
 
          To further demonstrate that p53 interacts with the other proteins in mediating CYP2A6 
transactivation, a series of mutated constructs were co-transfected with the p53 expression 
plasmid into the C3A cells as shown in Figure 5.14. A significant upregulation of the 
wildtype proximal CYP2A6 promoter activity was observed when the p53 was overexpressed 
in cells, which is almost as strong as the p53 positive control. As could be expected, mutation 
of the p53RE either alone or together with the other REs on the promoter dramatically 
abolished the p53 responsiveness of the promoter, thus demonstrating its role in maintaining 
the CYP2A6 expression (Figure 5.14). 
          A very weak and non-significant up-regulation was observed with the construct where 
the p53RE was the only intact one. An equally weak/nonsignificant upregulation was 
observed with the intact p53RE and pairwise mutations of the CAR/C/EBP/Oct-1/HNF-4α 
REs respectively (Figure 5.14). The results confirm observations in Figure 5.13 that p53 
cannot support CYP2A6 expression alone but needs cooperation with the other factors. And 
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further that interaction with only one of the other proteins is not sufficient. Interestingly, co-
transfections with constructs possessing intact p53RE and a single mutation at one of the 
three other sites respectively showed that while mutation of the CAR or the C/EBP/Oct-1 RE 
compromised the expression partially, mutation of the HNF-4α site did not, as compared to 
the wild type. This result confirms the picture emerging from Figure 5.13 where CAR and 
C/EBP/Oct-1 are essential partners for p53 in its CYP2A6 regulation while the HNF-4α plays 
a supportive function.   
 
Figure 5.14: Effect of p53 co-transfection on the REs mutated CYP2A6-5’-160/+9 Luc 
construct activities in C3A cells. C3A cells were co-transfected with a series of RE mutated 
CYP2A6-5’-160/+9 Luc construct together with p53 expression plasmid (pcDNA3-hp53) or 
empty expression plasmid (pcDNA3). The schematic representation of the mutated CYP2A6-
5’-160/+9 Luc constructs is shown on left with a cross for the mutated REs. The pGL4.38-
p53RE plasmid containing two copies of consensus p53RE was used as positive control to 
indicate p53 co-transfection in C3A cells. Promoter less pGL3-Basic was used as negative 
control to indicate the transfection in C3A cells. The measured luciferase activities were 
normalised against co-transfected pMAX-GFP control plasmid activities. The values (n = 4) 
represent the means ± S.D. p53 response of each reporter construct is indicated by -fold 
induction of the Relative Luciferase Activity (RLA) to control co-transfection with pcDNA3. 
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Mean difference is significant from control group at ****, p < 0.0001; ***, p < 0.0005; **, p 
< 0.005; *, p < 0.05 (Student’s t test). ns = no significance. 
 
5.3.4 Replacing the p53RE at the CYP2A6 promoter with consensus p53RE 
dramatically increases the expression level 
 
            A consensus RE has been previously described for the p53. It contains two repeats of 
[5’-RRRC(A/T)(T/A)GYYY-3’], where “R” represents purine and “Y” represents 
pyrimidine, as discussed in section 2.5.1. This DNA sequence is characterised by a specific, 
high affinity interaction with the p53, and has been used in vectors assessing p53 activity 
levels in in vitro cell assay (Mukudai et al., 2013; Promega, 2015) . 
           The double - repeat p53 consensus sequence vector, pGL4.38 [luc2P/p53 RE/Hygro] 
has been used as a positive control to assess p53 activation in this study (Figure 5.1, 5.3, 5.4, 
5.5, 5.7 and 5.14). When the CYP2A6-specific p53RE was mutated into the p53 consensus 
sequence (Figure 5.15A, boxed regions) while keeping the promoter otherwise intact, an 
extremely high expression level (up to 30-40 times higher) as compared to the CYP2A6 wild 
type or indeed the p53 positive control was achieved (Figure 5.15B). When this construct was 
co-transfected with the p53 expression plasmid, no further increase in the expression, unlike 
in the case of the wild type CYP2A6 or the p53 positive control, was achieved (Figure 5.15B). 
This is an unexpected result, particularly since the p53 positive control contains two copies of 
the consensus sequence while the modified CYP2A6 promoter contains only one. The result is 
not easy to explain but it possibly demonstrates the importance of the adjacent transacting 
factors, present at the CYP2A6 promoter, for p53 to achieve its full gene activating capacity. 
This would be in accordance with the results obtained throughout the present investigation. 
 
  (A) 
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(B) 
 
Figure 5.15: Effect of p53 co-transfection on the luciferase activity of the proximal 
CYP2A6 promoter containing a consensus p53RE. (A) The differences between the 
CYP2A6-5’p53RE and the consensus p53RE sequences are indicated in the boxed regions, 
showing different satellite sequences. The p53 binding core sequences are shown in bold. (B) 
The p53RE on the proximal CYP2A6 promoter was mutated into a consensus p53RE as 
described: 5’-ATTCATGGTGGGGCATGTAG-3’→5’-AGACATGCCTAGACATGCCT-
3’ in CYP2A6-5’-160/+9 Luc construct, with the mutated bases underlined and the core 
sequences in bold. The C3A cells were co-transfected with the wildtype CYP2A6-5’-Luc 
construct or the CYP2A6-5’-Luc construct containing consensus p53RE together with p53 
expression plasmid (pcDNA3-hp53) or empty plasmid (pcDNA3). The pGL4.38-p53RE 
plasmid containing two copies of consensus p53RE was used as positive control to indicate 
p53 co-transfection in C3A cells. Promoter less pGL3-Basic serves as a negative control for 
the transfection. The luciferase activities were measured 24h after transfection and were 
normalised against co-transfected pMAX-GFP control plasmid activities. The values (n = 4) 
represent the means ± S.D. p53 response of each reporter construct is indicated by -fold 
induction of the Relative Luciferase Activity (RLA) to control co-transfection with pcDNA3. 
Mean difference is significant from control group at ****, p < 0.0001; **, p < 0.005; *, p < 
0.05 (Student’s t test). ns = no significance.  
 
           It could be that introducing the consensus sequence into the CYP2A6 promoter has 
created a template with an extremely high p53 affinity (higher than the consensus sequence 
alone) binding aggressively all the endogenous p53 (facilitated by the other interacting 
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proteins) and leaving no place for the overexpressed p53. This could explain why no further 
upregulation of this construct took place by overexpressing the p53. Such a scenario would 
agree with a model where the other TFs (CAR, C/EBP/Oct-1) help recruiting the p53 into the 
complex and facilitate its binding to it’s RE.    
 
5.3.5 A model for the p53- mediated CYP2A6 transactivation  
 
            In this study, a “stress cluster” consisting of the stress activated transcription factors 
p53, CAR, and C/EBP-Oct-1 was described on the proximal CYP2A6 promoter spaning from 
-122 to -60 bp upstream the TATA box (Figure 5.16A). The CYP2A6 gene expression has 
been found to be governed by the interaction between these TFs binding to the promoter 
region. Particularly, the data show that p53 cannot act independently, but needs interaction 
with the other proteins for its activity. For full activity, the “stress protein cluster” needs to 
interact with the HNF-4α also binding to the same regulatory region (Figure 5.16B). 
          It has been previously shown that p53 is a transcriptional activator of the CYP2A6 
during oxidative and/or genotoxic stress (Hu et al., 2015); conditions that are known to 
upregulate the CYP2A6 (Abu-Bakar et al., 2013); indeed to activate the p53 (Meek, 2004; 
Gambino et al., 2013; Clewell et al., 2014). However, the present study shows that rather 
than acting alone, the p53 cooperates with other stress activated proteins to exert its 
regulatory function. The proteins included in the “stress cluster” have been found to be 
activated by various toxic insults, suggesting that the CYP2A6 induction in cells maybe 
complex and multifactorial (Jin et al., 2001; Li et al., 2008; Osabe et al., 2009; Hou et al., 
2012; Hu et al., 2015).  
           It should be noted that the CYP2A6 gene expression is also regulated by some other 
stress activated signalling pathways. Accordingly, the CYP2A6 is induced by the ligand 
activated transcription factors pregnane-X-receptor (PXR) and estrogen receptor-α (ER-α) 
(Itoh et al., 2006; Higashi et al., 2007).  The transcription factor, Nrf-2 activates CYP2A6 
gene expression under oxidative stress (Yokota et al., 2011). Additionally, the 
multifunctional, stress activated hnRNPA1 (Heterogeneous Nuclear Ribonucleoprotein A1) 
has been found to upregulate CYP2A6 expression at post-transcriptional level by stabilising 
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the mRNA and targeting it into the endoplasmic reticulum during transcriptional arrest 
(Christian et al., 2004).  
           These observations together with the findings of this study are in agreement with 
earlier, descriptive evidence on conditions leading to upregulation of the CYP2A6. For 
instance, it has been shown that viral and parasitic infestations, chronic inflammation, 
radiation, alcohol caused liver injury and toxic insults by a variety harmful, structurally 
unrelated chemicals, all can upregulate the gene (Kirby et al., 1994; Donato et al., 2000; 
Niemela et al., 2000; De-Oliveira et al., 2006; Kirby et al., 2011; Abu-Bakar et al., 2013). 
Upregulation by such diverse types of insults has led us to hypothesise that, rather than any 
specific chemical or agent, changes in intracellular conditions such as in redox potential, 
DNA or other macromolecular damage, maybe the cause of induction. Given the fact that the 
induction is often observed in tissues or cells such as liver (Nakajima et al., 2006), lung, 
oesophagus, intestinal, oral and nasal epithelium (Su et al., 1996; Koskela et al., 1999; 
Janmohamed et al., 2001), which encounter high levels of oxygen and chemical exposures, 
one can wonder what is the significance with such an CYP2A6 induction? Our recent work 
has shown that the CYP2A6 and the mouse CYP2A5 play an important role in maintaining 
optimal cellular BR homeostasis and antioxidant capacity (Abu-Bakar et al., 2011; Abu-
Bakar et al., 2012). The present data provide mechanistic insights into the cellular defense 
system consisting of the HMOX1 and CYP2A6: a machinery that maintains optimal 
intracellular BR levels for cellular protection (Discussed also in section 5.2.3).  
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 Figure 5.16: Schematic representation of the transcriptional regulation of the proximal 
CYP2A6 promoter. (A) A “stress cluster” on the proximal CYP2A6 promoter region. 
Proximal CYP2A6 transactivation is governed by the stress activated transcription factors 
p53, CAR, C/EBPα, Oct-1 and nuclear factor HNF-4α. (B) A model depicts the interaction 
between p53 and the other transcription factors in mediating CYP2A6 transactivation. P53- 
mediated CYP2A6 transactivation is dependent on the interaction with CAR and C/EBP-Oct-
1, and for its full activity it is supported by HNF-4α. 
            Although the p53 was shown to induce the CYP2A6 gene during stress and that the 
p53- mediated CYP2A6 transactivation is dependent on the interaction with other stress 
activated transcription factors that bind to the proximal CYP2A6 promoter region, there are 
some questions still to be answered. For instance, it is not clear whether other transcription 
factors interact with the “stress cluster”, especially these activated by stress.  
           P53 has been found to play a dual role both in regulating cyto-protective pathways and 
triggering apoptosis (Bensaad and Vousden, 2007). When cells are under a mild stress, p53 
induces intracellular antioxidant capacity to scavenge excess ROS and maintain cellular 
homeostasis. However, severely damaged cells invoke the strongest possible cell death signal 
by enhancing the expression of p53 and intracellular ROS generation. It is therefore logical to 
assume that CYP2A6 expression may be downregulated to decrease BR oxidation, which 
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leads to accumulating of intracellular BR. As BR has been found to induce p53, inhibit cell 
proliferation, activate cell cycle arrest, and increase apoptosis at concentrations ≥ 25 µM 
(Ollinger et al., 2007), possible downregulation of CYP2A6 may promote apoptosis to 
remove the severely damaged cells. Does p53 also have a role in mediating the CYP2A6 
downregulation? Could it be that when p53 turns from protective to apoptotic mode, its role 
in the regulation of the CYP2A6 changes? To explore these questions, a series experiments 
were designed, which are illustrated in the next section.  
 
5.4 Interaction between p53 and Nrf-2 in mediating CYP2A6 
transactivation and identification of potential repressor region(s) on 
the CYP2A6 promoter 
 
5.4.1 Nrf-2 restrains p53- mediated CYP2A6 transactivation through the C/EBP-Oct-
1RE 
 
            It has been well demonstrated that direct binding of p53 to ARE (Nrf-2 binding site) 
has a suppressive effect on some stress responding genes including the phase II metabolising 
genes NQO-1 and GST-1 (Faraonio et al., 2006; Wakabayashi et al., 2010). A similar 
interaction was observed between transcription factors C/EBPβ and Oct-1in regulating the 
interleukin-8 (IL-8) gene expression (Wu et al., 1997), a known neutrophil chemoattractant 
which has been found to induce ROS production in human umbilical vein endothelial cells 
(HUVECs) (Miyoshi et al., 2010). In the absence of immune activation, Oct-1 binds 
independently to an element overlapping that of C/EBP, repressing IL-8 promoter 
transactivation (Wu et al., 1997), suggesting that activation of a stress responsive gene may 
involve complex interactions with other transcription factors, possibly for cells to deal with 
different levels of cellular perturbations. Notably, it has been reported that, under oxidative 
stress, the activated Nrf-2 expression induces C/EBPβ (LAP) and its truncated form LIP in 
3T3-L1 mouse pre-adipocytes (Hou et al., 2012). The LIP forms heterodimers with the other 
C/EBPs, which has been found to negatively regulate CYP2A6 gene expression (Pitarque et 
al., 2005).  As the present “stress cluster” on the proximal CYP2A6 promoter contains a 
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p53RE and C/EBP-Oct-1RE, it is plausible that the Nrf-2 may interact with these proteins, 
and play a role in its expression.  
             A series of CYP2A6 promoter constructs were co-transfected with p53 alone, Nrf-2 
alone, p53 and Nrf-2 in combination or empty vector expression plasmid (pcDNA3) into the 
C3A cells to detect possible interaction between Nrf-2 and p53 in regulating the CYP2A6 
gene. As shown in Figure 5.17, p53 and Nrf-2 co-transfections induced the luciferase activity 
of both the pGL3-ARE-TK plasmid and pGL4.38-p53RE plasmid compared to empty 
plasmid (pcDNA3) transfected cells, which indicate Nrf-2 and p53 over-expression in the 
transfected cells. Interestingly, p53 over-expression dramatically inhibited the Nrf-2 mediated 
activation of pGL3-ARE-TK plasmid, whereas Nrf-2 co-expression did not affect the p53- 
mediated activation of pGL4.38-p53RE plasmid (Figure 5.17). These results are accordance 
with the previous observations that p53 overexpression interferes with the Nrf-2 mediated 
induction of ARE containing gene promoters (Faraonio et al., 2006). In contrast, an opposite 
effect was observed with both the wildtype distal and the wildtype proximal CYP2A6 
promoters, where Nrf-2 overexpression significant hampers the p53- mediated CYP2A6 
transactivation for both the distal and proximal promoters (Figure 5.17). This result indicates 
that Nrf-2 somehow blocks the p53- mediated CYP2A6 transactivation through the REs 
present on the proximal promoter region (Figure 5.17). Furthermore, this inhibitory effect by 
Nrf-2 disappeared when the DR-4RE, C/EBP-Oct-1RE and HNF-4αRE of the “stress cluster” 
were replaced with a TK promoter, suggesting that the Nrf-2 may supress the p53- mediated 
CYP2A6 transactivation through the interaction of these REs (Figure 5.17). In accordance 
with this, when the C/EBP-Oct-1RE was mutated on the proximal CYP2A6 promoter region, 
the inhibitory effect by Nrf-2 was totally abolished (Figure 5.17).  
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 Figure 5.17: Effect of p53 and Nrf-2 co-expression on the luciferase activity of the 
CYP2A6 promoter constructs. The CYP2A6 promoter constructs together with pcDNA3-
Nrf-2 alone, pcDNA3-hp53 alone, pcDNA3-Nrf-2 and pcDNA3-hp53 in combination or 
empty expression plasmid (pcDNA3) alone were co-transfected into the C3A cells. The 
luciferase activities were measured 24h after transfection and were normalised against co-
transfected pMAX-GFP control plasmid activities. The values (n = 4) represent the means ± 
S.D. Mean difference is significant from control group at ****, p < 0.0001; **, p < 0.005 
(Student’s t test). ns = no significance.  
 
              The observed results suggest that the Nrf-2 restrains p53- mediated CYP2A6 gene 
expression through the C/EBP-Oct-1RE on the proximal CYP2A6 promoter region. It could 
be that Nrf-2 overexpression may induce the truncated C/EBPβ form, LIP in C3A cells. It is 
known that the LIP heterodimers with other C/EBPs binding to the C/EBP-Oct-1RE on the 
proximal CYP2A6 promoter (Pitarque et al., 2005), which may restrain the p53- mediated 
CYP2A6 transactivation. In any case the results further strengthen the proposed hypothesis 
that the induction of CYP2A6 is complex and multifactorial. How do the stress activated 
transcription factors interact in regulating CYP2A6 gene expression when cells cope with 
different types of cellular perturbations? What is the significance of such interactions in 
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regulating CYP2A6 gene expression? Further research is warranted to answer these questions. 
It has been shown that high intracellular BR levels (≥ 50 µM) significantly induce Nrf2 
expression in primary hepatocytes (Kim et al., 2013). Constrained induction of CYP2A6 in 
cells under stress may cause accumulation of BR, which may turn it from antioxidant to a 
pro-apoptotic. Could it be that in extreme stress, BR potentially downregulates its own 
oxidation by suppressing p53-dependent transcription of CYP2A6 to ensure sufficient supply 
to maintain apoptosis once the cells are severly damgaged?   
 
5.4.2 Potential repressor region(s) at CYP2A6 promoter 
 
           As discussed in section 3.1 and 5.2.1, it is likely that suppressive element(s) may exist 
on the CYP2A6 promoter to repress the CYP2A6 gene. The reasons for this are not known but 
could be related to an adaptive mechanism to external stress possibly to promote cell 
apoptosis. This is supported by the previous evidence suggesting the presence of potential 
suppressor(s) upstream the CYP2A6 promoter (Pitarque et al., 2005; Itoh et al., 2006; Higashi 
et al., 2007).  
          To investigate the potential suppressor region(s) on the CYP2A6 promoter, a series of 
stepwise 5’-truncated CYP2A6 promoter constructs with 200 - 300bp intervals were 
generated from the distal CYP2A6-5’-2901/+9 Luc construct, followed by their transfection 
of the constructs into the C3A cells. As shown in Figure 5.18, the region from -250bp to TSS 
containing the “stress cluster” plays an essential role in mediating CYP2A6 gene expression. 
Interestingly, deletion of the sequence from -2253 to -1955bp totally abolished the promoter 
activity compared to the previous longer promoter, while further deletion of the promoter 
from -1955 to -1700bp resulted in a substantial recovery of the activity. This result suggests 
the presence of a negative regulatory region between -2253bp and -1700bp. It could be that 
deletion of the region from -2253 to -1955bp may have created a space for binding of a 
repressor to the promoter, blocking the transcription. Further deletion from -1955 to -1700bp 
may have resulted in a loss of the suppressor, and recovery of the promoter activity. It is also 
worth noticing that deletion of the sequences from -688 to -437 and further to -250bp 
significantly enhances the promoter activity in a stepwise manner compared to the previous 
longer CYP2A6 promoter constructs. This result suggests the existence of other repressor 
regions at the promoter from -250bp further upstream.  
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 Figure 5.18: Luciferase activities driven by the 5’-truncated proximal CYP2A6 
promoters in C3A cells. A series of 5’-truncated CYP2A6 promoter constructs were 
generated with 200-300bp intervals. The generated CYP2A6 promoter constructs together 
with pMAX-GFP were co-transfected into the C3A cells. The promoter activity of a certain 
CYP2A6 promoter construct was compared to the promoter activity of the previous longer 
CYP2A6 promoter construct. The values (n = 4) represent means ± S.D. Mean difference is 
significant at ****, p < 0.0001; *, p < 0.05 (one-way analysis of variance (ANOVA) 
followed by the least significant difference post hoc test). 
            It has previously been shown that distal p53REs may play a suppressive role in 
mediating Polo-like kinase-2 (PLK-2) gene expression, whereas the proximal p53RE 
functions as a gene activator (Burns et al., 2003). Up to five putative p53REs were detected 
upstream TATA box at the CYP2A6 promoter within the 3k bp region (Figure 5.2). It is not 
clear whether these p53REs have a role in regulating CYP2A6 gene expression. Interestingly, 
however, one putative p53RE was identified between -2253bp and -1700bp of the CYP2A6 
promoter (Figure 4.1 and 5.2): the region which was shown to contain repressor activity 
(Figure 5.18). Could the putative p53RE residing in this region functions as a gene repressor, 
negatively regulating the CYP2A6 gene? And could other repressor elements exist further 
downstream between -1700 and -437bp. Further investigations should be undertaken to 
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identify the possible repressor(s) regulating CYP2A6 gene expression, and to understand their 
biological significance.  
 
5.5 Conclusions  
 
            While the CYP2A6 has been shown to play only a minor role in xenobiotic 
metabolism, it has been recognised as a stress responsive enzyme, with an important role in 
maintaining BR homeostasis for cell protection (Abu-Bakar et al., 2005; Abu-Bakar et al., 
2012). In contrast to other CYP enzymes, the CYP2A6 is induced in various stress conditions 
such as viral and parasitic infestations, chronic inflammation, radiation, alcohol caused liver 
injury and structurally unrelated toxic insults (Kirby et al., 1994; Donato et al., 2000; 
Niemela et al., 2000; De-Oliveira et al., 2006; Kirby et al., 2011). Furthermore, the induction 
is typically observed in tissues or cells which suffer from high level of oxygen and chemical 
exposures.  
            Recent studies have shown that the CYP2A6 is regulated by a group of stress 
activated proteins including the PXR, CAR, Nrf-2, C/EBP, Oct-1 and hnRNPA1 (Christian et 
al., 2004; Pitarque et al., 2005; Itoh et al., 2006; Yokota et al., 2011). While the Nrf-2, 
C/EBP/Oct-1 and hnRNPA1 are non-ligand binding, activated by divers cellular disturbances 
(Jin et al., 2001; Christian et al., 2004; Li et al., 2008; Riley et al., 2008; Ma, 2013), the PXR 
and CAR are activated by a multitude of ligands including toxins, drugs and other diverse 
chemicals and xenobiotics (Kliewer et al., 2002; Timsit and Negishi, 2007; Kachaylo et al., 
2011).  
             In this work, sequence analysis of the CYP2A6 promoter revealed six putative 
p53REs, suggesting a potential role for the p53 in regulating CYP2A6 transactivation. A 
series of experiments were designed to investigate the role of p53 in CYP2A6 regulation with 
a special emphasis in understanding its interaction with the other stress activated proteins. 
The results presented in the thesis are obtained from a series of in vitro transfections in 
human immortalised cell lines, which may not direct reflect the situation in vivo. Hence, 
chromatin immunoprecipitation (ChIP) of TFs on the CYP2A6 promoter in human primary 
hepatocytes might further strengthen the extrapolations that are elaborated in the thesis. Such 
approach would also suit for the future toxicological studies on toxic substances in activation 
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of CYP2A6 gene expression in human cells. In relation to the study of TFs interaction in 
mediating CYP2A6 transactivation, a protein immunoprecipitation assay between p53 and the 
other TFs would have provided a direct evidence of such interaction. Considering the 
complex binding of these TFs on the restricted region of the proximal promoter, it may 
however be difficult to reach the detection limit required by the assay. A computational 
simulation of the TFs binding to the CYP2A6 promoter together with the current observations 
on the promoter mutational and transfection studies could offer further valuable interpretation 
for the CYP2A6 transactivation mediated by the TFs interaction. Although there is a 
limitation of the approaches used in the study, the findings demonstrated that: 
i) Stress activated transcription factor p53 has a role in regulating CYP2A6 gene 
expression.  
 
ii) P53- mediated CYP2A6 transactivation takes place through the proximal p53RE 
on the CYP2A6 promoter region.  
 
iii) BaP induced endogenous p53 activates CYP2A6 transactivation in MCF-7 cells.  
 
iv) BaP activates native CYP2A6 and HMOX1 gene expressions in a dose dependent 
manner along with the elevation of the p53 expression in C3A cells, suggesting a 
key role for p53 in the regulation.  
 
v) Proximal CYP2A6 gene promoter transactivation is regulated by a complex 
interaction between transcription factors p53, CAR, C/EBPα, Oct-1 and HNF-4α 
binding to this region.   
 
vi) P53- mediated CYP2A6 transactivation requires interaction with CAR and 
C/EBP/Oct-1, with a support function by HNF-4α.  
 
vii) Replacing the p53RE at the proximal CYP2A6 promoter region with a consensus 
p53RE dramatically enhances the CYP2A6 promoter activity.  
 
viii) Nrf-2 restrains p53 induced CYP2A6 transactivation probably through interfering 
with C/EBP-Oct-1RE binding to the proximal promoter region.  
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ix) The presence of suppressor regions further upstream on the CYP2A6 promoter 
may have a role in mediating CYP2A6 downregulation.  
            Collectively, these results provide a mechanistic explanation for the earlier, 
descriptive observations where the CYP2A6 was found to be up-regulated by a multitude of 
seemingly unrelated toxic insults.  
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6. GENERAL CONCLUSIONS AND FUTURE 
DIRECTIONS 
 
6.1 General conclusions  
 
           The findings presented in this thesis have helped to understand the underlying 
mechanisms by which the CYP2A6 gene is regulated during diverse toxic insults. The study 
demonstrated in particular that: 
i) The bilirubin oxidase CYP2A6 gene is an immediate target of the stress activated 
transcription factor p53.  
 
ii) The transcriptional activation of the CYP2A6 gene by p53 involves complex 
interaction with CAR, C/EBP/Oct-1 and HNF-4α. 
          CYP2A6 has been demonstrated to play an important role in maintaining intracellular 
BR homeostasis (Abu-Bakar et al., 2005; Abu-Bakar et al., 2012). Bilirubin is an efficient 
scavenger of reactive oxygen and nitrogen species at intracellular concentrations ranging 
from 0.01 to 20 µM (Liu et al., 2003; Jansen et al., 2010). However, at concentrations ≥ 20 
µM, toxicity of BR overrides the beneficial effects, disrupting mitochondria membrane 
permeability amongst other things and promoting apoptosis (Rodrigues et al., 2002). 
Therefore, a system should be in place to efficiently maintain an optimal intracellular BR 
level.  
           When cells are under acute stress, the stress activated TFs have been found to induce 
the CYP2A6 gene. The gene product enzymatically metabolises BR to BV to curb BR 
cytotoxicity. Once cells suffer from depletion of intracellular BR, it can be efficiently 
reduced back by biliverdin reductase (BVR). This hypothesis is supported by the recent 
finding that in cells under stress, the induced CYP2A6 together with the HMOX1 producing 
BR are targeted to mitochondria to adjust the BR levels locally according to needs, probably 
to protect the organelle (Muhsain et al., 2015). On the other hand, it is known that when cells 
are under chronic stress, it leads them to trigger apoptosis pathway eventually. It is tempting 
to speculate that instead of upregulation of the CYP2A6, a downregulation may occur in 
these conditions to decrease the BR oxidation thereby rapidly accumulating intracellular BR 
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to its toxic levels. The elevated intracellular BR in turn can enhance apoptosis to remove the 
severely damaged cells. It is plausible that the CYP2A6 downregulation may be activated 
through the repressor element(s) present on CYP2A6 promoter. Could it be that under chronic 
oxidative stress, the repressor(s) is activated to mediate CYP2A6 downregulation? In 
addition, interplay among the stress activated TFs in regulation of CYP2A6 gene expression 
has been demonstrated, which may act as a sensitive control system to cope with different 
types of cellular stress. Such mechanisms of CYP2A6 gene regulation may form an essential 
part of the cell defense system against different levels of cellular stress either in strengthening 
cell antioxidant capacity or promoting apoptosis.  
 
6.2 Future directions  
 
           Compared with several xenobiotic metabolising CYP enzymes, the unique way the 
CYP2A6 responds to cellular perturbations by various stressors has attracted researcher’s 
attention. Understanding the fundamental gene regulatory mechanisms of the CYP2A6 
promoter is critical for explaining the observed upregulation in perturbed cells, which may 
also provide potential targets for studying diseases in relation to gene polymorphisms or in 
vitro bioassay developments. 
           In addition to the findings in this thesis, some questions remain to be answered; these 
include:  
(a) How does Nrf-2 and p53 interact in regulating CYP2A6 and HMOX1expressions 
when cells are exposed to different levels of cellular perturbations?  
 
(b)  How does the potential suppressor(s) on the promoter region block CYP2A6 
transactivation? 
 
(c) Are the stress activated transcription factors binding to the CYP2A6 promoter acting 
in a coordinated way in regulating CYP2A6 gene during multiple forms of stresses? 
 
(d) How is the CYP2A6 gene expression regulated in different organs or cell systems?  
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(e) When cells are under stress, and the p53 is attacking the mitochondria, are the 
CYP2A6 and HMOX1 still targeted into mitochondria? 
 
(f) How is the CYP2A6 gene expression affected by the polymorphism of the regulatory 
regions on the CYP2A6 promoter?  
 
(g) Could the CYP2A6 induction by multiple forms of stress be applied in an in vitro 
bioassay system to assess the biological response to toxic agents? 
 
           Addressing these questions would provide a systematic theoretical explanation for the 
previously observed CYP2A6 induction by various stress conditions, and would significantly 
improve our understanding of the cell defense system against cellular perturbations. In 
addition, as the CYP2A6 is a regulator of BR - and may play a dual role in either scavenging 
intracellular ROS or promoting apoptosis, understanding the fundamental mechanisms of 
CYP2A6 regulation may help identifying a target to maintain the intracellular BR 
concentration within a therapeutic range thereby exerting a role in reducing risk for some 
ROS related chronic diseases such as cardiovascular disease, neurodegenerative disorder and 
cancer. The characteristics of CYP2A6 induction by various toxic insults may also indicate a 
role of CYP2A6 as a delicate, intracellular stress sensor to assess the intracellular stress 
levels.  
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8.  APPENDICES  
 
Appendix A: List of materials and instruments 
 
                Chemicals/ reagents          Manufacturers/ supplier  
Benzo[α]pyrene (BaP), DMSO, Methanol, 
Ethanol, 2-propanol, Chloroform, PBS, 
phenylmethylsulfonyl fluoride (PMSF), 
MgCl2, KCl, KOH, NaCl, HCl, H2PO4, 
NaOH, Hepes, EDTA, IGEPAL, glacial 
acetic acid (CH3COOH), sodium dodecyl 
sulfate (SDS), cyclohexanediamine 
tetraacetic acid (CDTA), saline sodium citrate 
(SSC), Triton X-100, 2-mercaptoethanol, 
sucrose, glycerol, glycine, leupeptin, bovine 
serum albumin (BSA), p-coumaric acid, 
luminol, ampicillin, kanamycin, biological 
agar, Tween-20, RIPA buffer, RNAse and 
DNAse free water 
 
William’s Medium E, Fetal Bovine Serum 
(FBS), Glutamax, Penicillin-Streptomycin,  
Dulbecco's Modified Eagle Medium 
(DMEM), TrypleTM, Trizol Reagent 
 
Boric acid 
 
Dithiothreitol (DTT), 
 
Ethidium bromide, laemmli buffer, western C 
marker, iQTM SYBR® Green Supermix   
 
BactoTM yeast extract, BactoTM Tryptone 
 
O’ Gene RulerTM 50bp DNA ladder, O’ Gene 
RulerTM 1kb DNA ladder, 6x loading dye 
solution, Trizol Reagent 
  
Polyethylenimine (PEI) 
 
Agarose  
 
Sigma-Aldrich, Sydney, Australia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Life Technologies, Vic, Australia  
 
 
 
 
Merck, Germany  
 
Applichem, Germany  
 
Bio-Rad Laboratories Pty. 
Ltd.,Sydney Australia 
 
Becton Dickison, Australia 
 
Thermo Fisher Scientific Inc. Melbourne, 
Victoria, Australia 
 
 
Polysciences Inc., PA, USA 
 
PROGEN Biosciences Ltd, Brisbane, 
Australia  
 
                 Restriction enzymes            Manufacturers/ supplier 
Fast digest KpnI, Fast digest NheI, Fast Thermo Fisher Scientific Inc. Melbourne, 
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digest BamHI, Fast digest ApaI, Fast digest 
EcoRI, Fast digest BsmBI 
Victoria, Australia 
 
 
                     Cell lines                       Supplier 
Human hepatocellular carcinoma  HepG2 cell 
 
Human hepatocellular carcinoma C3A cell 
 
Human breast adenocarcinoma MCF-7 cell 
 
 
 
XL-1 blue competent cell 
 
ATCC, Manassas, VA, USA 
 
 
 
Kind gift from Dr Greg Monteith, Pharmacy 
Australia Centre of Excellence, University of 
Queensland 
 
Agilent technologies Inc., CA, USA 
         Antibodies /cell lysates          Manufacturers/ supplier 
Mouse monoclonal anti-p53 antibody 
 
Mouse monoclonal anti-C/EBPα antibody  
 
Mouse monoclonal anti-Oct-1 antibody  
 
Rabbit polyclonal anti-HNF4α antibody 
 
Rabbit polyclonal anti-RXR antibody  
 
A-431 whole cell lysate 
 
HepG2 whole cell lysate 
 
Mouse monoclonal anti-CYP2A6 antibody 
 
Mouse anti-HMOX1 antibody 
 
Rabbit polyclonal anti -β-actin antibody 
 
Rabbit polyclonal anti-CAR antibody 
 
Rabbit polyclonal anti-digoxigenin-AP 
 
Goat anti-mouse antibody conjugated with 
horseradish-peroxidase 
 
Goat anti-rabbit antibody conjugated with 
horseradish-peroxidase 
 
Santa Cruz Biotechnology Inc. Dallas, 
Texas, USA 
 
 
 
 
 
 
 
 
 
 
 
 
Abcam, Cambridge, UK 
 
 
 
 
 
 
 
Roche Diagnostics, Sydney, Australia  
 
Thermo Fisher Scientific Inc. Melbourne, 
Victoria, Australia 
 
 
 
                Plasmids /cDNAs        Manufacturers/ supplier 
pGL4.38-p53RE 
 
pGL3-Basic, pGL3-CYP2A6-2901/+9, 
Promega, Madison, WI, USA 
 
Kind gift from Dr Jukka Hakkola, Institute of 
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pGL3-ARE-TK, pCB6-HNF4α 
 
 
pcDNA3.1/V5-His-C/EBPα 
 
 
 
 
 
pSG5-hCAR 
 
 
Human Oct-1 expression plasmid 
 
 
 
 
pMAX-GFP 
 
pcDNA3-basic,pcDNA3-hp53, pcDNA-Nrf-2 
 
 
 
GAPDH cDNA 
Biomedicine, University of Oulu, Finland 
 
 
Kind gift from Dr. Masahiko Negishi, 
Laboratory of Reproductive and 
Developmental Toxicology, National 
Institute of Environmental Health Sciences, 
Research Triangle, NC.  
 
Kind gift from Dr. P. Honkakoski, University 
of Kuopio, Finland  
 
Kind gift from Dr. Peter Mackenzie , 
School of Medicine, Flinders Medical 
Centre, Flinders University,  Bedford Park 
SA, Australia 
 
Lonza group Ltd, Sydney, Australia 
 
Dr Matti Lang, Entox, Faculty of Health and 
Behavioural Sciences, The University of 
Queensland, Australia 
 
CLONTECH, Palo Alto, CA, USA 
 
                Lab consumables           Manufacturers/ supplier 
0.22 μm filter 
 
Hybond ECL nitrocellulose membrane 
Hybond-N nylon membrane  
 
0.2µm PVDF membrane  
 
25cm2 cell culture flask 
75cm2 cell culture flask 
96-well, F-Bottom white microplate  
 
10mm × 20mm cell culture dish 
96-well cell culture plate 
 
NunclonTM Delta surface 6-well plate 
NunclonTM Delta surface 24-well plate 
 
Lazy-L spreaders  
 
Inoculation loops  
 
Merck Millipore Ltd, Germany  
 
Amersham Biosciences UK, Ltd 
 
 
Bio-Rad Laboratories, USA 
 
greiner bio-one, Germany  
 
 
 
Corning, NY, USA 
 
 
Thermo Fisher Scientific Inc. Melbourne, 
Victoria, Australia 
 
Sigma-Aldrich, Sydney, Australia 
 
Sarstedt AG & Co, Germany  
                           Kits         Manufacturers/ supplier 
QIAGEN Plasmid Midi Kit (25) QIAGEN, Hilden, Germany 
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QIA quick PCR purification kit 
 
Trans-Blot® Turbo™ RTA Mini 
Nitrocellulose Transfer Kit 
 
4-15% Mini-PROTEANTM TGX Stain-
FreeTM Protein Gels 
 
DC protein assay kit 
 
BriteliteTMplus Reporter Gene Assay System 
 
GenElute™ Plasmid Miniprep Kit 
 
DIG gel shift kit  
 
SuperScript®III First-Strand Synthesis kit  
 
Ligase kit 
 
 
 
 
Bio-Rad Laboratories, USA 
 
 
 
 
 
 
 
PerkinElmer, USA 
 
Sigma-Aldrich, Sydney, Australia 
 
Roche Diagnostics, Sydney, Australia  
 
Life Technologies, Vic, Australia 
 
Thermo Fisher Scientific Inc. Melbourne, 
Victoria, Australia 
 
                Instruments          Manufacturers/ supplier 
Pellet PESTLE® cordless motor  
 
HERA cell 150i CO2 Incubator 
 
Orbital shaker incubator  
 
NanoDrop 1000 Spectrophotometer  
 
SpeedVas concentrator SPD 1010 
 
Eppendorf centrifuge 5810R 
 
PC700 pH meter  
 
Mini incubator  
 
GELAIRE® class II biological safety cabinet  
 
 
Nikon, ECLIPSE, TS100 microscope  
 
EXPLORER, Semi-micro Balance® 
 
Corbett RotorGene 3000  
 
Allegra X-15R Centrifuge 
 
Sigma-Aldrich, Sydney, Australia 
 
Thermo Fisher Scientific Inc. Melbourne, 
Victoria, Australia 
 
 
 
 
 
 
 
 
 
 
Labnet International, Inc, NJ, USA  
 
The Kelly Company, Pty, Ltd, Sydney, 
Australia 
 
Nikon, Japan 
 
OHAUS, Melbourne, Australia  
 
QIAGEN, Hilden, Germany 
 
Beckman Coulter Inc, USA 
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xMark™ Microplate  
Spectrophotometer 
 
TC20TMCell counter  
 
My CyclerTM thermal cycler  
 
ChemiDocTM MP imaging system  
 
Trans-blot® Turbo™ Transfer system   
 
FLUOstar Omega multimode microplate 
reader 
 
UV StratalinkerTM 1800  
 
Bio-Rad Laboratories Pty. 
Ltd, USA 
 
 
 
 
 
 
 
 
 
 
 
 
Integrated Sciences, Australia 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
Appendix B: Transformation of CYP2A6 promoter constructs into the XL-
1 blue competent cell 
 
The generated CYP2A6 promoter constructs were propagated in the XL-1 blue competent cell 
(Agilent technologies Inc., CA, USA). In brief, 50 µl of XL-1 blue competent cell was 
thawed on ice just before use. 10 ng of generated CYP2A6 promoter construct was added to 
the competent cell with gentle mixes. The plasmid DNA and competent cell mixtures were 
incubated on ice for 30 min before being heat activated for 90 seconds at 420C. The plasmid 
DNA and competent cell mixtures were returned to ice for 1-2 min followed by adding 300 
µl of Luria-Bertani (LB) broth (1% of tryptone, 0.5% of yeast extract, 0.5% of NaCl) into the 
mixtures. The mixtures were then incubated in a 370C orbital shaker incubator (Thermo 
Fisher Scientific Inc. Melbourne, Victoria, Australia) by shaking at 250 rpm for 1 hour. The 
transformed competent cell culture was plated to a selective LB medium (1% of tryptone, 
0.5% of yeast extract, 0.5% of NaCl, 2% of agar, 100µg/ml ampicillin) plate and was 
incubated in a 370C mini incubator (Labnet International, Inc, NJ, USA) for 12-16 hours. The 
colonies were selected and were subcultured in 3 ml of selective LB broth (1% of tryptone, 
0.5% of yeast extract, 0.5% of NaCl, 100µg/ml ampicillin) respectively. The selected cell 
cultures were incubated in a 370C orbital shaker incubator by shaking at 250 rpm for 12-16 
hours before harvest. The propagated CYP2A6 promoter constructs in the XL-1 blue 
competent cells were purified by using the GenElute™ Plasmid Miniprep Kit (Sigma-
Aldrich, Sydney, Australia) according to manufacturer’s instructions.  
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Appendix C: Gene sequencing procedures  
 
The generated pGL3-CYP2A6 promoter constructs were sequenced by using BigDye ® 
Terminator V3.1 Cycle sequencing Kit (Applied Biosystems, CA, USA). Briefly, a reaction 
mixtures was prepared containing 500 ng of plasmid sample, 8 µl of Terminator Ready 
Reaction mix and 3.2 pmol forward primer that amplify CYP2A6 promoter gene in a total 
volume of 20 µl. Plasmid DNA fragment was amplified by incubating the reaction mixture in 
a thermal cycler (Bio-Rad, Sydney, Australia) at the following conditions: initial denaturation 
at 960C for 1 min, 25 cycles of sample at 960C for 10 seconds, 500C for 5 seconds and 600C 
for 4 min. The samples were hold at 40C before purification. They were transferred to 1.5ml 
microcentrifuge tubes and 5ul of 125 mM EDTA was added to each sample. 60 µl of 100% 
ethanol were added to each sample and were incubated at room temperature for 15 min. DNA 
pellets were harvested by spinning the samples at maximum speed followed by washing with 
250 µl of 70% ethanol. Air dries the washed pellet in a laminar flow hood. The DNA samples 
were sequenced by using the facilities at AGRF (Australian Genome Research Facility Ltd, 
Brisbane, Australia). Plasmid DNA sequences were analysed by using software Chromas Lite 
2.4.  
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Appendix D: Generation of mutated CYP2A6 promoter constructs   
 
Mutated CYP2A6 promoters were generated by introducing four restriction enzyme cutting 
sites (BamHI, ApaI, EcoRI and BsmBI) into the proximal CYP2A6 promoter region. The 
mutated sequences on the proximal CYP2A6 promoter region are shown in the table below. 
The RE mutated CYP2A6 promoters were generated by using the forward and reversed 
primers that are shown in Appendix H. They were inserted into pGL3-Basic vector by a 
ligase reaction. Detailed procedures are shown in Materials and Methods, section 4.3.3. The 
correctness of the mutated proximal CYP2A6 promoters were verified by cutting the related 
restriction enzyme cutting sites followed by applying the digested plasmid DNAs to agarose 
gel electrophoresis. 0.5 µg of each pGL3-CYP2A6mut plasmid was digested by 1 µl of 
BamHI, ApaI, EcoRI and BsmBI restriction enzymes (Thermo Fisher Scientific Inc. 
Melbourne, Victoria, Australia) respectively. 1% of agarose (PROGEN Biosciences Ltd, 
Brisbane, Australia) gel was prepared by dissolving 0.4 g of agarose to 40 ml of 1 × TAE 
buffer (40 mM Tris, 20 mM acetic acid, 1mM EDTA, pH 7.6).  The digested plasmid DNAs 
were separated by agarose gel electrophoresis at the conditions of voltage 100V for 1 hour. 
The digested plasmid DNA products were visualised by the ChemiDocTM MP imaging 
system (Bio-Rad Laboratories, USA). 
Putative 
REs 
Putative RE sequences  
5’to 3’  
Mutated RE sequences  
5’ to 3’  
Restriction 
cutting sites  
p53RE 
 
 
ATTCATGGTGGGGCATG
TAG 
 
ATTACCAGTGGGGATCC
TAG 
 
GGATCC 
(BamHI) 
 
DR-4RE GGGAGGTGAAATGAGG
TAA 
GGGCCCCGAAATGAGGT
AA 
GGGCCC 
(ApaI) 
 
C/EBP RE 
 
GTAATTATGTAAT 
 
GTAACACGAATTC 
 
GAATCC 
 
 
HNF-4α RE 
 
 
CAGCCAAAGTCCA 
 
 
 
CAGCCAACGTCTC 
(EcoRI) 
 
CGTCTC 
(BsmBI) 
 
 
 
 
 
113 
 
Appendix E: List of CYP2A6 promoter constructs in the thesis  
 
Constructs Schematic diagram 
5’-truncated 
CYP2A6 promoters  
-2901 
 
        -2541 
 
               -2253 
 
                     -1955 
 
                          -1700 
 
                               -1463 
 
                                    -1246 
 
                                             -942 
 
                                                     -688 
                     
                                                              -437 
 
                                                                -367 
 
                                                                  -308 
 
                                                                    -250 
              
                                                                      -160 
 
                                                                           -74 
 
Mutated distal  
CYP2A6  promoters 
    
  
                                                           p53RE 
-2901 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2901   
 
 
 
 
 
 
 
 
 
 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC × 
LUC × TK 
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Mutated proximal 
CYP2A6 promoters  
                       -160 
 
                                                                 Oct-1 
                                       p53       CAR    C/EBP   HNF-4α 
                       -160 
 
                       -160 
 
                       -160 
 
                       -160 
 
                        -160 
                        
                        -160 
                                                                                                                   
                        -160 
 
                        -160 
 
                        -160 
 
                        -160 
 
                        -160 
 
                        -160 
 
                        -160 
 
                        -160 
 
                        -160 
  
 
 
 
 
 
 
 
 
 
× LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
LUC 
× 
× 
× 
× × 
× × 
× × 
× × 
× × 
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Appendix F: Preparation nuclear and cytosolic extracts from cultured cells  
 
5 × 106 cells in a 100 mm culture dish were washed and resuspended in 5 ml cold PBS. The 
cell suspension was centrifuged at 1600 × g for 10 min at 4oC. The resulting pellet was 
resuspended in 200 µl of buffer A (10 mM Hepes-KOH, pH 7.9, 1.5 mM MgCl2, 10 mM 
KCl, 0.5 mM DTT, 0.2 mM PMSF, 10µg/ml leupeptine, 0.4% IGEPAL) and kept on ice for 1 
h. Thereafter, the cell suspension was vortexed, homogenised and centrifuged at 12,000 × g 
for 10 min at 4oC. The supernatant containing cytoplasmic proteins was aliquoted and stored 
at -80oC. The pellet containing nuclei was resuspended in 50 µl of cold buffer B (20 mM 
Hepes-KOH, pH 7.9, 25% glycerol, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 0.5 mM 
DTT, 0.2 mM PMSF, 0.4% IGEPAL) and gently agitated with magnetic stirrer for 30 min at 
4oC. The suspension was homogenised and centrifuged at 15,000 × g for 15 min, at 4oC.  The 
supernatant containing nuclear proteins was diluted 1:1 with the dilution buffer (20 mM 
Hepes-KOH, pH 7.9, 15% glycerol, 0.2 mM EDTA, 0.5 mM DTT, 0.2mM PMSF), aliquoted 
and stored at -80oC. 
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Appendix G: Western blotting procedures  
 
The p53, CYP2A6 apoprotein, HMOX1, CAR, C/EBPα, Oct-1 and HNF-4α protein levels in 
the subcellular fractions were assessed by Western Immunoblotting. In brief, 30 µg of 
cytosolic or nuclei proteins were separated by 4%-15% SDS-polyacrylamide gel (Bio-Rad 
Laboratories, USA) electrophoresis. The p53 protein was electrophoretically transferred onto 
a Hybond ECL nitrocellulose membrane (Amersham Biosciences UK, Ltd), and the CYP2A6 
apoprotein, HMOX1, CAR, C/EBPα, Oct-1 and HNF-4α proteins were transferred onto a 0.2 
µm PVDF membrane, and blocked overnight in Tris-buffered saline containing 0.1% Tween 
20 (TBS-T) and 5% non-fat milk. The membranes were then incubated with the anti-p53, 
anti-CYP2A6, anti-HNF-4α antibodies (1:500 dilution), anti-HMOX1, anti-CAR, anti-
C/EBPα, anti-Oct-1 and anti-beta actin antibodies (1:1000) respectively for 2 h, washed with 
TBS-T, and incubated for 1 h with horseradish peroxidase-conjugated goat anti-mouse IgG 
(1:3000 dilution). After further washing with TBS-T, the membrane was incubated with 
luminol solution (1 M Tris pH 8.5, 90 mM p-coumaric acid, 250 mM luminol, and 3% H2O2) 
for 5 min and immunoreactive bands were visualised and captured by the ChemiDocTM MP 
imaging system (Bio-Rad Laboratories, USA). 
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Appendix H: List of primers, probes and oligonucleotides used in the thesis  
 
Primers Sequences 
PCR Amplification: 
CYP2A6 5’ -2901KpnI FW 
CYP2A6 5’ -2541KpnI FW 
CYP2A6 5’ -2253KpnI FW 
CYP2A6 5’ -1955KpnI FW 
CYP2A6 5’ -1700KpnI FW 
CYP2A6 5’ -1463KpnI FW 
CYP2A6 5’ -1246KpnI FW 
CYP2A6 5’ -942KpnI FW 
CYP2A6 5’ -688KpnI FW 
CYP2A6 5’ -437KpnI FW 
CYP2A6 5’ -368KpnI FW 
CYP2A6 5’ -308KpnI FW 
CYP2A6 5’ -250KpnI FW 
CYP2A6 5’ -160KpnI FW 
CYP2A6 5’ -74KpnI FW 
CYP2A6 5’ +9NheI RV 
EMSA 
 
 5’-GACGGTACCCATCCATCCGCTTCATCCTACAG-3’ 
 5’-GACGGTACCACCATTCTCTCACTCCATGCTC-3’ 
 5’-GACGGTACCGTGCTAATCTTCCTTCCCACCTC-3’ 
 5’-GACGGTACCATATCAGCACCTGCCTCATGC-3’ 
 5’-GACGGTACCGGCCATACCTGATGCTGATATC-3’ 
 5’-GACGGTACCGGATGATCATGATGAACCAACC-3’ 
 5’-GACGGTACCCCAATCTCTTCTGCCACTGTTC-3’ 
 5’-GACGGTACCCAATCTAGTGGGTTTCCCTG-3’ 
 5’-GACGGTACCCTGAGGTTCCAATGAGGATTC-3’ 
 5’-GACGGTACCCCTAAATGCACAGCCACACTTTG-3’ 
 5’-GACGGTACCCCCCCAGATCCACAACTTTG-3’ 
 5’-GACGGTACCGTGCTCCCCTATGCAAATATTC-3’ 
 5’-GACGGTACCTCCTAAATCCACAGCCCTGC-3’ 
 5’-GACGGTACCTTATCCTCCCTTGCTGGCTG-3’ 
 5’-GACGGTACCATCAGCCAAAGTCCATCCCTC-3’ 
 5’-GACGCTAGCGGTGGTAGTGGGATGATAGATG-3’ 
 
Primer 1 
Primer 2 
CYP2A6-5’-127/-98-FW 
CYP2A6-5’-127/-98-RV 
 5’-TGCTGGCTGTGTCCCAAGCTAG-3’ 
 5’-GGGATGGACTTTGGCTGATTAC-3’ 
 5’-CAGGATTCATGGTGGGGCATGTAGTTGGGA-3’ 
 5’-TCCCAACTACATGCCCCACCATGAATCCTG-3’ 
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CYP2A6-5’-103/-80-FW 
CYP2A6-5’-103/-80-RV 
CYP2A6-5’-92/-65-FW 
CYP2A6-5’-92/-65-RV 
CYP2A6-5’-77/-53-FW 
CYP2A6-5’-77/-53-RV 
Consensus p53RE-FW 
Consensus p53RE-RV 
Site directed mutagenesis  
 5’-GTTGGGAGGTGAAATGAGGTAATT-3’ 
 5’-AATTACCTCATTTCACCTCCCAAC-3’ 
 5’-AAATGAGGTAATTATGTAATCAGCCAAA-3’  
 5’-TTTGGCTGATTACATAATTACCTCATTT-3’ 
 5’-GTAATCAGCCAAAGTCCATCCCTCT-3’ 
 5’-AGAGGGATGGACTTTGGCTGATTAC-3’ 
 5’-AGACATGCCTAGACATGCCT-3’ 
 5’-AGGCATGACTAGGCATGTCT-3’ 
 
CYP2A6-p53mut FW1 5’-ACCAGTGGGGATCCTAGTTGGGAGGTGAAATG-3’ 
CYP2A6-p53mut FW2 5’-ACCAGTGGGGATCCTAGTTGGGCCCCGAAATG-3’ 
CYP2A6-p53mut FW3 5’-GACATGCCTAGACATGCCTTTGGGAGGTGAAATGAG-3’ 
CYP2A6-DR4mut FW1 5’-GGGCCCCGAAATGAGGTAATTATGTAATCAGCC-3’ 
CYP2A6-DR4mut FW2 5’-GGGCCCCGAAATGAGGTAACACGAATTCCAG-3’ 
CYP2A6-C/EBPmut FW1 5’-GTAACACGAATTCCAGCCAAAGTCCATCCCTC-3’ 
CYP2A6-C/EBPmut FW2 5’-GTAACACGAATTCCAGCCAACGTCTCTCCCTC-3’ 
CYP2A6-HNF4αmut FW1 5’-CAGCCAACGTCTCTCCCTCTTTTTCAGGCAGT-3’ 
CYP2A6-p53mut RV1 5’-TAGGATCCCCACTGGTAATCCTGCCTAGCTTGG-3’ 
CYP2A6-p53mut RV2 5’-AGGCATGTCTAGGCATGTCTCCTGCCTAGCTTGGGA-3’ 
CYP2A6-DR4mut RV1 5’-CCTCATTTCGGGGCCCAACTACATGCCCCA-3’ 
CYP2A6-DR4mut RV2 5’-CCTCATTTCGGGGCCCAACTAGGATCCCCA-3’ 
CYP2A6-C/EBPmut RV1 5’-CTGGAATTCGTGTTACCTCATTTCACCTCCC-3’ 
CYP2A6-C/EBPmut RV2 5’-CTGGAATTCGTGTTACCTCATTTCGGGGC-3’ 
CYP2A6-HNF4αmut RV1 5’-GGGAGAGACGTTGGCTGATTACATAATTACCTC-3’ 
CYP2A6-HNF4αmut RV2 5’-GGGAGAGACGTTGGCTGGAATTCGTGTTAC-3’ 
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mRNA Analysis  
CYP2A6 NM_000762 
 
 
GAPDH NM_002046 
 
 
HMOX1 NM_002133 
 F: 5’-AAGATCAGTGAGCGC TATGG-3’ 
 R: 5’-TGAATACCACGCATAGCCT-3’  
 Amplicon size: 178 bp 
  F: 5’- CATGAGAAGTATGACAACAGCCT-3’ 
  R: 5’-AGTCCTTCCACGATACCAAAGT-3’ 
  Amplicon size: 113 bp 
  F: 5’- CAGTGCCACCAAGTTCAAGC-3' 
  R: 5’-GTTGAGCAGGAACGCAGTCTT-3' 
  Amplicon size: 112 bp 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
Appendix I: Paper I 
 
Click here to download the original publication of paper I  
 
Hu, H., Yu, T., Arpiainen, S., Lang, M.A., Hakkola, J., Abu-Bakar, A., 2015. Tumour 
suppressor protein p53 regulates the stress activated bilirubin oxidase cytochrome P450 2A6. 
Toxicology and applied pharmacology 289, 30-39. 
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Abstract 32 
The Cytochrome P450 (CYP) 2A6 hemoprotein plays an important role in regulating 33 
intracellular antioxidant capacity (Abu-Bakar et al., 2012), and is induced by toxic insults 34 
including oxidative stress. This paper describes the mechanism by which stress activated 35 
transcription factors: CAR, C/EBPα/ Oct-1 and the p53, together with the HNF-4α, regulate 36 
the encoding CYP2A6 gene. Overexpression of these proteins individually in the human 37 
hepatocellular carcinoma cell line C3A, upregulated (with the exception of CAR) a 38 
recombinant gene consisting of proximal promoter of the CYP2A6 including all the RE:s of 39 
the regulatory proteins. Mutations introduced at the RE:s respectively preventing the proteins 40 
from binding, reduced the gene expression levels as compared to the wild type, thus 41 
suggesting a role for all five proteins in the regulation. Introducing a series of triple mutations 42 
leaving only one of the four RE:s intact, demonstrated that only the CAR and the  43 
C/EBPα/Oct-1 could support the gene expression partially independently form the other 44 
proteins. For the HNF-4α and p53 interaction with the other proteins was necessary to exert 45 
their regulatory function. A series of pairwise mutations revealed a complex interaction 46 
between the proteins including a close cooperation between the stress-activated proteins: p53, 47 
Oct-1/ C/EBPα and CAR, supported by the HNF-4α for full activation of the gene. An EMSA 48 
analysis was performed to confirm specific binding of the regulatory proteins to their 49 
respective RE:s at the CYP2A6 promoter. Replacement of the p53RE at the CYP2A6 50 
promoter with p53 consensus sequence resulted in an extremely high expression of the 51 
recombinant gene upon overexpression of the p53. While unexpected, this result agrees with 52 
the rest of the evidence and supports a model where the stress activated proteins form a 53 
compact cluster, assisted by the liver specific HNF-4α for full activity. The significance of 54 
this model in cellular defense against toxic insults is discussed.  55 
 56 
 57 
 58 
 59 
 60 
 61 
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Introduction 62 
 The human cytochrome P450 (CYP) 2A6 enzyme is  a key catalyst for the metabolism of 63 
nicotine (Nakajima et al., 1996), several nitrosamines (Yamazaki et al., 1992) and other 64 
toxins (Abu-Bakar et al., 2013). Unlike most other CYP:s, the CYP2A6 gene is known to be 65 
upregulated by diverse toxic insults such as oxidative stress, radiation, chronic inflammation, 66 
cellular perturbation and transcriptional arrest, as well as by a variety of structurally unrelated  67 
chemicals (Kirby et al., 1994; Donato et al., 2000; Niemela et al., 2000; Christian et al., 68 
2004; De-Oliveira et al., 2006; Kirby et al., 2011). Such mode of regulation which seems to 69 
be related to cellular events or processes, caused by external toxic agents, rather than by any 70 
specific ligand or chemical per se (Donato et al., 2000; Onica et al., 2008; Jin et al., 2012), 71 
has led us to believe that the gene product may have a protective function (Christian et al., 72 
2004; Yokota et al., 2011). The observed up-regulation of the CYP2A6 following toxic 73 
insults is reflected in the complex regulation of encoding gene by several stress activated 74 
transcriptional and post-transcriptionally signaling pathways each contributing to its 75 
expression depending on the nature of perturbations. Accordingly, the transcriptional 76 
regulation is mediated by transcription factors (TFs) involved in cellular homeostasis and 77 
cyto-protection, such as bile acid/steroid homeostasis and energy metabolism by pregnane-X-78 
receptor (PXR), peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) and 79 
oestrogen receptor α (ERα) (Staudinger et al., 2001; Xie et al., 2001; Goodwin et al., 2003) 80 
by interacting with the relevant response elements on the 5′-flanking region of CYP2A6 gene 81 
(>−2400 bp) (Itoh et al., 2006; Higashi et al., 2007). Similarly, stress activated nuclear factor 82 
(erythroid-derived 2)-like 2 (Nrf2) mediates transcriptional activation of CYP2A6 by direct 83 
interaction with the antioxidant response element (ARE) at position −1212 of the gene’s 84 
distal promoter (Yokota et al., 2011). In addition, we have shown that the multifunctional, 85 
stress activated hnRNPA1 involved in nucleocytoplasmic mRNA transport and mRNA 86 
stabilization, contributes to the gene upregulation through stabilizing the CYP2A6 mRNA 87 
during transcriptional arrests (Christian et al., 2004).  It is noteworthy that some of the critical 88 
regulatory proteins involved in the regulation, such as the Nrf-2 and the hnRNPA1 are not 89 
ligand activated. 90 
        Recently, we have demonstrated that the CYP2A6 plays a role in regulating the 91 
intracellular antioxidant capacity by optimizing the bilirubin levels (BR, one of the most 92 
potent endogenous antioxidants), together with the Heme-Oxygenase 1(HO-1) (Hu et al., 93 
2015). During toxic insults the CYP2A6 and the HO-1 are upregulated in a coordinated 94 
fashion leading to increased BR production and antioxidant capacity in cells under stress. We 95 
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have also shown that in cells under stress the mouse CYP2A5,and HO-1 are targeted into 96 
mitochondria, to regulate the local BR levels (Abu-Bakar et al., 2011; Muhsain et al., 2015). 97 
  These observations are well in accordance with our earlier evidence showing that the 98 
CYP2A6 is induced by various external insults causing cellular perturbations, and the 99 
hypothesis that the CYP2A6 is somehow involved in adaptive response to the stress 100 
(reviewed in Abu-Bakar et al., 2013).  101 
  In our recent paper we reported that the stress activated transcription factor, p53, is a 102 
regulator of the CYP2A6 gene (Hu et al., 2015). The p53, induced by various forms of stress 103 
such as chemical insults, radiation, oxidative stress, DNA damage and transcriptional arrest 104 
(Latonen et al., 2001; Meek, 2004; Riley et al., 2008; Gambino et al., 2013; Clewell et al., 105 
2014) upregulated the CYP2A6 gene by interacting with its response element (RE) on the 106 
proximal CYP2A6 promoter region (Hu et al., 2015). Interestingly, the functional p53RE is 107 
only five base pairs upstream of an RE cluster consisting of functional binding sites for HNF-108 
4α, CAR, C/EBPα, C/EBPβ, and Oct-1 (Pitarque et al., 2005), of which three are activated by 109 
chemical or oxidative stress.   110 
  In the present study we demonstrate a close cooperation between the four stress-111 
activated TF:s: the CAR, C/EBPα, Oct-1 and p53, in the regulation of the CYP2A6 gene, 112 
complemented by the liver enriched TF, HNF-4α for full activity. 113 
 The results are in accordance with, earlier observations on the upregulation of the 114 
CYP2A6 by various toxic insults and with its protective role in the cells. Together with the 115 
earlier identified, stress activated proteins and regulators of the CYP2A6 gene, the proximal 116 
promoter binding stress- protein cluster, identified in this paper, suggest a machinery of  117 
extreme complexity on CYP2A6 regulation by various stress related signaling pathways and 118 
may suggest a role for the gene product as a delicate, intracellular stress sensor.  119 
 120 
Materials and methods 121 
Chemicals and antibodies 122 
         Ampicillin, kanamycin, biological agar, Tween-20, saline sodium citrate, 2-123 
mercaptoethanol, sucrose, glycerol, glycine, leupeptin, bovine serum albumin (BSA), DMSO, 124 
PBS, dithiothreitol (DTT), phenylmethylsulfonyl fluoride (PMSF), MgCl2, KCl, KOH, NaCl, 125 
Hepes, EDTA, IGEPAL, boric acid, cyclohexanediamine tetraacetic acid, Triton X-100, p-126 
coumaric acid and luminol were purchased from Sigma-Aldrich (Sydney, NSW, Australia). 127 
Agarose were obtained from PROGEN Biosciences (Brisbane, QLD, Australia). BactoTM 128 
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yeast extract and BactoTM Tryptone were purchased from Becton Dickison (Sydney, NSW, 129 
Australia), Polyethylenimine (PEI) was purchased from Polysciences Inc. (PA, USA). Mouse 130 
monoclonal antibodies anti-p53 (sc-126X), anti-C/EBPα (sc-365318X), anti-Oct-1(sc-131 
8024X), rabbit polyclonal antibodies anti-HNF-4α (sc-8987), anti-RXR (sc-774X), A-431 132 
whole cell lysate (sc-2201) and HepG2 whole cell lysate (sc-2227) were obtained from Santa 133 
Cruz Biotechnology Inc. (Dallas, Texas, USA). Rabbit polyclonal antibodies anti-CAR 134 
(ab186869) and anti -β-actin (ab8227) were sourced from Abcam (Cambridge, UK). Goat 135 
anti-mouse and goat anti-rabbit antibodies conjugated with horseradish-peroxidase were from 136 
Thermo Fisher Scientific Inc. (Melbourne, Victoria, Australia). All cell culture consumables 137 
were sourced from Invitrogen (Scoresby, Victoria, Australia). 138 
 139 
C3A cell culture maintenance  140 
             The C3A human hepatocellular carcinoma cells (ATCC, Manassas, VA, USA) were 141 
propagated in T75 flasks in William’s Medium E containing 10% FBS, 1% Glutamax and 1% 142 
Penicillin-Streptomycin. The cells were maintained in a humidifier incubator at 37°C in 5% 143 
CO2 and were sub-cultured at least two times per week. Cells were washed twice by 1× PBS 144 
and were detached by TrypLE Express Enzyme (1×) before sub-culturing. Cells with passage 145 
number between 5 and 15 were used in all studies.  146 
 147 
Site-directed mutagenesis 148 
             Previous studies have shown that the CYP2A6 gene expression is mediated by a 149 
cluster of transcription factor binding sites including one for p53 spanning from -122 to -60 150 
bp on the proximal CYP2A6 promoter region (Pitarque et al., 2005; Hu et al., 2015). To 151 
investigate possible interplay between factors binding to these sites in mediating CYP2A6 152 
gene transactivation, a series of  response element- mutated, proximal CYP2A6 promoter 153 
constructs were generated as follows, (mutated region underlined); the p53RE 5’-154 
ATTCATGGTGGGGCATGTAG-3’ was mutated to 5’-ATTACCAGTGGGGATCCTAG-155 
3’; CAR/DR-4RE 5’-AGGTGAAATGAGGTAA-3’ to 5’-CCCCGAAATGAGGTAA-3’; 156 
C/EBP-Oct-1RE 5’-GTAATTATGTAAT-3 to 5’-GTAACACGAATTC-3’ and the HNF-157 
4αRE 5’-CAGCCAAAGTCCA-3 to 5’-CAGCCAACGTCTC-3’. The four response elements 158 
were mutated individually and in combination by the two steps PCR. Firstly, individual RE 159 
mutations were introduced. The mutated constructs were amplified from the template plasmid 160 
CYP2A6 5’ -160/+9 by priming with the forward primer CYP2A6 5’-160 FW and reverse 161 
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primers CYP2A6-p53mut RV1, CYP2A6-DR-4mut RV1, CYP2A6-C/EBPmut RV1 or 162 
CYP2A6-HNF4αmut RV1 respectively (Table1). The CYP2A6 constructs from RE mutated 163 
sites to +9 were amplified from the template plasmid CYP2A6 5’ -160/+9 by priming with 164 
the forward primer CYP2A6-p53mut FW1, CYP2A6-DR4mut FW1, CYP2A6-C/EBPmut 165 
FW1 or CYP2A6-HNF4αmut FW1 (Table1) and the reverse primer CYP2A6 5’+9 NheI RV 166 
respectively (Table 1). Equal amount of PCR products from the two reactions were mixed 167 
together, which acted as a template to amplify the mutated p53RE, DR-4RE, C/EBP-Oct-168 
1RE, HNF-4αRE respectively. The CYP2A6-160/+9 constructs containing the mutated 169 
p53RE, DR-4RE, C/EBP-Oct-1RE or HNF-4αRE were generated by priming with the 170 
forward CYP2A6 5’ -160 KpnI FW and the reverse primer CYP2A6 5’+9 NheI RV (Table1). 171 
The constructs were ligated to the pGL3-Basic plasmid respectively. The same method was 172 
applied to generate multiple RE- mutated constructs which were amplified from the 173 
previously generated single RE mutated CYP2A6 constructs by using the primers listed in 174 
Table 1. Similarly, the CYP2A6 p53RE: 5’-ATTCATGGTGGGGCATGTAG-3’ was 175 
mutated into a “consensus p53RE”: 5’-AGACATGCCTAGACATGCCT-3’ (mutated 176 
sequences, underlined) in the proximal CYP2A6 promoter construct by forward primer 177 
CYP2A6-p53mut FW3 and reverse primer CYP2A6-p53mut RV2 (Table 1). The generated 178 
CYP2A6 promoter constructs were transformed in XL-1 blue competent cells for expansion 179 
(Agilent technologies, CA, USA) and were purified by using QIAGEN plasmid midi kit 180 
(QIAGEN, Hilden, Germany). The validity of the mutations was confirmed by gene 181 
sequencing. The primers used for site directed mutagenesis were obtained from Sigma-182 
Genosys (Sydney, Australia), which were shown in table 1.  183 
 184 
Plasmids and transient transfection assays 185 
            The CYP2A6 5’ promoter region -160/+9 was amplified using high-fidelity PCR 186 
polymerase and cloned in front of the luciferase cDNA in pGL3-Basic vector (Promega, 187 
Madison, WI). Thereafter, a series of site mutations of the REs on the CYP2A6-5’-160/+9 188 
Luc plasmids were generated by the site directed mutagenesis method. Empty expression 189 
plasmid (pcDNA3) and transcription factor expression plasmids including the pcDNA3-hp53, 190 
pSG5-hCAR, pcDNA3.1/V5-His-C/EBPα, pCB6-HNF-4α and Oct-1 expression plasmids 191 
were used for co-transfection experiments. Promoterless pGL3-Basic and pGL3-Basic 192 
containing a SV-40 promoter were used as negative and positive controls for cell transfection 193 
respectively. The pGL4.38 [luc2P/p53 RE/Hygro] vector (Promega, Madison, WI) was used 194 
as the positive control for p53 co-transfection in C3A cells.  195 
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 Polyethylenimine (PEI) (Polysciences Inc., PA, USA) was used to transiently transfect 196 
cultured cells with the various promoter constructs, as previously described in (Hu et al., 197 
2015). The optimized PEI:DNA ratio was set at 1:2 for C3A cell transfection. The DNA-PEI 198 
mixture was then incubated at room temperature for 15 min before being added to each well 199 
of the 24-well plates or the 100 mm dishes. 200 
          Cells were seeded in 24-well plates (1.2 × 105 cells/well) for 24 h. Thereafter, the cells 201 
were washed once in 500 µl PBS, followed by addition of 500 µl of fresh FBS-free medium 202 
to each well. The cells were then transfected with 0.5 µg of CYP2A6-5’-Luc constructs. In the 203 
co-transfection experiments, the cells were co-transfected with 0.3 µg of CYP2A6-5’-Luc 204 
constructs, 0.1 µg of each transcription factor expression plasmid or empty expression 205 
plasmid pcDNA3 and 0.1 µg of pMAX-GFP (transfection control). The same co-transfections 206 
were scaled up by 25 times in 100 mm dishes for protein extraction and analysis. The 207 
transfected cells were incubated for 24 h in a humidifier incubator at 37°C in 5% CO2. 208 
Thereafter, the transfected cells were harvested and lysates used for measuring luciferase 209 
activity (BriteliteTMplus Reporter Gene Assay System, PerkinElmer, USA). Transfections 210 
under each condition were performed in quadruplets. The fluorescence and luminescence 211 
signals were captured on a FLUOstar Omega multimode microplate reader with automatic 212 
gain settings. 213 
 214 
Isolation of nuclear and cytoplasmic proteins  215 
           Nuclear and cytoplasmic extracts from cultured cells were prepared as described 216 
previously (Abu-Bakar et al., 2007). Briefly, 3 × 106 cells in a 100 mm dish were washed and 217 
resuspended in 5 ml cold PBS. The cell suspension was centrifuged at 1600 × g for 10 min at 218 
4oC. The resulting pellet was resuspended in 200 µl of buffer A (10 mM Hepes-KOH, pH 219 
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF, 10µg/ml leupeptine, 0.4% 220 
IGEPAL) and kept on ice for 1 h. Thereafter, the cell suspension was vortexed, homogenized 221 
and centrifuged at 12,000 × g for 10 min at 4oC. The supernatant containing cytoplasmic 222 
proteins was aliquoted and stored at -80oC. The pellet containing nuclei was resuspended in 223 
50 µl of cold buffer B (20 mM Hepes-KOH, pH 7.9, 25% glycerol, 1.5 mM MgCl2, 420 mM 224 
NaCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF, 0.4% IGEPAL) and gently agitated 225 
with magnetic stirrer for 30 min at 4oC. The suspension was homogenized and centrifuged at 226 
15,000 × g for 15 min, at 4oC.  The supernatant containing nuclear proteins was diluted 1:1 227 
with the dilution buffer (20 mM Hepes-KOH, pH 7.9, 15% glycerol, 0.2 mM EDTA, 0.5 mM 228 
DTT, 0.2mM PMSF), aliquoted and stored at -80oC.  229 
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Protein analysis  230 
             Protein concentrations of the subcellular fractions were measured by the DC protein 231 
assay kit (Bio-Rad Laboratories, USA). The expression levels of transcription factors p53, 232 
CAR, C/EBP-α, Oct-1, and HNF-4α were assessed by Western immunoblotting. Briefly, 30 233 
µg nuclei proteins were separated by 4%-15% SDS-polyacrylamide gel (Bio-Rad 234 
Laboratories, USA) electrophoresis. The proteins were electrophoretically transferred onto a 235 
0.2 µm PVDF membrane (Bio-Rad Laboratories, USA) and blocked overnight in Tris-236 
buffered saline containing 0.1% Tween 20 (TBS-T) and 5% non-fat milk. The membrane was 237 
then incubated with the relevant antibody (1:500 dilution) for 2 h, washed with TBS-T, and 238 
incubated for 1 h with horseradish peroxidase-conjugated goat anti-mouse IgG (1:3000 239 
dilution).  After further washing with TBS-T, the membrane was incubated with luminol 240 
solution (1 M Tris pH 8.5, 90 mM p-coumaric acid, 250 mM luminol, and 3% H2O2) for 5 241 
min and immunoreactive bands were visualized and captured by the ChemiDocTM MP 242 
imaging system (Bio-Rad Laboratories, USA). Densitometry analysis of protein expression 243 
levels was performed by using the software NIH imageJ 1.49. 244 
 245 
Electrophoretic mobility shift assay  246 
                 Four double stranded probes used for EMSA analysis were obtained from Sigma-247 
Genosys (Sydney, Australia). The probes containing respective p53RE, DR-4RE, C/EBP-248 
Oct-1RE, and HNF-4αRE spanning from -122 to -60 bp on the proximal CYP2A6 promoter 249 
were listed in table 1. These probes were labelled with digoxigenin on the 3’ end of the 250 
oligonucleotide using DIG gel shift kit (Roche, Germany). Thereafter, 32 fmol of each 251 
digoxigenin-labelled probe was incubated with 16 µl of binding buffer and 4 µg of nuclei 252 
proteins for 15 min at room temperature. The nuclei proteins were extracted from C3A cells 253 
transfected with pcDNA3-hp53, pSG5-hCAR, pcDNA3.1/V5-His-C/EBPα, pCB6-HNF-4α 254 
and Oct-1 expression plasmids respectively. In antibody shift assay, 1 µl of anti-p53, CAR, 255 
RXR, C/EBPα, Oct-1, HNF4α or Nrf2 antibody was added to the reaction mixture and was 256 
incubated for 15 min. The samples were loaded to a pre-electrophoresed, non-denaturing 4-257 
15% polyacrylamide gel in 0.5 × TBE buffer (44 mM Tris-HCl, pH 8, 44 mM boric acid, 1 258 
mM EDTA). Samples were separated electrophoretically at 80V for 1 h and transferred to a 259 
positive-charged nylon membrane Hybond-N (Amersham Biosciences, UK, Ltd) by an 260 
electro-blotting device (Bio-Rad Laboratories, USA) set at 1 h at 30V, 300mA. Thereafter, 261 
the membrane was baked at 140oC for 15 min and crosslinked in a UV StratalinkerTM 1800 262 
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(Integrated Sciences, Australia) at 120 mJ. The membrane was briefly rinsed for 3 min in 263 
washing buffer and was blocked in blocking solution for 30 min before immunological 264 
detection. The digoxigenin-labelled probes on the membrane were detected by incubating the 265 
membrane with an anti-digoxigenin-AP antibody (1:10,000). The chemiluminescence signal 266 
of the labelled probes was captured by ChemiDoc™ MP imaging system after applying the 267 
alkaline phosphatase substrate CSPD on the membrane. A longer probe covering all intact 268 
REs of the proximal CYP2A6 promoter was also used for EMSA analysis, which was 269 
amplified from the wildtype CYP2A6 promoter construct by priming with the CYP2A6 5’-270 
141-FW forward primer and CYP2A6 5’+9-RV primer (Table 1).  271 
 272 
Statistical analysis  273 
Two group comparisons were analyzed by Student’s t test. Multiple group comparisons were 274 
done with one-way analysis of variance (ANOVA) followed by the least significant 275 
difference post hoc test. Differences were considered significant when p < 0.05. 276 
 277 
Results  278 
Role p53, CAR, C/EBPα, Oct-1 and HNF-4α in the regulation of the CYP2A6 gene 279 
          Our recent studies have demonstrated that transactivation of the human CYP2A6 is 280 
mediated by the stress activated transcription factor p53 (Hu et al., 2015). In addition, we and 281 
others have shown that also the CAR, C/EBPα/ Oct-1 and HNF-4α interact with the proximal 282 
promoter of the CYP2A6 and may thus play a role in its regulation (Pitarque et al., 2005; Hu 283 
et al., 2015). Interestingly, like p53 also the CAR and C/EBPα/Oct-1 are part of the cellular 284 
stress – responding machinery (Jin et al., 2001; Li et al., 2008; Osabe et al., 2009; Hou et al., 285 
2012). Therefore, a series of experiments were designed in order to investigate possible 286 
interaction between these proteins in mediating the CYP2A6 gene transactivation. The 287 
CYP2A6-5’-160/+9 Luc promoter construct was first co-transfected with the transcription 288 
factor expression plasmids p53, CAR, C/EBPα, Oct-1 and HNF-4α respectively, into the C3A 289 
cells. As shown in Figure 1A, the p53, Oct-1 and HNF-4α all increased the expression 290 
significantly. A very strong increase in the expression was achieved by overexpression of the 291 
liver enriched transcription factor C/EBPα (Fig. 1A). By contrast, co-transfection of CAR 292 
downregulated the CYP2A6 gene expression compared to the control (Fig. 1A). These results 293 
indicate that all five transcription factors play a role in the regulation of the CYP2A6 gene but 294 
that the roles may differ. Levels of the respective transcription factors in the C3A cells, 295 
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transfected with expression plasmids or the empty vector were confirmed by Western blotting 296 
and subsequent semi quantitative scanning of the band. As shown in Figure 1B and 1C, all 297 
transcription factors were highly expressed in expression plasmid transfected cells compared 298 
to the control. It is worth noticing that the level of C/EBPα appears to be extremely low in 299 
control cells but is highly expressed in expression plasmid transfected cells.  300 
           Next, roles of these transcription factors in the CYP2A6 regulation were confirmed by 301 
mutating the corresponding response elements on the proximal CYP2A6 promoter. The RE 302 
mutated CYP2A6-5’-160/+9 Luc constructs were co-transfected together with pMAX-GFP 303 
into the C3A cells. Figure 2A shows the locations of the respective binding sites at the 304 
CYP2A6 promoter region. These sites were mutated individually and in combination (Fig. 305 
2B).  Figure 3A shows the impact of single mutations on the expression levels. A significant 306 
reduction by about 40-55% was observed in each case, as compared to the wild type promoter 307 
(Fig. 3D). The SV-40 promoter driven Luc-activity, used as a control, was expressed at about 308 
50% of the activity of the wild type CYP2A6 (Fig. 3D). As expected, no significant activity 309 
was observed in the cells transfected with pGL3-Basic plasmid (negative control). The results 310 
demonstrate that each of the four response elements, present on the proximal CYP2A6 311 
promoter, has a role in mediating CYP2A6 gene transactivation essentially confirming results 312 
summarized in Figure 1. In the case of CAR, apparently opposite effects were found with its 313 
overexpression respectively mutation of the RE (Fig. 1 and 3A). The results are in agreement 314 
with previous studies by (Pitarque et al., 2005; Hu et al., 2015).   315 
         Next, in order to investigate possible interplay between p53 and the four other proteins, 316 
in the regulation the CYP2A6 expression, a series of multiple mutations were introduced as 317 
shown in Figure 3B, C and D. The mutated constructs were transfected into C3A cells 318 
respectively. When all four RE:s were mutated, the expression was totally abolished, as could 319 
be expected. Interestingly, almost a zero level activity was also observed with triple 320 
mutations where only the p53 or HNF-4αRE was left intact (Fig. 3B). On the other hand, 321 
when either CAR or C/EBP/Oct-1 RE was kept intact, a significant expression at about 40 to 322 
60% from the wild type could be observed (Fig. 3B). These results suggest that, while all four 323 
proteins are needed for the optimal activity, their respective roles in assembling the 324 
transcription complex seem different: While for the HNF-4α and the p53 interaction with the 325 
other proteins appears necessary, in order to contribute to the transcriptional activity, the 326 
CAR and especially the C/EBPα seem to be able to function partially independently although 327 
not in their full capacity. 328 
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         When a series of double mutations was introduced an even more complex picture 329 
emerged (Fig. 3C):  A zero level activity was observed when only the p53 and HNF-4αRE:s 330 
were intact supporting the observation above that these TF:s need the other two proteins to 331 
function. In addition, this result seems to suggest that p53 and HNF-4α do not interact 332 
directly with each other to support transcription. On the other hand, when p53RE was kept 333 
intact together with either CAR or C/EBP/Oct-1 RE, the expression could partially be 334 
restored suggesting an interaction between these proteins and the p53. 335 
         In conclusion, the results suggest complex interaction between the four/five proteins 336 
where all of them are needed for optimal transcriptional activity, and where the p53 cannot 337 
act alone but needs interaction with the other proteins in regulating the expression of the 338 
CYP2A6 gene. The results also suggest a tight interaction between the stress activated p53, 339 
CAR and Oct-1, complemented by the HNF-4α for full activity. 340 
 341 
Over-expression of p53 emphasizes its interaction with CAR and C/EBP/Oct-1 in the 342 
regulation of CYP2A6   343 
         To further investigate the interaction of p53 with the other transcription factors, a series 344 
of mutated constructs were co-transfected with the p53 expression plasmid into the C3A cells 345 
as shown in Figure 4. As expected a strong upregulation of the wild type gene took place 346 
which was almost as strong as with the positive control. Also expected was the absence of 347 
upregulation with constructs where the p53RE was mutated, either alone or together with the 348 
other RE:s, thus demonstrating its role in maintaining the CYP2A6 expression (Fig. 4). A 349 
very weak and non-significant up-regulation was observed with the construct where the 350 
p53RE was the only intact one. An equally weak/nonsignificant upregulation was observed 351 
with the intact p53RE and pairwise mutations of the CAR/C/EBP/Oct-1/HNF-4α RE:s 352 
respectively (Fig. 4). The results confirm observations in Figure 3 that p53 cannot support 353 
CYP2A6 expression alone but needs cooperation with the other factors. And further that 354 
interaction with only one of the other proteins is not sufficient. Interestingly, co-transfections 355 
with constructs possessing intact p53RE and single mutations at the three other sites 356 
respectively showed that while mutation of the CAR or the C/EBP/Oct-1 RE compromised 357 
the expression partially, mutation of the HNF-4α site did not, as compared to the wild type. 358 
This result confirms the picture emerging from Figure 3 where CAR and C/EBP/Oct-1 are 359 
essential partners for p53 in its CYP2A6 regulation while the HNF-4α plays a supportive 360 
function.   361 
 362 
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Electrophoresis Mobility Shift Assay (EMSA) confirms binding of CAR, C/EBPα, Oct-1 363 
and HNF-4a to the CYP2A6 proximal promoter 364 
         A series of EMSA analysis was performed to demonstrate binding of p53, CAR, 365 
C/EBPα, Oct-1 and HNF-4α to the CYP2A6 promoter. Direct interaction of p53 with the 366 
promoter has been shown previously (Hu et al., 2015). Sequences covering the respective 367 
RE:s and binding sites of the proteins at the CYP2A6 proximal promoter (Fig. 3A) were used 368 
as labelled probes and specific antibodies raised against each of these proteins were added to 369 
the incubation mixtures. Anti Nrf-2 antibody was used as control for unspecific binding: (a 370 
protein present in the nuclear extract but with no binding site at the promoter).  371 
         A protein/DNA complex was supershifted by the p53 ab, but the formed complex did 372 
not recognized by the Nrf-2 ab, indicating the specific binding of p53 to the RE (Fig. 5A). 373 
Figure 5B shows a gel-shifted band specific to the CAR and the RXR: (a protein forming a 374 
heterodimer with the CAR upon binding to the DNA), however, no complex was observed 375 
with the anti Nrf-2 ab. Similarly, a gel-shifted band is seen in Figure 5C with Oct-1 ab but not 376 
with the Nrf2 ab, suggesting specific binding of the protein to it’s RE. Only a weak and 377 
diffuse shift was observed in Figure 5D with anti C/EBPα ab, nonetheless, a pattern distinctly 378 
different from that obtained with anti-Nrf2 antibody, where no trace of shift were observed. 379 
This could indicate a weak binding of the anti-C/EBPα antibody to the protein, possibly due 380 
to some interference by the Oct-1 (See Figure 7). Two bands appeared on the gel when the 381 
probe specific to the HNF-4α was incubated with the protein extract (Fig. 5E). A distinct, gel-382 
shifted band appeared with simultaneous disappearance of the upper band upon addition of 383 
the anti-HNF-4α to the incubation mixture, suggesting that the upper band represents the 384 
HNF-4α. We do not know what the lower band is, but at least it is not the Nrf2 as antibody 385 
against it caused no changes in the migration of the protein DNA complexes on the gel (Fig. 386 
5E). 387 
          Finally, the entire proximal promoter region of the CYP2A6 gene including all binding 388 
sequences of the investigated proteins was used as a probe. A complex appears when this 389 
probe is incubated with nuclear proteins containing all five TF:s but no antibody (Suppl. Fig. 390 
1, complex indicated by arrow). Same size of complex also appears in the presence of Nrf2 391 
antibody but disappears when ab:s against the other five proteins were used respectively 392 
(Suppl. Fig. 1). However, no obvious, gel shifted, antibody specific complexes could be 393 
identified on the gel. 394 
         Using excessively large probes in EMSA assays is known to be challenging for several 395 
reasons: for example unpredictable and diffuse migration of huge DNA–protein complexes 396 
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on the gel and conformations formed interfering with antibody binding. Nevertheless, 397 
disappearance of the characteristic band seen in the absence of Ab:s or in the presence of the 398 
anti Nrf2 antibody, when specific antibodies were used, seems to support results obtained 399 
with the smaller, specific probes suggesting that all five proteins seem to interact with the 400 
large probe as well.  401 
 402 
Replacing the p53RE at the CYP2A6 promoter with consensus p53RE dramatically 403 
increases the expression level. 404 
        A consensus RE has been previously described for the p53. It contains two repeats of 405 
[5’-RRRC(A/T)(T/A)GYYY-3’], where “R” represents purine and “Y” represents pyrimidine 406 
(el-Deiry et al., 1992). This DNA sequence is characterized by a specific, high affinity 407 
interaction with the p53, and has been used in vectors assessing p53 activity levels in in vitro 408 
cell assay (Mukudai et al., 2013; Promega, 2015) . 409 
        In our present and previous studies we have used a double - repeat p53 consensus 410 
sequence vector, pGL4.38 [luc2P/p53 RE/Hygro], as a positive control to assess p53 411 
activation (Fig. 4 and 6, Hu et al., 2015). When the CYP2A6 specific p53RE was mutated 412 
into the p53 consensus sequence (Fig. 6A, boxed region) while keeping the promoter 413 
otherwise intact, an extremely high expression level (up to 30-40 times higher) as compared 414 
to the CYP2A6 wild type or indeed the p53 positive control was achieved (Fig. 6B). When 415 
this construct was co-transfected with the p53 expression plasmid, no further increase in the 416 
expression, unlike in the case of the wild type CYP2A6 or the p53 positive control, was 417 
achieved (Fig. 6B). This is an unexpected result, particularly since the p53 positive control 418 
contains two copies of the consensus sequence while the modified CYP2A6 promoter 419 
contains only one. The result is not easy to explain but it possibly demonstrates the 420 
importance of the adjacent transacting factors, present at the CYP2A6 promoter, for p53 to 421 
achieve its full gene activating capacity. Such explanation is in accordance with the results 422 
obtained throughout this investigation. 423 
        It could be that introducing the consensus sequence into the CYP2A6 promoter has 424 
created a template with an extremely high p53 affinity (higher than the consensus sequence 425 
alone) binding aggressively all the endogenous p53 (facilitated by the other interacting 426 
proteins) and leaving no place for the overexpressed p53. This could explain why not further 427 
upregulation of this construct took place by overexpressing the p53. Such a scenario would 428 
agree with a model where the other TF:s (CAR, C/EBP/Oct-1) help recruiting the p53 into the 429 
complex and facilitate its binding to its RE.    430 
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Discussion  431 
         This study demonstrated that stress activated transcription factors: the p53, CAR and 432 
C/EBP/Oct-1 form a cluster at the proximal promoter of the CYP2A6 gene; - 61 - 122 bp 433 
upstream the TATA box. And that the cluster formation appears to be necessary for the 434 
proteins to exert their regulatory function. For full activity the “stress cluster” needs to 435 
interact with the HNF-4α, also binding to the same regulatory region. Based on the results a 436 
model is proposed for the “stress cluster” formation and protein - protein interactions at the 437 
CYP2A6 promoter (Fig. 7). 438 
        In a recent study (Hu et al., 2015) we demonstrated that p53 is a transcriptional activator 439 
of the CYP2A6 contributing to its upregulation during oxidative and/or genotoxic stress 440 
(Abu-Bakar et al., 2013); condition known to activate  the p53 (Meek, 2004; Gambino et al., 441 
2013; Clewell et al., 2014). However, the present study shows that, rather than acting alone 442 
the p53 cooperates with other stress activated proteins to exert its regulatory function. Given 443 
the various toxic insults that are known to activate the proteins included in the “stress cluster” 444 
it seems that conditions and cellular processes leading to upregulation of the CYP2A6 gene 445 
maybe complex and multifactorial (Jin et al., 2001; Clewell et al., 2014; Kobayashi et al., 446 
2015).  447 
         Earlier studies have identified other stress-activated signaling pathways up- or 448 
downstream the gene-expression pathway contributing to the expression of the CYP2A6 gene. 449 
Accordingly, the “pregnane-X-receptor (PXR), estrogen receptor-α (ER-α), and stress 450 
activated nuclear factor (erythroid-derived2) like2 (Nrf-2) (Itoh et al., 2006; Higashi et al., 451 
2007; Yokota et al., 2011) have shown to be regulators of the gene. In addition, we have 452 
shown that the multifunctional, stress activated hnRNPA1 (Heterogeneous Nuclear 453 
Ribonucleoprotein A1) mediating nucleo-cytoplasmic mRNA transport and mRNA 454 
stabilization, upregulates the CYP2A6 by stabilizing the mRNA and targeting it in the 455 
endoplasmic reticulum during transcriptional arrests (Glisovic et al., 2003; Christian et al., 456 
2004).  457 
        Based on sequence alignment analysis we have found up to five putative p53 binding 458 
sites further upstream the CYP2A6 promoter within the 3k bp region upstream TATA box 459 
(Hu et al., 2015). Some of these sites seem to overlap with an Nrf-2 binging site (Yokota et 460 
al., 2011; Hu et al., 2015). We do not know whether all these sites are functional but our 461 
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preliminary studies have shown that some of them may contribute to the regulation of the 462 
CYP2A6 gene. We made an intriguing observation suggesting that the Nrf-2 and p53 interact 463 
at some of these sites in a way where the Nrf-2 seems to contain upregulation by p53. Such 464 
interaction between the p53 and Nrf-2 has been observed for other genes including the phase 465 
II metabolizing genes, NQO-1 and GST-1 (Faraonio et al., 2006; Wakabayashi et al., 2010) 466 
and maybe related to optimizing cellular response to stress.  467 
         Four of the six stress-activated proteins now known to be involved in the CYP2A6 468 
regulation: the hnRNPA1, Nrf-2, C/EBPα/Oct-1 and p53 are non-ligand binding proteins, 469 
activated by divers cellular disturbances such as oxidative stress, macromolecular damage 470 
and transcriptional arrests (Jin et al., 2001; Christian et al., 2004; Li et al., 2008; Riley et al., 471 
2008; Ma, 2013). The PXR and CAR, on the other hand are activated by a multitude of 472 
ligands including toxins, drugs and other diverse chemicals and xenobiotics (Kliewer et al., 473 
2002; Timsit and Negishi, 2007; Kachaylo et al., 2011). The mechanisms of regulation of the 474 
CYP2A6 gene by these proteins include both transcriptional and post-transcriptional 475 
processes. For instance, during extreme form of stress leading to major disturbances in 476 
cellular processes including transcriptional arrest, the CYP2A6 and its mouse analogue the 477 
CYP2A5 are upregulated through posttranscriptional mechanisms including mRNA ( by 478 
hnRNPA1) and protein (by substrate) stabilization (Glisovic et al., 2003; Christian et al., 479 
2004; Abu-Bakar et al., 2012). Such mode of regulation is characteristic for genes vital for 480 
cell survival. 481 
         In conclusion, it appears that the expression of the human CYP2A6 gene is controlled by 482 
multiple, stress activated signaling pathways including ligand activated and non-ligand 483 
activated TF:s. This could provide an explanation for the earlier observations where the 484 
CYP2A6 was found to be up-regulated by a multitude of seemingly unrelated external insults. 485 
Accordingly, viral and parasitic infestations, chronic inflammation, radiation, alcohol caused 486 
liver injury and toxic insults by a variety structurally unrelated chemicals, are all known to 487 
upregulate the gene (Kirby et al., 1994; Niemela et al., 2000; Glisovic et al., 2003; De-488 
Oliveira et al., 2006; Kirby et al., 2011). Such diversity of activators has led us to 489 
hypothesize that, rather than any specific chemical or agent, changes in intracellular 490 
conditions such as in redox potential, DNA or other macromolecular damage, maybe 491 
important causes of the CYP2A6 induction.  Indeed our recent findings that several, non- 492 
ligand activated TF:s are involved in the regulation support this view.  493 
15 
 
          In a series of investigations we have demonstrated that the CYP2A6 and its mouse 494 
analogue, play an important role in maintaining optimal cellular homeostasis, besides 495 
contributing to xenobiotic metabolism (Raunio et al., 2008; Miyazawa et al., 2011). The 496 
enzymes have been shown to act as Bilirubin (BR) oxidases and, together with the HO-1 497 
build a machinery that maintains optimal intracellular BR levels for cellular protection (Abu-498 
Bakar et al., 2011; Abu-Bakar et al., 2012; Abu-Bakar et al., 2013). BR is one of the most 499 
potent antioxidants and because of its high lipophilicity, attaches to hydrophobic cellular 500 
structures, such as membranes, lipids and protein surfaces (Stocker et al., 1987). Its 501 
production in cells is known to increase during stress conditions and its crucial role in 502 
protecting macromolecules against toxic insults is increasingly appreciated (Liu et al., 2003; 503 
Jansen et al., 2010). On the other hand BR is toxic at high concentrations (Rodrigues et al., 504 
2002). Therefore, a system needs to be in place to efficiently maintain its concentrations 505 
within the therapeutic range. We have demonstrated that the two enzymes: CYP2A6/HO-1, 506 
are upregulated in a coordinated fashion by similar stress stimuli and by similar mechanisms 507 
to optimize the BR levels according to needs (Abu-Bakar et al., 2005; Muhsain et al., 2015). 508 
We have also shown that in cells under stress, these enzymes are targeted to mitochondria to 509 
adjust the BR levels locally according to needs. Probably, in order to protect the organelle 510 
(Muhsain et al., 2015).   511 
         This crucial role of the CYP2A6 in cellular and mitochondrial protection may explain 512 
its complex regulation by multiple, stress activated transcription factors and signaling 513 
pathways. Some important questions remain to be answered regarding the role of the 514 
CYP2A6 in cell protection. We have used the liver derived C3A cells as a model because the 515 
CYP2A6 gene is highly expressed in the liver (Nakajima et al., 2006) and because most of the 516 
transcription factors were expressed in these cells at rather high levels (Rodriguez-Antona et 517 
al., 2002). How does the regulatory system work in other organs and/or cell types? This is 518 
poorly understood, however, it is interesting to note that, in addition to the liver, the CYP2A6 519 
or its close analogues are highly expressed in tissues or layers of cells, heavily exposed to 520 
chemical or oxidative stress including the esophagus, lung, intestinal oral and nasal epithelia 521 
(Su et al., 1996; Koskela et al., 1999; Janmohamed et al., 2001).  522 
         Another intriguing aspect of the CYP2A6 regulation is the contribution by p53: this 523 
protein plays a dual role in cellular protection and apoptosis (Bensaad and Vousden, 2007). 524 
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Could it be that when p53 turns from protective to apoptotic mode, its role in regulation of 525 
the CYP2A6 also changes? Our current work is focused on these challenging questions. 526 
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Primers Sequences 
Site-directed mutagenesis:  
CYP2A6-p53mut FW1 5’-ACCAGTGGGGATCCTAGTTGGGAGGTGAAATG-3’ 
CYP2A6-p53mut FW2 5’-ACCAGTGGGGATCCTAGTTGGGCCCCGAAATG-3’ 
CYP2A6-p53mut FW3 5’GACATGCCTAGACATGCCTTTGGGAGGTGAAATGAG-3’ 
CYP2A6-DR-4mut FW1 5’-GGGCCCCGAAATGAGGTAATTATGTAATCAGCC-3’ 
CYP2A6-DR-4mut FW2 5’-GGGCCCCGAAATGAGGTAACACGAATTCCAG-3’ 
CYP2A6-C/EBPmut FW1 5’-GTAACACGAATTCCAGCCAAAGTCCATCCCTC-3’ 
CYP2A6-C/EBPmut FW2 5’-GTAACACGAATTCCAGCCAACGTCTCTCCCTC-3’ 
CYP2A6-HNF4αmut FW1 5’-CAGCCAACGTCTCTCCCTCTTTTTCAGGCAGT-3’ 
CYP2A6-p53mut RV1 5’-TAGGATCCCCACTGGTAATCCTGCCTAGCTTGG-3’ 
CYP2A6-p53mut RV2 5’-AGGCATGTCTAGGCATGTCTCCTGCCTAGCTTGGGA-3’ 
CYP2A6-DR-4mut RV1 5’-CCTCATTTCGGGGCCCAACTACATGCCCCA-3’ 
CYP2A6-DR-4mut RV2 5’-CCTCATTTCGGGGCCCAACTAGGATCCCCA-3’ 
CYP2A6-C/EBPmut RV1 5’-CTGGAATTCGTGTTACCTCATTTCACCTCCC-3’ 
CYP2A6-C/EBPmut RV2 5’-CTGGAATTCGTGTTACCTCATTTCGGGGC-3’ 
CYP2A6-HNF4αmut RV1 5’-GGGAGAGACGTTGGCTGATTACATAATTACCTC-3’ 
CYP2A6-HNF4αmut RV2 5’-GGGAGAGACGTTGGCTGGAATTCGTGTTAC-3’ 
PCR Amplification  
CYP2A6 5’ -160KpnI FW 5’-GACGGTACCTTATCCTCCCTTGCTGGCTG-3’ 
CYP2A6 5’ +9NheI RV 5’-GACGCTAGCGGTGGTAGTGGGATGATAGATG-3’ 
CYP2A6 5’ -141 FW 5’-TGTGTCCCAAGCTAGGCAG-3’ 
CYP2A6 5’ +9 RV 5’-GGTGGTAGTGGGATGATAGATG-3’ 
EMSA  
CYP2A6-5’-127/-98-FW 5’-CAGGATTCATGGTGGGGCATGTAGTTGGGA-3’ 
CYP2A6-5’-127/-98-RV 5’-TCCCAACTACATGCCCCACCATGAATCCTG-3’ 
CYP2A6-5’-103/-80-FW 5’-GTTGGGAGGTGAAATGAGGTAATT-3’ 
CYP2A6-5’-103/-80-RV 5’-AATTACCTCATTTCACCTCCCAAC-3’ 
CYP2A6-5’-92/-65-FW 5’-AAATGAGGTAATTATGTAATCAGCCAAA-3’ 
CYP2A6-5’-92/-65-RV 5’-TTTGGCTGATTACATAATTACCTCATTT-3’ 
CYP2A6-5’-77/-53-FW 5’-GTAATCAGCCAAAGTCCATCCCTCT-3’ 
CYP2A6-5’-77/-53-RV 5’-AGAGGGATGGACTTTGGCTGATTAC-3’ 
Table 1: Oligonucleotides used for amplifications in site directed mutagenesis, Real-time 746 
PCR and EMSA experiments.   747 
 748 
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Figure legends 749 
Figure 1: Effect of transcription factors p53, CAR, C/EBPα, Oct-1 and HNF-4α on CYP2A6-750 
5’-160/+9 Luc construct activity in C3A cells. (A) Effect of p53, CAR, C/EBPα, Oct-1 and 751 
HNF-4α co-transfections on CYP2A6 promoter driven luciferase activities. C3A cells were 752 
co-transfected with either CYP2A6-5’-160/+9 Luc plasmid or pGL3-Basic plasmid together 753 
with p53, CAR, C/EBPα, Oct-1 or HNF-4α expression plasmids, or empty cloning vector 754 
(pcDNA3) respectively, and pMAX-GFP (transfection control plasmid). The firefly 755 
luciferase activities were measured 24 h after transfection. The measured activities were 756 
normalized against pMAX-GFP activity, and the expression vector/empty vector ratios were 757 
calculated and normalized with regard to the related pGL3-Basic activities. The CYP2A6-5’-758 
160/+9 Luc construct activity driven by each overexpressed transcription factor is indicated 759 
by -fold induction of the Relative Luciferase activity (RLA) to control co-transfection with 760 
pcDNA3. The values (n = 4) represent means ± S.D. Mean difference is significant from 761 
control group at ****, p < 0.0001; **, p < 0.005; (Student’s t test). (B) Western blotting and 762 
(C) densitometry of p53, CAR, C/EBPα, Oct-1 and HNF-4α expressions in C3A cells 763 
transfected with p53, CAR, C/EBPα, Oct-1 and HNF-4α expression plasmids. Each 764 
transfection was done in triplicate. Positive controls (+), A-431 whole cell lysate was used to 765 
indicate p53, C/EBPα transfected C3A nuclear extract was used to indicate C/EBPα and 766 
HepG2 whole cell lysate was used to indicate CAR, Oct-1 and HNF-4α. Relative protein 767 
expression (bar graph) = the intensity of overexpressed bands relative to the intensity of β-768 
actin bands. The values (n = 3) represent means ± S.D. Mean difference is significant from 769 
control group at ****, p < 0.0001; **, p < 0.005; *, p < 0.05 (Student’s t test). 770 
 771 
Figure 2: Site direct mutagenesis of the response elements on proximal CYP2A6 promoter 772 
region.  (A) Schematic representation of the response elements on the CYP2A6-5’-160/+9 773 
Luc construct. Four REs including p53RE, DR-4RE for CAR binding, C/EBP-Oct-1RE and 774 
HNF-4αRE are underlined. (B) Schematic representation of the mutated REs on the CYP2A6-775 
5’-160/+9 Luc construct. The REs were mutated individually and in combination (mutated 776 
bases in bold).  777 
 778 
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Figure 3:  Mutational analysis of the CYP2A6-5’-160/+9 Luc construct in C3A cells.  (A) 779 
Effect of single RE mutations on the proximal CYP2A6 promoter activities in C3A cells. (B) 780 
Effect of triple RE mutations on the proximal CYP2A6 promoter activities in C3A cells. (C) 781 
Effect of double RE mutations on the proximal CYP2A6 promoter activities in C3A cells. (D) 782 
Effect of all sites mutations on the proximal CYP2A6 promoter activities in C3A cells. The 783 
REs on the CYP2A6-5’-160/+9 Luc construct were mutated individually and in combination 784 
(figure 2B), followed by co-transfection of the mutated promoters and pMAX-GFP into the 785 
C3A cells. The negative and positive controls for transfection were indicated by transfections 786 
of pGL3-Basic and pGL3 containing SV-40 promoter into the C3A cells respectively. A 787 
schematic representation of the mutated CYP2A6-5’-160/+9 Luc construct is shown on the 788 
left, where the mutated REs for transcription factors are shown with a cross. The promoter 789 
activity of each mutated construct was compared against the pGL3-Basic activity and 790 
wildtype proximal CYP2A6 promoter activity, indicated by “*” and “#” respectively. The 791 
firefly luciferase activities were measured 24 h after transfection. The measured activities of 792 
each mutated construct were normalized against pMAX-GFP activity (transfection control 793 
plasmid), and were expressed as arbitrary units relative to the wildtype proximal CYP2A6 794 
promoter activity. The values (n = 4) represent means ± S.D. Mean difference is significant at 795 
****, p < 0.0001; ***; p < 0.0005; ####, p < 0.0001 (one-way analysis of variance 796 
(ANOVA) followed by the least significant difference post hoc test). 797 
 798 
Figure 4: Effect of p53 co-transfection on the REs mutated CYP2A6-5’-160/+9 Luc construct 799 
activities in C3A cells. C3A cells were co-transfected with a series of RE mutated CYP2A6-800 
5’-160/+9 Luc construct together with p53 expression plasmid (pcDNA3-hp53) or empty 801 
expression plasmid (pcDNA3). The schematic representation of the mutated CYP2A6-5’-802 
160/+9 Luc constructs is shown on left with a cross for the mutated REs. The pGL4.38-803 
p53RE plasmid containing two copies of consensus p53RE was used as positive control to 804 
indicate p53 co-transfection in C3A cells. Promoter less pGL3-Basic was used as negative 805 
control to indicate the transfection in C3A cells. The measured luciferase activities were 806 
normalized against co-transfected pMAX-GFP control plasmid activities. The values (n = 4) 807 
represent the means ± S.D. p53 response of each reporter construct is indicated by -fold 808 
induction of the Relative Luciferase activity (RLA) to control co-transfection with pcDNA3. 809 
Mean difference is significant from control group at ****, p < 0.0001; ***, p < 0.0005; **, p 810 
< 0.005; *, p < 0.05 (Student’s t test). ns = no significance. 811 
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Figure 5: EMSA analysis of the transcription factors p53, CAR, C/EBPα, Oct-1 and HNF-4α 812 
binding to the proximal CYP2A6 promoter. EMSA procedures are shown under Materials 813 
and Method. The DNA probes covering the respective REs on the proximal CYP2A6 814 
promoter region and the antibodies used in the assay are shown above the EMSA blot. The 815 
nuclei protein fractions were extracted from the transcription factor expression plasmids 816 
transfected C3A cells. The Nrf-2 antibody was used as control for unspecific binding (a 817 
protein present in the nuclear extract but with no binding sites at the promoter). (A) The 818 
probe CYP2A6-5’-127/-98 corresponding to the p53RE was incubated with p53 819 
overexpressed nuclear extract (lane 2). The formed DNA/protein complex was supershifted 820 
by p53 antibody (lane 3) but not with the Nrf-2 antibody (lane 4). (B) The probe CYP2A6-5’-821 
103/-80 corresponding to the DR-4RE was incubated with CAR overexpressed nuclear 822 
extract (lane 2). The formed DNA/protein complex was recognised by CAR and RXR 823 
(heterodimer of CAR) antibodies (lane 3 & lane 4), but not with the Nrf-2 antibody (lane 5).  824 
(C) And (D) The probe CYP2A6-5’-92/-65 corresponding to the C/EBPα-Oct-1RE was 825 
incubated with Oct-1 or C/EBPα overexpressed nuclear extracts (C and D, lane 2). The 826 
formed DNA/protein complex was shifted by Oct-1 antibody (C, lane 3), but only weakly and 827 
diffusely shifted by C/EBPα antibody (D, lane 3). No supershifted complex was observed 828 
when the mixtures were incubated with Nrf-2 antibody (C and D, lane 4). (E) The probe 829 
CYP2A6-5’-77/-53 corresponding to the HNF-4αRE was incubated with HNF-4α 830 
overexpressed nuclear extract, forming two DNA/protein complexes (lane 2). Only the upper 831 
complex was totally pulled up by HNF-4α antibody (lane 3). No supershifted complex was 832 
observed with the Nrf-2 antibody (lane 4). Lane 1 in all EMSA blots represents probe 833 
incubations without nuclei proteins. The supershifted DNA-protein complexes are indicated 834 
by arrows. The experiment was repeated 3 times with similar results. 835 
 836 
Figure 6: Effect of p53 co-transfection on the luciferase activity of the proximal CYP2A6 837 
promoter containing a consensus p53RE. (A) The differences between the CYP2A6-5’p53RE 838 
and the consensus p53RE sequences are indicated in the boxed regions, showing different 839 
satellite sequences. The p53 binding core sequences are shown in bold. (B) The p53RE on the 840 
proximal CYP2A6 promoter was mutated into a consensus p53RE as described: 5’-841 
ATTCATGGTGGGGCATGTAG-3’→5’-AGACATGCCTAGACATGCCT-3’ in CYP2A6-842 
5’-160/+9 Luc construct, with the mutated bases underlined and the core sequences in bold. 843 
The C3A cells were co-transfected with the wildtype CYP2A6-5’-Luc construct or the 844 
25 
 
CYP2A6-5’-Luc construct containing consensus p53RE together with p53 expression plasmid 845 
(pcDNA3-hp53) or empty plasmid (pcDNA3). The pGL4.38-p53RE plasmid containing two 846 
copies of consensus p53RE was used as positive control to indicate p53 co-transfection in 847 
C3A cells. Promoterless pGL3-Basic serves as a negative control for the transfection. The 848 
luciferase activities were measured 24h after transfection and were normalized against co-849 
transfected pMAX-GFP control plasmid activities. The values (n = 4) represent the means ± 850 
S.D. p53 response of each reporter construct is indicated by -fold induction of the Relative 851 
Luciferase activity (RLA) to control co-transfection with pcDNA3. Mean difference is 852 
significant from control group at ****, p < 0.0001; **, p < 0.005; *, p < 0.05 (Student’s t 853 
test). ns = no significance.  854 
 855 
Figure 7: Schematic representation of the transcriptional regulation of the proximal CYP2A6 856 
promoter. (A) A “stress cluster” on the proximal CYP2A6 promoter region. Proximal 857 
CYP2A6 transactivation is governed by the stress activated transcription factors p53, CAR, 858 
C/EBPα, Oct-1 and nuclear factor HNF-4α. (B) A model depicts interaction between p53 and 859 
the other transcription factors in mediating CYP2A6 transactivation. P53- mediated CYP2A6 860 
transactivation is dependent on the interaction with CAR and C/EBP-Oct-1, and for its full 861 
activity it is supported by HNF-4α.  862 
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 943 
Suppl. Figure 1: EMSA analysis of transcription factors binding to the proximal CYP2A6 944 
promoter.  The CYP2A6-5’-149/+9 probe covering all the response elements binding to the 945 
proximal CYP2A6 promoter region and the antibodies used in the analysis are indicated 946 
above the EMSA blot. Nuclei proteins are the mixture of the nuclear fractions that were 947 
extracted from p53, CAR, C/EBPα, Oct-1 or HNF-4α transfected C3A cells. Lane 1 948 
represents the probe incubation without nuclei proteins. Lane 2 represents the probe 949 
incubation with nuclei proteins. Lanes 3-8 represent the probe incubations with nuclei 950 
proteins and respective antibodies. The experiment was repeated 3 times with similar results. 951 
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